var title_f38_40_39552="Vertebral extension teardrop fracture";
var content_f38_40_39552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extension teardrop fracture of the cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 441px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG5AXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuS17WdRbXH0vSnjg8mNXlldQxy2cAA8dB+tVVi8QE5fV5D/ALqIP6VyzxcIScbN2N44eUle9jt6K4xYdYP39WmH4KP6Ux7K6k4n1S7cdx5pA/IVm8dFfZZSwz7nX3V3bWi7rq4ihX1kcL/OsO98X6bDkW3nXb+kScfmcfpmsddF0+Nt8mHc9Sxyam32VquI0QYrCePl9lWNY4aPXUD4i1e85t7e3tE/2wZG/oK0PDuu3NzqMmnamIRciPzYpIgQJFBwRgk4IyPz9q5rUNejjG2GF5G7BVrnoNT1FPEFnqYt222rHMecblIww/I1jSxdTnTk9DWeHi4tJantdFVdOvrfUbRLi0kDxMPxB9COxq1XtJpq6PNatowooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK5jxHr1xb6jHpmmCP7SyB5JH5EYJwOO5ODWYdL8395q9/c3bnkqXIX8FHArlq4qMHyrU3hQcld6HdUVwyaZapzZXV3aN/wBM5mA/LNTxtrcA/wBH1RZ1HRZ4gf1GD+tTHGxe6KeHfRnZUVxkviPWrQfvtOtZ/dJGj/mDTU8cyAgT6NcKf9iVW/nirWLpdWT9XqdEdrRXGP46UcJpN2W/2nUD+ZqvN4u1SZf9HsrW2B6GVzIf0xRLGUV1BYao+hF8TrWTTVXxDZT7J0CW8sRGRKC3GPcZP4VzljrGvXEYf7KFQ9CTV+/ebUJI5dZv2uVjO5YeFjU+uB1P1pJNcgjAUMoUcDFeTiKkak+aCPQowcIcstR8cmqzH52Cj2qwkF1j55Dn61Uh1yFzgOKsLq1u7YEgzXPqaE62bt/rJGP41ai0yPGW5+tR29yjcjmr8MpfnGFFILleazhjjztANY7XsB1RbQDJZSeB0HvVTxT4jW0jfZ8xHAA7nsKxfDCTSTvdXLfvZTk+w9BTsNI62WRvDV3BqNuxEDMBcR54ZO5x6jqK9ILKqlmICgZJJ4xXivjTVQbP7KjbnYbQPrXr9xZC60eSxndgJYDA7L15XBIr18vm2muh5+Ljaz6nn2lfF6x1m9Q6N4b8S3+itci0GsQWim2LFtpYfNuMYPVscYPFbcHxG0K5+Ip8F2xu5dXWF5ZHEO2GPb1UsxBJ/wB0Ee9cV8NbX4heCNG07wefCtjf2NnOY01tNSSOIwNIWLGE/PuAY8euPxn1vSfF03x10zxLbeGkl0iytG07zf7QiUujuSZdp5GAx+XqcV6Bxno3jPxJYeEfC+o67qzMtnZR+YwX7znICqvuzEAe5rJ8R+O7Xwt8P08U+JrG6s1KRs1jGVknDOQBGMlQWGckZ4weuKw/2i7C6vPhdezWcDXJ0+4gv5bdRkyxRSBnH4Llv+A1m/ErQtV+J9z4Ibw1eQR+F0lOqzaiQkoMirmACIkbudwIPHzc9MUAdLdfFLw1a+D9A8Szzypp2tSxQ2+dgdGfIO8bsAKQQxBOMd6s23j/AEmfxjd6GskX2e30tdVbUfPT7OYi+z72ccYznOK8cb4WeLLH4fyeHDplprEejeIo9R0wPJFH9qtMkvGAxwhJ5IY4+Y9cV0WqeEPFVxreu6zofh/T9Ma78MJp9rY3DQSxxTibcYygyh+XJGQVzjORQB61pXibQdXtri40nW9Lvre2GZpba7jlWIdcsVJA6Hr6VVPivTr7RNRvvC1zZeIZbKMu1vp93HIzHBOzKkgMQDgHqa8K0z4X+I5JfFFxqOg3bQarokdo1s+pWsc8s4mVmAeJBGuFUkZUjgAnnA7H4QaXrfgaw8T6n40ji07RY4omga5FubpY4lct5jwDawG75cknk9M8gHpfgzxJYeLvC+na7pLM1nex+Yob7yHJDK3urAg+4rarzP8AZ0sLqz+F1lNeQNbHULie/it2GDFFLIWQfiuG/wCBV6ZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeX67IYPiFqIkOBJFC6fTbj+YNbaXURjG5hVL4kaJqM+q2OqaVavclYzDMiY3AA5U479TWFFpPiq7H7jSjCp/imkVcfhnP6V4eIoTdV2R6lKpD2auzdv9XsrJd00gWqMHi7TCcLOR9QagT4bavdnfqGp2kTH+6jS4/PbVpPhXhf3mtOT/s2wA/9CpRwdbsN16XVmrba3ZXaYEqN+NOlgsrhThtpPdT0rJHwtdGzFrjqe3+jD/4qlPw+1iE5t9dhk9pLcr+oY1bwtfqrk+2pdGMu/D925JstTT/dlT+orKuPDXifnypbOUf75H9K128N+KbX7htLkf8ATOYqf/HgP50yS81XTV/4mVjdwqOrqm9R+K5FZypTj8UC1UT+GSMe38F+IrqQfbLq3t4+/l5c/wBK2E+H9mkWbp5rl8dXcj9BgVf07XIblQYblH+jVtW10cjJyKzUoPRjbmjxLxfbnw3qB8pmS1ddwBOQCOo5/D8648+MLgTExRMY89zivZPip4d/tnSZkhH7wfvYW9GHY+xHFeBohjLRyoUdThlIwQaF5msfe1PVfAXitL64ELkg5AKN1Fej+ItQh03R2lZgi7Mk14H4EtJZvFNmtspJ3ZbHYV6N8SLo3F3Y6TGcsSHkA/ujp+v8qVuwpLVI56383U7o3lypWPOY4z2Hqferd7qctlFiHgHgetaUESpGEVeela3gPQl1LxeLi4QNb6eglIPQyE/J+WCfqBTpw9pJRQTmoRcmangTwJM09vrPiT5pxiSG0P8AAeoZ/fvjt39K9Poor3qVKNKPLE8epUlUd5BRRRWhAEZGD0pkUaQxhIkVEHRVGAPwp9FABRRRQAUyWNJoykqK6HqrDIP4U+igAAwMDpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkXxV06C78SWcNiq21zHbmWSSEbWO5sDJHX7p/OubtL/wASaOwEcq3sQ/gmHP510fie+h0nxtqJ1lSouCrQSMcBowoGB9DnNOTVNDuAMXSDPrXgYlt1ZXR7FHSmkTeHvF9prJNjfRNaXp4MMh4b/dPeo9X+H2n6lP57xjcerDIJ+pB5rB8SW2lXEYmhvIlljOUkRsMDWevxKvbGz+zTtbzyLwJg/X6gd6yjFyehb01R2FlpOk+D7aa4j2K6rlm9Px6mud0Gxl13V7jVrgFfMPyhv4V7D/PrXMNr99r04/0S61FgcrFDGVjU+p9fxro7HRvGOpRLHLLb6LZH+EcyY/z9KtwktJaE8y3Wpr63qGjaDETc3CvL2jTlmP0rd+D9/HcnUvtEM1tf3BWYRSAAGIcKR+J5zjqKx9K8K6HoTfaXDX1+OfPuDuIPsOgqfwnfNP8AEe22nhoJUP0xn+YFa4WSjVVtTOtFypu563RRRXuHlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMmljhQvNIkaDqzkACgB9FYVz4p02JisDS3bjtbxlh+fA/WoV8UqPmm029SP8AvAK35gGsXiKSdnJGqozetjo6Kx4PEukzcfbFjb0lBT+Yq0dY0wLuOoWePXzl/wAatVIPZkOElui9RXP3vi/R7YEJcG4k7JApbP49P1rn73XNW1jMVohsbY9Spy7D/e7fh+dZVMVTpre5pDDzn0sdVq/iDT9Lby7iUvP2hiG5/wAfT8cVzVxr2s6m22zRbC3P8Rw8hH16D8B+NJpvh+KBd0nJPJJ71osij5YwFUelebWxlSS00R1woQj5s5bV9Gs7yIDVjNfkc/vpGbH054rl7vwL4bmO6OK5tz6Rykj9c16TcWyulZxsoxneOO9ciqzWzZ0csXujhIPA3hmLmZr2b2aXA/QVq2mleGrAg2mlW5cfxOC5/wDHs1W13W7G1naK2iMzr1IPFQ6Rr+nzzrFdQmEk4yTxTdSclq2UqcVqkdOmsbECQxhVHQKMYphuru5PAOK27bS7YwJNGAyN0IqWZI7aEkKOlQ9AuuhyOqgwCFZmwZm2r9etZuk3K6N4t0y9kb5BLskb0VhtJ/DOfwqPWrxrvX7SIH5YUaQ/jwP61S8QR+bbH6VcJOLUkOS5lZ9T6GorI8Iag2qeGNMvJDmSWBd5/wBoDDfqDV7UrY3mnXVqsjRNPE8YkXqpYEZH0zX0cXzK6PEas7M4WH4xeEbjWBY2lzfXMf2lbM30FlK9qJmYKE80LjqQM9OeuKmb4seFk8Troc819BcPeNp8dxNZSpbyXCtsMayEYJ3AjPT3rjPhPqPiPwT4a0zwTqHgTV5720uGh+3W3l/YZI3lLGYyk8YDE4wScdicCj4vvvE/ib4i2P8AbfgnXn8LaHfC4soLVI2+1zoSFnlZnGEHUKAc5OT2piPbfEetWPhzQr3V9XmEFhZxGWVyM4A7AdyTgAdyRWVqPjXSdJ8EJ4q1oXOm6Y0ccpW4i/eqHICgopJydw46jPOMGuT/AGlLeWb4U3kqRPPbWt1bXN3EoyXgSVS/HoOp9hms/wCNGk6349uvBmleGYLa40SS4/tS6vbhS9owRcxI+0gsr5bIBHVee4APU9A1ey1/RbLVtKmE1jeRLNDJgjKkZ5B5B9QelJrOp/2XFbyfYr6886dINtpF5hTd/GwyMIO57V86xeDvEtr8HdX8E3/h26v9U0/VsaFdWx2JGrPvWdZGOVVDvzk5wwHqRJpngjX4fAmn6fdaBdnxLB4ut73VLwsJBfIJGP2hX7oAcY6jk45oA+k/Nj87yvMTzcbtm4bseuKwvD3izT9c1nWtJgW4t9T0iVY7m2uECsAwyki4JBRh0P8AKvCtC8J63a/Gn7db+H729gm1iS6ubvVtPWNrVMn5obtZMyLjG1COnBFd9opF/wDtK6/dafzaWHh+GyvmX7v2lpvMQH3EdAHq9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV574q1y7vfEU2h2UrQwwqomKcM5IDYz2GCKyrVlRjzM0pU3Ulyo7a61SxtM/aby3iI7NIAfyrKn8W6aoItvPun7CKI4P4nArBstDsrCHzrlFz1waSTU4V/494gAO+K86ePn0SR1xwseruXpNR1vUX/clLGA9FUBn/Fj/QUySytIyHvne6nHeRy386yJdekAKqMe9Uzeyy+tck68p/E7nRGko7aG7JqECHZDEqr7ClOoKVAGM1zolYHmpoZEByTzWLbe5pypG6scMozIq0C0sB96Jc1mLdA9M0vnk9BSWgWNWC301Xz5AzWirwxj91EB9aw7bOcnrWpFkjmq52tiHFE0krP948VE0iL95gPqacVyOlc54q0r7fAAGkjdeVZGIINS7vcaS2OnhVZRtB+bt71k+IleHSrooMSBDivPrHXdV8N3Srfs9xZZxv6sv+Nel6fqFn4h08PBIr7l7dxWiimrdQd4u/Q+ddU1oWihVXzJ25Oe31rKi1+5L7pooyvtxW98R/CtxoWuvIUJsZmzDJ291PuK5aVBt4FWrGm+p9B/CXVjqnhmcMxYQybVz24zV/xTfC2tpCWCoiksfSsz4Rac2k+B45Jhte7kM/P93AA/QZ/GsTx/eNf6ha6XAfvnzZsf3QeB/n0qJatIiK1ZnaKJLiSa8lUh5jwD2XsKv36hoGBHNXrWEW8I3LgAVSvJUkJ20iz0T4RXPneDkizk208kX053f+zV2teafBucJLrVn0AeOdR9QVP/AKCK9Lr3sNLmpRZ5GIVqjCiiitzEZPDHcQyQzxpLDIpR0dQyspGCCD1BqLTrG00yyis9NtYLS0iG2OC3jEaIPQKAAPwqxRQAUUUUAFU9O0uw0z7R/Ztja2n2iUzzfZ4Vj82Q9XbAGWPcnmrlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV+LB/ZPxNhuFH7u/t1Y/76/Kf0C16pXAfGDT5JNIs9Wt1Jl06bc2OvltgN+RCn865sXDnpM3w0uWovMsXoe+CjOEJ5pDp0WzGKy9N1uCW0SRXByM4zTLrxLBCDudQfrXgO7Z6iVtEWX0gFs4p6aVjviubm8aorEKd341Vl8Z3QP7q3dh9DT5Ww1OvOkqepoGkqOhrhJfHOoDpb4+tQ/8ACf6kDjyU/E0+Vjsz0VNPAHSnLY8153H4+1DI3wRt9DWvpXjdZ51S4Ro8+tLlYrM7i3tQuKvxw4FV7C4juY1eJgc1duZ47WPc5Ga1pwVuZmM5O9kNMZ7CsvUpoo1IdgDXOeKfHEGno2ZguPTvXERTeKfFLGXT4Ra2bfduLg7QR6gdT+tU4qSuthr3dzqNaa0mjZZGTB9TXG6f4gXwhqgaOUtYTPhlHVT/AHh/WujsfA9uuH13Wru7fvHE3lJ+nJ/StKbwV4UvIHh+x8sMeYJnLD3ySf1rN8sdL3NFJvdHSTw6d4z0FoJ9kkcyBgyn8nU+tcJZfB/y9RRrzUfNs1bcUWLazD0JzxXCw65rXw+8QXOjrJ9qtIHyiPxlTyCp7ZB6ciu4tvijLc25P2W5z0IwDg1b7iSkvh2O/wBauobKyEQZI4oxzjgACvIItRuG1+TUms5ZY5yTHgZ+Udh74GcVeu77VPE8qw+U9vaE/Pu6t/8AWroLTT4RELKT5cj92w6qw6EfjWeiepaVkWNO1zTNWjCBxHJ0weKmuNCDKXhcFTzxVW30Gz1+HzJkEN8BtaSM7XDjg/Xn1pG8L+JLBSlpqCyw9hKpBH4jNdUsFNaw1RhHEw2lozU+GcLW3jS8jByv2Nt313pj+Zr1avMvhZZS2OuakNTmD6hJCpQLnGwH5uvvtr02vTwsJU6aUtzhxE1Od0FFFFdBgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyaJJonilQPG6lWVhkEHqDT6KAODb4XaH5jGG41GFCc7EmGB7DKk1csvhz4dtjuktprpvWeZj+gwK7CislQpp35UautUfUqWOnWVhGEsbSC3Qdo4wv8AKrdFFapW2Mr3GSRRyjEkauP9oA1mXXhrRLpi0+k2LsepMK5P6VrUUnFPcabWxyt18P8AwzcA50uOJj/FE7IR+RxXIa98K3jBl0C7L4/5YXB5/Bv8a9ZoyM4zzWU8PTmtUaRr1I7M8N0LUL7R7x7G+R4bmE4ZG6ipvFfiMi1keSXYoGTXafEbw9BqCw6jDe2tjf242h7hwqSr/dY9vY15toHhWfxJqD3WrXETaZBKVWKFtwnKnGc9l4/GvJrUPZSs3oejTqqpHmS1KHgnw8dauzruuofsan/RoX6P/tEen867nUdQkYFLYYUccVo3doXkSGNQkKAAKowAPSp49MjVOlc058zNIpROPVZpGzMTVq0zDICCc5rZvrRFUkDmsmaMqcrUl3OP+MukM7aZrcYypX7NMQOh5Kn+Y/AVh+DgRHIxGQXx+lew/YrfXdBn027Aw64/wP1BrzptOl8NXS2d7Fti3fu5h91/8D7VfQUX0OvswFjVsAE03xXmzsrW4jHLSBd3pVOG9Ro0KkEVu3NsmuaFLabtrkZQ+jDkGoAxLG8W8n823m+y3xwHyMpJj1Hr710UGu6vZJi5tVnjH8cLZP5H/GuDszvdopgYruI7HXuCK2rfULqH5JSJF7HvXRTxFSlpF6Gc6EJ6tHR+GtVj1TxtZSQAgiOQSAjBX5e4+uK9MrxPwlqP2bx5YSKNouGa3k9wwyP/AB4LXtlevhq3tocz3PNr0vZSsgoooroMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKyde1mLSolVV868l/1UIPLe59B71yupT6lKgbU9Wa3U8+Vb/uwPxHJ/OuatioUtHqzanQlU1PQKrXt/aWUZe7uIolH95sH8B3rzNnjHJ1W9KHrmZuf1qe2XS4cOInmc87mOa5nmCeyN/qdt2dFeeIrjUA0WjRPHH/ABXUoxgf7Kn+Z/KuI1PSdPkmZ51aWcnLSFjuY+pNdDLeyXCeXEnlxegqsNLaVtzVw1q8qj1Z1UqagtEc1/Y9gEYpZgsOjE5NS+A7trbWbmwbiKUeYi+jDr+n8q6r7AsULDHauPhj+y+MLIjqzMP/AB01he5ruei7AWzjmnMMLSxDcAaWUYBpWIuYupfdIFZEgwMVragw5rJzul9qC0O06cx3GM4Pat65t7PV7VrfUIkkRhjkVxXiHUIdIge7nbbGnJI574q74V8S22r26yQSBucfj7iqTa1E43MvxB4Uu9B3XGls1xZ/eMLHJUexpPDWtgsjKflNelwkXNnJG3JxxXzP4ekutK1trWcsrLMYpEbswOKtpNXQRbejPY/FWhm+jGqaWoF6g+ZRwJR6H3rn7a/S5t/mUrIp2srDBB9DXW+HL/cywseorA8YWsMXiWMQqFaaLc+O5B4NZrsNdjnr24a11G1uo2wYZUlB9CrA19Jg56dK+atdtykeT6V714J1D+1PCel3ZbLtAquf9tflb9Qa9TL5bxOLGx0TMj4w+KLnwZ8Ntc16wiWW7tYlEIcZAd5FjDEdwC+ce1Yfhjwj4uTT4L6b4iX91c3lk4mElpC8KSPGdkkSgDGxirY6MBg4zXoWsaZZ6zpd1puqW6XNjdRmKaF+jqeo9vqORXBaX8HdA09DENR8RXFqsMkFvbz6pI0dorqVPlLxtO1iAecV6ZwHK/D/AFfxFp/xmk8O6trety6bLYySRw67bxrJdSo+C9uYxgIAM4JBwfu9x7nXDeFPhlo3h3xB/bn2zWNW1ZYTbxXWrXrXLwxnqqZ6A/4+pruaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqjrl2ljo95cySrCI4mIdjjBxx+OcUm7K40ruxHqGu6XpzMt7f28Tr1QuC3/AHyOa5+XxqLyUw6JatL/ANNpvlUfQdT+leY6boWp36LNcn7DbH5jJKPnf3A6/nXSwvb6barb2hZsdXY5LH1ryquNqdFY9CGFgt9TUnuVspJbu6k+06jL1Y9vQAdhWQtrNfTme6dnJ6DsKdZwPdzB3ya6e2tVjQDFefKbludKSjsY0WlqxGVrUt9LTA4qe4nhtYy8jKqjuTXFa38QI4JWg09DIw43dqIq+4Nt7HeRWCoOMU8x7K8pt/HeqLIC+CnoRXX6P4qS+jHmcNTkl0Fyy6m7fOFiNcPaj7Z41gC8iFGc/wAv6102p3avCWU9qwPA0Yl1bUbo8/MsQP0GT/MVMStkehwqFjFUr6YIDViSYJH1rnNUvckgGrk1ayM4R1uVby4MrkCoF+Xr1qnLeJAC8hxXK6z4sWO4ENpvmmY4WOIbmJpRg5O0UaNqKuzR8ewpeaLcQ9WKEr/vDkfyryjwvqt3od+tzAC0TcSR5wGH+Nep6b4Z8Q64BLqM0WlWzDhWXzJiD7dB/OvM9T099K1O80+Vt7W8rRh8Y3AHg/iKtLl0HF8x7l4V8WW99GjxuCOhB4I9iKyPFvglb7WW1vSJgZJGDyW7dCw7g9u1cXoulTPZwzQO8M4HVTituOXxFEvlpfnHqVGf5VO2gcut0bmmRS6TL9u1qaO2hjGQgbJY1VjuZNe1ebUvLZIQojiU9do7n61kzaFe3++fULyWWRFLKWOQMe3Sr2k6rc6NBENStCLeRQVlQZXBHr2/GhRbTaBtJjdaQMjKRXcfA7UfM0rUNMc/NbTCVB/suOn5qfzrm7iOz1KBpra4XkZxmrHwbjki8Y6gq8xG0O70zvXH9a6MHK1VGOJV6bPaaKKK9w8kKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjPirDM/h2G5hRnS0uUnlVefkAIJ/AkGuzoPPWoqQ54uPcqEuSSkeD6v4tt7lx5RZuOAKqW+qTH941ncFB3EbEfyr32C1t4P9RBFFn+4gH8qmrg/s9dZHZ9dtoonjWmeKdPSMfvEBHUE81ZufGtgkZxKM16jdabY3Zzd2VtOfWWJW/mKhh0LSYXDw6XYRuP4lt0B/lU/2b/eH9cXY8OvbjVvFc6waRZ3U8ecFlUhPxY8D8TXZ+FPhXaW8KT+IXa4uCMm3jcrGnsSOWP5D69a9OACjAAAHYUtdFLBQhq9TKpipS0joc2/gfw28ez+yLdR6rlT+YOa5nWvhqIcz+HLlo3HP2edsqfo3UfjmvSqK2nQpzVmjKNacXdM8Iu7q6smks9Rie3u4xyj9/cHoR7itvwIVi0Hzjw0srufzx/SvQ/E/h6y8Q2Jgu12yrzFMv3oz7e3tXkxmuPC0cmk6qYoZYSxR3cKsqE5DKT1HP4d68nE4WVLVao9CjXVVWejOn1DUlRCWYBa4zxB4ntbGPLv8zfdUcsfoP61ky6rqOv3RtdAtzdyDhpiMRRfUnr/nrXUeGvAtlpkwv9alGo6kfmy4/dofYd/qfyFZKmoa1Pu6/wDALc76QOZ0zw94g8VlZrxjpelvzub/AFjj2HX+Q+tdtpOlaP4XhMemwAzkYeZ/mdvqf6DArS1DUGdSkVUbe335eQ5NTKq5Ky0XYcYJO71ZKl5NNJuyQK88u7CC88T6hJOgaUS5yf8AdFehPhWULXGarF9l8TzZ4Eyq4P6H+QqEaI2NLhVG24GBwKuXbQQ3AjJXzMBtvtUNiAShFU/F8b2uo2V7g+TIvkufQ9R/WjqBsCSKZJIhgB1K5+op2i3sEKxWGpqEkVQnPRwOMj1rmzNJAVkQ5FalvqFtdw+VeRK6ns4zW9CvKg7rUyq0VUVmbF14L0K9Jmt28hzz+6cp+g4q/wDDjToNF1zUbKEbzLCsokZtzYVsEZ9PmFYIsIRGWsb64g9FD7lH4HNafwzunbxNeQ3LiWY2x2SAYwAwyCPfI59q9CjiKNSatGzOOrSqxjq7o9PooorvOMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKparqdrpcAlu3xk4VFGWc+gHeuR1HUdS1RS8szabY9o0bDsP9phz+A/WsK2IhS33NadGVTbY63UNWsNPH+mXUUbf3Ccsfoo5rzL4jaro+tyac9xp808NpKxZpl2qVYAHAzk8hT+BpftdtAWisYlLd3Pc/WuV195WSRp2yuDwK82rjZ1FypWR3UsLGLu9Tu4BFbWkcWnwRwwAfKsahV/IUxop5jyTirXhyHOh2PmD5vJTP5CtVYlXtXBc6L2Me30zu1Nu4vKUha3cYrJ1Yhc0AmYc0uCnruqDx3o7yafb6naIXkh5YL1KnqP6/hVbUJgGXB5BrttAmS404RzDKMMfStIW2Yp3WqPN9L1KNkXDjkZFdNbm21ixezu1Dowxg1zfxJ8FanCGv/DO9lyWlgiOCfdR/SuN8GeK7qC+FtqJYOrbd7DBB9GFDgyk1LY7W88KapZN/od0JoR0WVeQPrUOngXHmRTxiKeJtrAHvXo+n3CXdmrjB4rztD5nibVSn3RLj/wAdFSncE7lqSP7Omd5x9a2vhPF53ifULkD5YrbZ+LMD/wCyGua1iYrERnpXc/Ba226Jf3bD5prjZn1CqP6sa68HG9VGOJdqbPRKKKrT39nBcx2893bxXEn3InkCs30BOTXtnklmimSyxxbfNkRNx2ruYDJ9BT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKiubiG1gaa4kWKJeSzHAFGwEtFcvc+K9+RpljNOvaWX92n4Z5P5Csi41HXboFnvI7eP+7AoH6nJrlqYynDrc3hh5y8jurm5gtY99zNHEn952Cj9a56+8Uxu3k6PC13KePMIIjX8e/4fnXJraq03mTiW7m7vIxP6mti3a4VAsUKxj2riqZhJ6RVjpjhEtZah5YgkN1fSG6v2HVui+wHYe1ZOoebdsfNc49BW2LclcyHLVXmtsngVwym5M6YpI5O5tHhJZeVrI1WJroRQjOZpFj/M4ruL23C27ZFYOlwC48S2sWMrErSn+Q/nSRpc7iwh8u3RAMADAqwy1NEmFFI+KvksjDmuyuRisHXn7Cty4lVFPNcxqk29mLHisramkTlL928zA+9niup0DUVjiVI3ilGPmWNwxH4CvMPiBd/8Sq5VXKkuqjB+9z0/LNebQbopVlt2eOVTlWRiCPoa0UOZFM+w7C6SYDacqeoNeL/G+0gt/FNnJbRLHLLCTIyjG8hsAn3p/hfxjfadHB/azPPE6gicD5l47jv/AD+tdV4lstP8XQWV8k8YlhB2yDkEHsfypp2VmSo8srk3he9+zaA81w2FRCxJ9hzXPeGg9ws90ww08jSH2yc4qtrFyGjTR7GbzskedIvRR/d/Gum0izW0sUUdcVGxZz+sxnL16l8J4/L8F25/vyyt/wCPkf0rzfWgNrnuK9Q+GIx4H03PU+Yfzkau/L/4j9Dkxn8Nep1FfLngeP4d3Vh4um+LkunjxX/ac4vf7SlK3CoCNggGd20Dps5/DFfUdZ93oek3l9He3el2M95HjZPLbo0i46YYjIr1zzT5m+Ouo6xdeL9Iv9Z0LXIodP8AEltbaYqon2eWFS5ZlO/LTSsqkAgAKgGc5z9S28hmt4pTG8RdQxjkGGXI6HHcU25tbe6EYuoIphG4kQSIG2sOjDPQ+9TUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBheJtfGkG2t4IxNf3RIijJwoAxlmPoMj61x/iXVZ4mh/tGRbm76xwRrtjjPrjufrVj4pbrPVtB1IZCK0kDH0JwR/I1yV7I9xqTXMrblI4NeRjK01Nw6Ho4alHlUjoNNinvU8y8kZ2POwHAFbMNoEXaBhfSuXsPEMMP7uFXncdREpcj8quXPiG7EDMmlal04JtJAPz21w8s5a2OltLQ6KOJEPJAqwrRdN4rx/UfEWpTzEPN9mH90gg/rVjShrN2Q1qNQuc94oWK/njFNQb6A11bPX1ERH3xTWiHbmvPp/+Els4cyaZqJHqsW/H/fOaTSfFl7Z3iW+sQTRJIcK0sbIf1HNVKDS1jYhK+zudZrHELAVieFVB8Q3j/wByFF/Mk/0rZ1KRZrYOhBVhkEVz3hmcJ4g1CM8Fo42H4bgf6VktDTod80yqnWs281BI85YVl61qYtI+T8x6CvONY8UXN1ffYdNhkvLxzgRQ84+prRc1TRGfKo6s7m/1yBA2ZBxXFax4rtXl8i2ZriZuFjhG8k+nFS2vw/1XUUEviXUhbQnn7Lbcn6E9M/8AfVdVpOlaNoMBTS7REkIw0rfM7fUn+Q4qnGnDd3fl/mNSlLZWR5D4s0nWJNN+3Xsawwo4b7PnLKDxuNc1bKhQEDmvYvFr+dYXW7BQoQRWBo/hOx81LgmTGd3lk/Lmlz3NYqxr+HdGS+0uKKdcMqAfpUF/4PuIBItncvErdQCcH613Gh2iw4AHWt2e0WROnasuawmzx/Q7mPRp2hv7ZkdeGbGR9c12FvcQXUe6zuAM/wAJNSa3pxjYXCRCRo85Ujh07qf89aqweEbXUoxPpc0lqzDcBGflP/AT/TFdNKg6yvB6roZVKypv3tihrNtOsbO+3p1B616p8M33+B9LOMYV1P1EjD+leW6p4b8QQIV8+KeId2yp/r/OvXfBFpHZeFNMhik81fK3l8YyWJY8duSa7MHRnTm+ZHNiqsJwSizcooor0jhCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKGuaTZ63pz2WoRl4WIPBwVI6EHsa5zT/h3o1q+Z3vL1c5EdxKNo/BQM/jmuyoqJUoSd5IuNSUVZMitbaC0hWG1hjhhX7qRqFUfgKlooqyBCoOMgHHrS0UUAFVdUsLTUrKS21CFJrdh8yv2989j71m6j4p0qycxeebi4H/ACytx5hz6EjgfiRXJ65c6p4hjKT50/Te8Ib5pB/tH+nT61zVsTTprXXyN6dCcnfYxdIvIBe6jpNtdfaoLZz5MvXcn174PGe+KztdM+lTrqcBChFKSH/ZNMvdOSzv0k0++8mZRtztyMehqhq9opEBvLuS9nkkVRuPyqCQOB0rw203c9VIoRHWPGNx5WmeZHbZxNfSqVVR6L6n/PFeh+HtG03wxZeRYRgzMP3s7cvIfc+ntWiFfy1SNQqgYAAxinRWZzuanKpdcq0RCjrd7lO6eafqSFrOmTygQTya3LpQq4rBvzluDWaLRi65avdaTcLENzj5seuDmqWg3iSoAD+HpXR6VKI5QXG5c8ik8TeD2Y/2jopCSHlkHRvrVpXQOSWjLlnehQoPBFdFaXKyoOea8qj1SS0k8rUEaGVezd/p61t6P4msZ3EcN3GZB1XdUtA0ddqUqW0gM4Hkvxn0NY8sFxYSfadGdWiY7mhJ4PuD2NR+MJZLjQkuIssIJFdwvPy9Cf1rL0y9dIhJbSblIyV6g1VOcoPmi9SXBSVmbz+KwYTFexvA2MHzE4/McV2PgKQy+GLZshlLy7CDkEeY2K88utRintH8yPD4rsPhKjr4ULsT5UlzK0Q9Fzjj/gQY/jXrYXFSqy5ZI4MRh4048yO0ooorvOQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqOpatY6cm68uY4z2TOWP0UcmuVv9c1DVcpaK9hZd5Cf3rj8Pu/zrCriIUl7z1NadGVTY3da8RW2nuYIVa7vT0hjPT/AHj/AA/zrnL37fqXz6vemGA/8usJ2rj0Pc/jWV9tj09zb6bDvmbkuecVYgt7qcbrlyWP6V5VbFyqeh308PGBZW5sLBAtnbruHAJFV1a41GXL5CVct9LQHLjNaMUSRLhQBXI5tmySWxgahpkSIBsHTrXG38e/XdPtk5UzocD2OT/KvQNYmWKB3fgKM1yng20bVdfl1Fl/cW+VQ+rH/AfzoRSdlc71IwAMClf5VNWRHgVDcABDmnyMy5jFvH+Via5q7l4Y1vak4CMAa5i8cYYZpWNULYXKxjfK8ccYP3pHCj8zXcaTdNsUNgcZHOQRXzj8SLiQ6pbwBz5SQhgoPGSTk/yrR+HHjW70qdbK8keXT8cA8mL3X29RV8jtzIT10PeNe8N6d4gt2iuIgrkdRwR7g18/eNvB194P1ddjs9rIcwzjg5H8J9/519CaTqUV7AkkUisCAVZTkEetc/8AGiFLnwpyu6USxmP/AHs4/kTVRldXIV1JLoZ3w41J9T0lBc4JK4PvWfrFl/YGuIluf9FuAXWPshBGQPbkVa+H9r9ht4YictjJqn4ovBe+KSifMlqgT/gR5P8ASs+pr1Garchbd8DkivYvA1p9i8H6RCRhvs6uw92G4/qTXhessfKb0xX0XZII7OBF4Cxqo/AV6WXrWTOLGvRIwPiR4qi8E+B9W8QzwmdbKMFYgcb3ZgiDPYFmGT6VyOn6n8TrLRZtb15fC8tp/Z8121raxTCW3kETPGuS2HGQAw688HvXd+MPDlh4t8M6hoWrq7WV7H5b7DhlOQVZT6ggEZyMjvXHaD4E8Xafbi1vfiLe3dnBayW9qiadFE8ZaNkR3fJMhTIIzjJUE5r1Dzznvg38S/EHjDXILPXr3wzbytbNPJpkNpd294npjzTsYeu3Ne1V5x4a+HWp2/je38U+LfFMniDUrO2e1swtjHaJCrfeJCE7icn06/THo9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVkeLb99M8OX93FxKke1D6MxCqfzIpSfKrsaV3ZGD4i8TyeZLHYTi3tIWKS3WASzDqqA8cev5VyFx4lhuHKfadRu/XdKwX8hxVPUbOW5khtslLOFBgevvToorS2ITKKfUmvBqYidR3uevCjGC2NHTJQ8oMNqqZ6nFa11b3N3hFnKL6KKr6ZfabEAv2iMv6ZraW5twNwdcfWuZstkGnaVFaISfmc9WNWjdWsLbXlRT6E1i634ns7CJh5is2OgNcppmma/4wmaextkgsieLiclUP04y34DHvVwpym7JCbSV5Ox6bDLDN/q5Fb6GnOpXr0rkl8C69ocP2zTdTjvZ0G5rTyygYeisWOT9QK1tF1+HVdPZ8GOZPlkjYYZWHUEVpUoyp/GrGcZqWsXcwfH140dn5MfLSHbiur8M6ammaTb26gZVRuPqe5/OuE1F/7T8W6fbH7glDkf7oJ/oK9DkuVgiJYgACs4tLcuabVkWppVQHJxXK65r8EBZd4OOvtWH4x8ZQ2Nux3EKchQvVz6D/ABrA0jwlfeJ4o9Q8QzSWli53RWcZwxX1Y+/+cVrZyXNJ2RGkdFqw1XxjZFvLS5DueixAuT+XFVIxruqDdp2lSxxn/ltenyh9QvU/hXcW9npWhQeXpVlDCRxuVcsfqx5P51WubyWVSxfA9BU88F8Kv6lpTe7t6Hlvjzwfcafpi6pPfC7u2cC4CrhUzwNp9O3QdRXI6crRSLKvDDkV7NryC88PanE/OLd2/EDI/UV5RpFsbi6toACS7gY/GhSbWppFWO58OaxcaKInmhlW0mwxU/w57r/hXokmoab4j0c2s8qyxNjDK2GUjkH2NUrbT7e9s/KmQYxtxiuX8Q+DnsoZLvTyZEUZaLODjvg1FxNJm3c39j4ft2itbn7XfEbUjGMj3OOlZul6c6WzzTndPKxd29SetU9At9OjlCTIYphyVYc12i20E0AFu4ND00A4vXE2wOPQV9E2xBt4iOhUH9K+e/FMEkZZeoIr3jw7cC70DTbhekttG/5qK9LLn8Rx41aRZoUUUV6Z54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWZ4m006xoN7YqwV5U+Rj0DA5XP4gVp0Umk1ZjTs7o8mj8K+K9QZYZ1t7GFeDJJIHJHsFzn8cVsab8MLCJvM1G/u7uU9QmIl/qf1r0GiuaGDpQ6XN5YmpLrY5hfAfhwLg6duPq00hP8A6FUc/gDQpBiKO6t/+uVy+PyJIrq6K29jTf2UZ+1n3Zy9j4D8O2kiyGwFxIpyGuXaX9CcfpXTqoVQqgKoGAB0FLRVRhGOkVYmUpS3YV5j8RdMl0XVY9d0+Mi2uTsvFXoH7OR79CfUD1ru9Y1u10sBJCZblx+7t4+Xb8Ow9zXJarLr2sQSJczpp1pIpUwxKGZlPYsR/LFcmLqU+Rwlub4aM1LmWx5/b362viWC7YErtYA+5FR+IvGTXEgtbJXubhzhIIfmZj746Uuo+HtOs7q3tWBmSWRI3Lkk7SwBwT0rurHTNK0GMrpdjDbkjBZV+Y/Vjya8hOK1auelK/Q5Lwx4Ok89dX8WbJbsYMFpnKQ9+R0J9vzyenWXNzJOcR5xSsJbt+c4q9HbLDHyOaU5ubuyYxUTCmhwDv5NZs4AU+lat84aVgKy542llRF6ZqTRFPWEaLwvdyBf9ayxE/7JYA/pWbo2k6fBKs9vbhZ8cNknH0r0tNGiv/D89jKP9YmPf615tbG40y/Nnfrsnj6Hs49RVWsriUr3R2FhgALWiQM7W5UjFYNpKS4IPFSeIdRezSw2YAml2MT6YJ/pUgUp9KthefYL6MNAxzbS5wV9U3dRjtTp/DGq6evmaZdefEedsnBH4jr+Vanm21/bG3vAOehNLZ3eoaM2AWvbTt/fUf1ruo1aU1yVl8zmqQqQfNTfyOC1OTU/NZb60l3dBgZH5ivfvDFi+m+HdOs5iDJDAiNtORnHOK4LUtYsNSsJyqL5iqdwxgr9R1r0bSo3i0uzjl/1iQorfUKM16GHoQp3lF3uclatKpaMlaxaooorpOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKo6lq1lpqj7XOqufuxr8zt9FHNJtRV2NJvRF6iuTuPEmo3Gf7O04RR9pLo8/wDfI/xrLuH1a8BF7qbrG3WOACMfmOf1rlqY2nDbU3hhpy30Oo1bX7Swl8hA91ef88IcEj/ePRfxrKuNT1i7jIAg02I9XDea+PbIAH5GsS3SHTxstEwxOSe5q5tlnTMrHmuCpjpz20R1Rw0Y+ZURorKRzZK0ty5y08p3Mx9STUZW/nJaaY49K1ILRV6Ci+xDbMR1xXG5tnQkkefarmXX7ODqTNGM/wDAga9H+xCRstXn+mRfbPGtsOoj3SH8Bj+ZFeoooVapRuKcrFZLdYxwKp37bIyas3t5HAp3EVy2savvVlj6VMkr6BG7M+/uNjM2ah0y7VroMwJC1iX+pJEpe5kRF9WbArzzxL4gll1SOXTbmaJIVwroxXcc5Jx6dufSqUG1cu62PpjTbxZY1kiPI6iuf+JtlF/ZUWoooWaJ0YH6sAR+RrlPhd4uTVozDdOF1GJfnXoJV/vAevqP8jpfjFcOngCee3bBVo+fT5xTimk4szatJMyrXcsCSDoata7YyaroSG3GbiBhIg9cdvyzXiGl+ItZtZ0mW/mkUHmKRsqw9MV7/wCGbtLuwtrmLiOZA4HpntUyXKaHMaXdi8tyjZWReCDwQatRXk9q23zNy+hqx40sbe0v7O7t/wB3NPJscL0YYJyffiud1O5MeMGhagak+NS17S4IUXz5Z0Qkd1yC2fbANe61438IrI6h4muNQlGUsosJ7O/H/oIb869kr2MDBxp3fU83FyTnbsFFFFdpyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2WRIY2eV1RF5LMcAfjTq4bxewvPEsFncsTZW1sLho88MzMwyfpt/Ws6tT2ceYunDnlY6SbxFo8Iy2pWp9kkDn8hmqMvi/TsEWqXNy3bbEVH5tiuFuNXh84xWNrHxxkCmSXFy8JyApPpXmSx8+iR3Rwkep0WoeJbq5JWWdLC3PVYTulP/AALt+A/GqEGrWduSLKDc7HLSNyzH1JNYNrYPLJmUkk10+m6bDEgZlGa5Klec9ZM3jSjFWSEN7cXAzg4pqmVmwavysijbGvNSWtsB88pA+tZasq6Qy0tQo3PyathBThcWwO3zFz9al2qwyhzT5GTzEQ9qy9ekCWrZ9K1awfFW77DIV/umpRSMbwBD5uoX1+w4BESn9T/Suu1TUo7WIktiuP8ADWoxab4WSRuZGkk49TuNclNf6r4x1eTTNIfy4l/4+LvnbGPQe/8AP9a1gnJtdCZ2WrNHxL4yiW5FrZo93eMcLDENxz6VVi8O+LNWw95PBpFu3OCd8mPoO/4iuu8OeHtM8K25WzTzr1x+8uZB87ew9B7D9at3DTTEsxIWqdSMNIL5v/ISjKXxOxz2k+BtC02b7RfPLqdwOd1wcrn/AHf8c1n/ABis7G78KQ3UcMcc1tMqRlVA+U5yv06H8K355CzhB1rj/ixKyaRp1mM7ZZjK3/ARgf8AoVRzylJOTLjBR0R5poZmtNUtriNnRkcEMvUV7npmvWPiHRbjSNTwGmjKyR5/8eQ9/X2ryfwvbmfVoiq58v5vx7V6Lqng8T24ubBhHNjd5ecDPqD/AAmnKWpbSOKuPAuq2t2YYUWa3J+SdTwR7jqDXr3hnTxp2j2kG/IhTBYjGT3rz2yuNYs5/s39oywTD/llcKGz9CetX72PXLuHbdahI8J6pEAgI9yOal6gy54l1JdV1qNbU77e0DDeOjOeuPoB+tYeohmTmt7TrGO3tQqqAMVla2BGoA7mhAenfBez8jwrNcEfNc3Ltn2XCj9Qa7+uZ+GsPk+CNLUjBZGf/vp2b+tdNX0FBctOK8jxqzvNs831X4v6NaaxqNhp2keItbXTXMV9daVYefBbOOqs24cjnOAcYPpV/U/iVptvr02j6XpWt67fWyRvdrpdqJFtQ4yokZmUAkc4GT7VxPhO08bfDafxDo+m+ED4hsr7UptQsb6K/ihH7zHyzB+QRgZIHPauR8Y/DPxS2v8Aiw6doV1dajrF9FfaZrNtqfkR2DEgyCRd4PyjIBCnI6VqZn07RUNjHLDZW8dzL506RqskuMb2A5bHbJ5qagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArx+bWV1G51LUZmIFy2yH/AGYlOF/Pr9TXsFcpL4B8PyyszW0wRjny1uHVB9ADwK5sVSnVSUWb0KkabbkebWd9ZWe5mbcxpx8TWu/BTivUrbwZ4dtgNmj2j47yp5h/8ezV9ND0lF2ppdiq+gt0H9K41lz6s6XjI9EeY2GvWLEYwK3LXUrSYcTKPxrqrnwtoNypE2jWBz3ECqfzAzWFe/DbRZcmykvbFv8ApjMWX8n3fpipll0lsxrFwe6K11qVjaxF2lQke9chqviaS7YpA+yP24ron+FYkf8Aea7cGP0EC7vzzj9K6HRfAOg6UyyfZmvJl6SXbeZj3C8KPyqYYCp10G8VTW2p5Vbx6pf86Zb3t0QeXhjLKP8AgXT9a6PRNavtOuksdbt57WZhlRMm3cPUHofwr10AAYHAHaszxFotrrumPaXowPvRyD70Tjoyn1H/ANat5ZeuXR6mSxl3qtDHV1kUMpBBqpqduLi1kQ9wa4jT/ET6NfzWN7MtwkTFRcQKzxye4IH6VZ1PVtW1cBLCJ7KzPWWQfvH+gPQfWvLcWnqdqRyd1a6rdXkuiaYYgpYu07tjyVPXHrnn/PNd1omn23h/S0sNPTHd3/idu7GsjSdGubO9WcMx3cuzNlm+prsIrbgEjrTc3bl6A0r3K9tbNIdz81V1aYRLsWt118qE/SuQ1OTfcNk8VNhrUbpUZnustzzWT8RLVG1fToJkDR+U5we/IrofDy4uVz65qL4qWLg2GpxKWjhBSTHZTjn8x+tVFXVw5rSSKfhzQbO3iV4YkUnnitDULt7PWILZuIpIyR9Qaz/DeqxKEV2GK0PGtsZ7G31G2Uu1s25gvUoev+NT1H1G+IdMt9T0mctGGkVCyMOoYDPFYEMeoWEMdxYk3dm6hvLPLqCP/Hh+tbXh/U43XaWBRhVuwlTR702twgNrKSYH7YPJX6j+VdOGjCbcJ9djGtKcFzR6GLY6nZXfGRC56q3rWJ4nQRscMCMEgg5r0PVvC9hq8fnRKBJjh0OGH4/41z3h3wqi+MLO21C4ae3BMixlcElRkBj3HHpzW8sBOMvd1REcXBq70Z61oVv9l0TT7fbtMVvGhHoQoFXqKK9ZKysea3fUKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqN5q+nWT7Lu/tYX/uvKoP5ZpNpbjSb2L1FZseu6TIpZNUsiB1/fr/AI1TuvFuiQZAvo5m/uwAyfy4qXUgtWxqEnsjeorjZ/GFxcErpWmSNnpJOdo/75H+Iqo7+ILzJub1oEP8EICAfiOf1rnnjacdtTaOGm99DuLm4htozJcSxxIOrOwUfrXIa1f3HiB2s7B2g0sD99ccqZf9lf8AZ9T3+nWG30i0RhLch7mf+9KxY/rT9T8ySPy4vkjHZa46uOc1ZaI6KeHUXfc53WNW0/SI1gsLZJpU4BI6VhpearqcoLMUXsqityLQEmufMkHHvXRWenwW6jYgFcLmdSSRlaNaXkZUykkf7VdHGgOPakAAHFSxVMdWKT0KmqHZCfpXC6g2HJPc13OrLmI159rkm2QxqCzsQFUdSScAVT1dhw2NnQ5AJkOetdg0Ud3bNbzqHjcYwa4690vUfDdvHeapFELRcb57dy4iJ4+cEA4yeoyPpW9pGqRTrE6OrxnoynINU4SpytJWJbU1eLPAvH327QfFd3p1rcyRwRENFj+6RnH4dK7T4TeKbrUbh9L1H94du5X9R71mfF/Srq68dGW3geVZbdCNo9CRWv4G0I+FrSfW9Z2xOEwidwP8TRK1rGi1V2XvFFhHo2pQSWbbVuHIaIdjgnI9K2dMuIdRsjZaguQfut3B7EVytlNc67qzaheggdI07IvpW7Ogiw0fBFQM0BPe6E2LhzJa9FuB2/3h2+tbPhBTqPiR70cxW0J+YdCz9P0B/SuaOtSR2kkc6blx1au4+GVqYPCkMpXZ9qke4VfRScL+YAP416uCxE5vkl06nnYmjGC5kdXRRRXonGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNdlRGZyFVRkknAAp1cR4/1QSXEGjI+1GX7RdkHnywflX8SD+A96zq1FSi5MunB1JKKNoeK9KdiIZZpgON0cDsv54xSnxNZ9obw/8AbE15rd+LZh+40u3REXjeRT9N1PWZnDPKPpivNeOn/X/Dnb9Uieit4otAcfZ73/v1/wDXpH8Twbcx2d659NgH8zWTY3U4iBuWXP0pZtUgHDOoqXj59H+ALCx7fiLfalq+qKYoQNOtzwxVt0jD69vw/OqdtoVnAuBGGbqWPU1YGp2x6SL+dTx3McgyrCuOpWnUd5M6IwUFaKIBo1i5HmRRn6rVuKysbf8A1cCE/Sk81PWkNzEgyzCpUrA02WPMwMIoUewppJPU1X/tS1U4yKkTULV/4hTa5t2LboPprLuGKmXy5RmNhTGUqealxaGncjCAYxT6KKkYVJFUdKGC96cXZiauht6u6MivN/E6fZr1JuyMsn/fJB/pXf319FChLsBXAayZNe1OPT7FDJPKdoUc4B4LH0A65q43ctClotT2TXLIalot/ZkAi4geMfUqQK+b9GtdThj+0aPcSQydXj6qT7jpX06i7VVR2GK8X1Oybwt4snhmH+h3TtNA3YqxyV+qk4+mDXqZhBuKkjiwc7NxMyHxVqaBF1HR1uJo/uyKOh9een51laneanr16j6ghitkOViB4z6mvQ7i0SSLzYQCpGciuevbcyEjbjFeUmegiTToo4bdRHii7bcOKrwBofcVFfyu0ccUBxPcTR28fGfmdwo/nn8KaV3ZCbtqZt6ZtSvYNNtiTcXMixKo5IBIBOPQDkmvoa2hS2t4oIV2xxIEUegAwKyvDnhvTPD0DJp1viV/9bcSHdLKf9pjyfp0HYCtO8uoLK2kuLuaOCCMZeSRgqqPcmvbw2H9ind6s8uvW9q1bYmrxiz1Dxb8QPHXi600jxS/hvStAuVsoYrezinknlwSZHLj7uRwo4I9MZPdW3jzS77WrfTNNgvryaZseYkOxFA5LEuVOB6gGszxD8K9J1XxHd65Y6tr+g6heoqXj6Pe/ZxdbRgFwVPIHcYP4810RkpbMwcXHc5H4zX3jLwh4XtdUtfHMqajIlvYw6db6Tbv9tvCAGZSwLAMdzY7YwO1eteF4tTg8N6ZH4guFudXW2jF5MqqoeXaN5AUAYznoBWHP8PdHuNW8L31zJez/wDCOQiKwglm3RghQokcEZZ8BeSeqg12FUIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxTxFcH/hKtdS4bbcPNs5P8GBt/TFe11ka74b0nXQp1OyjmkUYWQEq4HoGGD+Fc+JoutGyZvQqqlK7PMtK0y2RFLEe+a1bm+sdPi/dshb61rP8NtNz+41DU4l/u+arAfmuafD8N9GVgbme/ufaSbaP/HQK836hVbOz61TPPNQ129upWWKQQxDvms6OC8vJMWwu7x/SGJn/AJCvcdO8L6JpxBtNMtlcdHZN7f8AfTZNbPQcVvDL/wCZmbxv8qPC7Xw74jdcx6Ve/wDA2RP0ZhVv7Nr2nR5utPv0A6lY/MA/Fc17TRWjy+n3ZH1yfY8LbxPKh2lgW9DwfyqtPq9zcAsHYD2r3O/06y1CPZfWkFwvpLGG/nXPXXgHQpiTDBLaMe8EpA/I5H6VjLL5L4WaRxkeqPHpJ7qVvllYU1ptRQZ81uK9HvvhnhWbTtWlWTstxGrA+2VwawJvC3ia0JEunR3KD+O2lVgfwOD+lYTwtWPQ3jiKcupk6J4ou7WcR3DFhXommatFfwKQw3VyFt4Q1m+cbdM+z54L3DqoH4Ak/pWy/gLV9PtxNp+oQXNwBloGjMYPsrZP6/pUrDVZK6QpVqd9WdJQTiuJtvEVxZXrWmpxSQTx/ejkGCPf3HuOKl1TxZAsJNud7dOPX0rmcWnZmiVzpL7UIbSMtI4GK5W41vUdXuDa6DbTXMnQmNflX6seB+JrX8PeDbrV3W/8TF44DzHZA4Yj/bPb/dHPr6V6LbW8NrAkNtEkUKDCoihQB7AV30MA5Lmnoc1TFRhpHU8/0jwHe3TLN4i1BgOv2e2b9Gcj+QH1rttJ0fT9IiMem2kUAb7xUZZvqx5P4mr9FenToQp/CjinVnP4mFZfiLQ7LX9PNpfx5Gd0ci8PG395T61qUVo0mrMhNp3R5Bvv/CF6LDWlMtk5xBdhfkceh9G9vyrVuYIbqHzbYqwIzxXol7awXtrJbXcKTQSDa8bjIIrzTV/CWp+HZWuvDzSXun9WtGOZIx/s/wB4e3X615OIwTj71PY9CjiVLSWjOe1oTWlhPJGQsgACsRkAkgZx+Nel6L4I0fTJobh4pL29iO5bi6beQ3qq8Kp9wBXJeDYLLxlqV698szW1isP+jbiitIS5O8Dk42rwTj1BrsfHmv8A/CP6F50TKt3cSpbW+4ZG9j1x3woZvwrbB0lCDqTM8TUcpKnEj8Y+K/8AhHp7K3hs/tlzdLI6oZfLCqm3JJwe7DtXn/inxLqev2kVve21tZWkcgmaOGZpTIV+6CSq8A89OoFMvFury5+36jeSXt15YiDsqKFTJOAFAHU+596w9UMswW2twWnnYRRr6sxwP51z1sXKo3GGxvSw8YJOW56N8JdGSLT5damGbi8JSIn+CIHH6kZ/AV30jrHGzyMqooLMzHAA7kmsmS407wn4bia+uI7axsoVQu564GOO5J9Bya+cPid8T73xZI9lp/mWeig/6vOHn93x2/2enrmuypXhhKai9+x15TkmJzqs3DSC3k9l5Lu/L7z6nor56Hx4vIbC3gtdFh82KJUaWacsGIXBO0AY59zWafit4+1piNItkUk4xZWJlI/763VLzGj0u/kdkODMyd3UUYLu5L9Ln0vRXzv4dh+Kmoa/pt1ejV/skVxFJMksgt0ZAwLBkJXIxnjFfRFdFCv7ZN8rXqeTmmWLLpRh7WM29+V3t6hRRRW55QUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXiHw/p2v2oh1KAPt+5Ip2un+63b6dKyPDXgTSdBuftKGa7uFOY3uCD5f+6AAM+/WusoqHTi5czWpaqSS5U9AoooqyAooooAKKKKACiiigCCG0t4biaeGCOOafHmuqgF8Zxn161n+J9AsvEWmm0vk5U74pV+9E+MBl/M/UVr0UnFNWY02ndHhGqRap4TufsurxGS2Y4iuUHyOPr2Psa1/hxp/9t+Jf7SKf6HYfMCejSkcD8Bz+Vet3NvDdQNDdRRzQuMMkihlP1BptlZ21hbiCyt4beEciOJAqj8BXFHBRjU509Dqli3KHLbUz/EnhzSfEtktrrdml1Ep3LklWQ+oYEEV5D4n+A6kPL4a1Ig9Rb3gz+TqP5j8a91orerhqVb41qdWX53jsu0w9Rpdnqvuf6HB/DDwfBo/hWyi1jRbCLWImdZZfKjd3+dtrbxkn5SO/wCVd2oCgAAADgAUtFaU6apxUY9DjxeLqYutKtVesm35K/a/QKKKKs5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39552=[""].join("\n");
var outline_f38_40_39552=null;
var title_f38_40_39553="Silver nitrate cautery of anterior epistaxis";
var content_f38_40_39553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silver nitrate cautery of anterior epistaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Kesselbach's plexus is hyperemic with a slight suggestion of oozing. Note that the area for cauterization is dry.",
"    <br>",
"     (B) Successful cauterization of the area which now has a white eschar.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Glenn Isaacson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39553=[""].join("\n");
var outline_f38_40_39553=null;
var title_f38_40_39554="Patient information: Lowering the risk of having another stroke (The Basics)";
var content_f38_40_39554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/56/40835\">",
"         Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/37/36435\">",
"         Patient information: Medicines after an ischemic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/54/40803\">",
"         Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/53/19286\">",
"         Patient information: Ischemic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lowering the risk of having another stroke (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lowering-the-risk-of-having-another-stroke-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13589279\">",
"      <span class=\"h1\">",
"       How can I keep from having another stroke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had an ischemic stroke&mdash;a stroke caused by a blocked artery in the brain&mdash;there are many things you can do to lower the chances of having another stroke.",
"     </p>",
"     <p>",
"      If you had a transient ischemic attack, sometimes called a &ldquo;mini-stroke&rdquo; or TIA, you can also lower the chances that you will have a full-blown stroke.",
"     </p>",
"     <p>",
"      To lower your risk of stroke, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lower your blood pressure, if it is high",
"       </li>",
"       <li>",
"        Keep your blood sugar as close to normal as possible, if you have diabetes",
"       </li>",
"       <li>",
"        Lower your cholesterol, if it is high",
"       </li>",
"       <li>",
"        Stop smoking, if you smoke",
"       </li>",
"       <li>",
"        Do something active for at least 30 minutes a day on most days of the week",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight",
"       </li>",
"       <li>",
"        Eat a diet rich in fruits, vegetables, and low-fat dairy products, and low in meats, sweets, and refined grains (such as white bread or white rice)",
"       </li>",
"       <li>",
"        Eat less salt (sodium)",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        If you are a woman, do not drink more than 1 drink a day",
"       </li>",
"       <li>",
"        If you are a man, do not drink more than 2 drinks a day",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Medicines and lifestyle changes work together to give the most benefit. It&rsquo;s very important that you take all the medicines your doctor prescribes. It&rsquo;s just as important to make the lifestyle changes your doctor recommends.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13589294\">",
"      <span class=\"h1\">",
"       Take your medicines every day",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had a stroke or TIA, your doctor or nurse will prescribe medicines to lower your risk of having another stroke. Some of these medicines work by &ldquo;lowering your risk factors.&rdquo; That means that they help lower blood pressure, blood sugar and cholesterol. Other medicines help by keeping blood clots from forming, which is what causes many strokes.",
"     </p>",
"     <p>",
"      Whatever medicines your doctor prescribes, make sure you take them every day as directed. If you cannot afford your medicines or if they cause side effects, talk to your doctor or nurse. There are often ways to deal with these problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13589309\">",
"      <span class=\"h1\">",
"       Lifestyle changes",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lifestyle changes can do a lot to lower your risk of stroke. That&rsquo;s partly because the right lifestyle choices can help control risk factors such as blood pressure, blood sugar, and cholesterol. To reduce your risk of stroke, make these lifestyle changes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stop smoking, if you smoke (this is discussed in more detail below)",
"       </li>",
"       <li>",
"        Do something active for at least 30 minutes a day on most days of the week",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight",
"       </li>",
"       <li>",
"        Eat a diet rich in fruits, vegetables, and low-fat dairy products, and low in meats, sweets, and refined grains (such as white bread or white rice)",
"       </li>",
"       <li>",
"        Eat less salt (sodium)",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        If you are a woman, do not drink more than 1 drink a day",
"       </li>",
"       <li>",
"        If you are a man, do not drink more than 2 drinks a day",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13589324\">",
"      <span class=\"h1\">",
"       Stop smoking",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you smoke, ask your doctor or nurse about how to quit. There are strategies and medicines that can improve your chances of success. Studies show that people are most successful at quitting if they take medicines to help them quit and work with a counselor. You might also have a better chance at success if you combine nicotine replacement with one of the prescription medicines that help people quit.",
"     </p>",
"     <p>",
"      You can also get help from a free phone line (1-800-QUIT-NOW) or online at",
"      <a class=\"external\" href=\"file://www.smokefree.gov/\">",
"       www.smokefree.gov",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13589339\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=see_link\">",
"       Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=see_link\">",
"       Patient information: Medicines after an ischemic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       Patient information: Ischemic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"       Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/40/39554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16544 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39554=[""].join("\n");
var outline_f38_40_39554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589279\">",
"      How can I keep from having another stroke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589294\">",
"      Take your medicines every day",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589309\">",
"      Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589324\">",
"      Stop smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13589339\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=related_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39555="Oculocephalic and caloric responses";
var content_f38_40_39555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Oculocephalic and caloric response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oculocephalic (doll's eyes) response: This test should not be performed if a cervical spine injury is suspected. Observe the motion of the eyes while passively moving the head. In a comatose patient, conjugate movement of the eyes in the direction opposite to the head movement is expected. An absent or asymmetric response in an unconscious patient implies brain stem dysfunction. Caloric response: After visually checking that the tympanic membrane is intact, ice cold water is used to irrigate the ear canal and should produce a slow conjugate deviation toward the irrigated side. An absent or asymmetric response indicates brain stem dysfunction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bateman, DE. Neurologic assessment of coma. J Neurol Neurosurg Psychiatry 2001; 71 Suppl 1:13.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39555=[""].join("\n");
var outline_f38_40_39555=null;
var title_f38_40_39556="Pseudopapill neoplasm gross";
var content_f38_40_39556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross image of pseudopapillary neoplasm of the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corresponding gross image of the solid pseudopapillary neoplasm depicted in Radiograph 5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39556=[""].join("\n");
var outline_f38_40_39556=null;
var title_f38_40_39557="Seborrheic keratosis 2";
var content_f38_40_39557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion has a warty, tortoise shell-like, \"stuck on\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39557=[""].join("\n");
var outline_f38_40_39557=null;
var title_f38_40_39558="Tiagabine: Pediatric drug information";
var content_f38_40_39558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tiagabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"    see \"Tiagabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/29/20949?source=see_link\">",
"    see \"Tiagabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gabitril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"      see \"Tiagabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Doses were determined in patients receiving enzyme-inducing AEDs; use of these doses in patients",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AEDs may result in serum concentrations more than twice those of patients receiving enzyme-inducing AEDS;",
"     <b>",
"      lower doses are required in patients not receiving enzyme-inducing agents;",
"     </b>",
"     a slower titration may also be necessary in these patients. Consider tiagabine dosage adjustment if enzyme-inducing agent is added, discontinued, or dose is changed. Do",
"     <b>",
"      not",
"     </b>",
"     use loading doses of tiagabine in any patient; do",
"     <b>",
"      not",
"     </b>",
"     use a rapid dosage escalation or increase the dose in large increments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: Only limited preliminary information is available; dosing guidelines are not established (Adkins, 1998; Pellock, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 12-18 years: Initial: 4 mg once daily for 1 week, then 8 mg/day given in 2 divided doses for 1 week, then increase weekly by 4-8 mg/day; administer in 2-4 divided doses per day; titrate dose to response; maximum dose: 32 mg/day (doses &gt;32 mg/day have been used in select adolescent patients for short periods of time)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 4 mg once daily for 1 week, then increase weekly by 4-8 mg/day; administer in 2-4 divided doses per day; titrate dose to response; usual maintenance: 32-56 mg/day in 2-4 divided doses; maximum dose: 56 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Twice daily dosing may not be well tolerated and dosing 3 times/day is the currently favored dosing frequency (Kalviainen, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     None needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Reduced doses and longer dosing intervals may be required",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gabitril&reg;: 2 mg, 4 mg, 12 mg, 16 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10913264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229203.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229203.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food (to avoid rapid increase in plasma concentrations and adverse CNS effects)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from moisture and light; store at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of partial seizures (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TiaGABine may be confused with tiZANidine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension, palpitation, peripheral edema, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, ataxia, chills, concentration decreased, confusion, confusion, depersonalization, depression, difficulty with memory, dizziness, euphoria, hallucination, hostility, insomnia, malaise, migraine, nervousness, paranoid reaction, personality disorder, somnolence, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, dry skin, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, gingivitis, increased appetite, mouth ulceration, nausea, stomatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthralgia, dysarthria, hyper-/hypokinesia, hyper-/hypotonia, myasthenia, myalgia, myoclonus, neck pain, paresthesia, reflexes decreased, stupor, tremor, twitching, vertigo, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, amblyopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain, hearing impairment, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, cyst, diaphoresis, flu-like syndrome, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abortion, abscess, anemia, angina, apnea, asthma, blepharitis, blindness, cellulitis, cerebral ischemia, cholelithiasis, CNS neoplasm, coma, deafness, dehydration, dysphagia, dystonia, electrocardiogram abnormal, encephalopathy, hemorrhage, erythrocytes abnormal, fecal incontinence, herpes simplex/zoster, glossitis, goiter, hematuria, hemoptysis, hepatomegaly, hypercholesteremia, hyper-/hypoglycemia, hyperlipemia, hypokalemia, hyponatremia, hypotension, hypothyroidism, impotence, kidney failure, leukopenia, liver function tests abnormal, MI, neoplasm, peripheral vascular disorder, paralysis, photophobia, psychosis, petechia, photosensitivity, seizure (when used for unlabeled uses), sepsis, spasm, suicide attempt, thrombocytopenia, thrombophlebitis, urinary retention, urinary urgency, urticaria, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tiagabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment. Possible long-term ophthalmologic effects exist (more studies are needed). Use with caution with alcohol or other CNS depressants. Safety and effectiveness have not been established in children &lt;12 years of age or for any indication other than as adjunctive therapy for partial seizures.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Current tiagabine dosing recommendations are based on studies in which most patients also received enzyme-inducing AEDs. Use of recommended tiagabine doses in patients",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AEDs may result in serum concentrations more than twice that of patients receiving enzyme-inducing AEDs. Use with caution and decrease the dose in patients who are",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AEDs; a slower titration of the drug may also be required in these patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     New-onset seizures and status epilepticus have been reported with tiagabine use (for unlabeled indications) in patients without epilepsy. Higher doses may be a risk factor, but seizures have occurred in patients taking doses as low as 4 mg/day. Seizures have also occurred shortly after a dosage increase. In most cases, patients were also receiving concomitant medications that are thought to lower the seizure threshold (eg, antidepressants, antipsychotics, stimulants, narcotics). Discontinue tiagabine and evaluate patients for an underlying seizure disorder in nonepileptic patients who develop seizures while receiving tiagabine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used to treat epilepsy, do not abruptly discontinue therapy; withdraw gradually to lessen chance for increased seizure frequency (unless a more rapid withdrawal is required due to safety concerns). Cognitive and neuropsychiatric adverse effects may occur. Exacerbation of EEG abnormalities associated with CNS adverse events (cognitive and neuropsychiatric) may occur in patients with an EEG history of spike and wave discharges and may require dosage adjustment. Nonconvulsant status epilepticus has also been reported and may respond to dosage reduction or discontinuation. Seizures and status epilepticus may also occur with tiagabine overdose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7793146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Patients exposed to tiagabine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, duration, and severity; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not established",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism unknown; thought to potentiate the action of GABA (an inhibitory neurotransmitter) by selectively binding to the GABA uptake carrier and blocking GABA uptake into presynaptic neurons. This allows more GABA to be available at its site of action to bind to postsynaptic neuronal receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and nearly complete (&gt;95%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Mean V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-10 years: 2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.3-1.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     values are more similar between children and adults when expressed as L/m",
"     <sup>",
"      2",
"     </sup>",
"     (Gustavson, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%, mainly to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via oxidation and glucuronidation; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diurnal effect: Trough concentrations and AUC are lower in the evening versus morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-10 years: Mean: 5.7 hours (range: 2-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-10 years receiving enzyme-inducing AEDs: Mean: 3.2 hours (range: 2-7.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults (normal volunteers): 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adult patients receiving enzyme-inducing AEDs: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Fasting state: &sim;45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;2% excreted unchanged in urine; 25% excreted in urine and 63% excreted in feces as metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-10 years: 4.2 &plusmn; 1.6 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-10 years receiving enzyme-inducing AEDs: 8.6 &plusmn; 3.3 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults (normal volunteers): 109 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult patients: 1.9 &plusmn; 0.5 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult patients receiving enzyme-inducing AEDs: 6.3 &plusmn; 3.5 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Clearance values are more similar between children and adults when expressed as mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     (Gustavson, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic impairment: Clearance of unbound drug is decreased by 60%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/29/20949?source=see_link\">",
"      see \"Tiagabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. If a dose is missed, do not increase or double the next dose; if multiple doses are missed, contact your healthcare provider for possible retitration of the dose as clinically needed. Do not discontinue abruptly (an increase in seizure activity may result). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Population pharmacokinetic analysis suggests that tiagabine may be administered at similar doses without adjustment for age, gender, or body weight in epilepsy patients &ge;11 years of age (Samara, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11459924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL tiagabine hydrochloride oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush ten 12 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Store in amber plastic prescription bottles; stable for 70 days at room temperature or 91 days refrigerated (preferred).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL oral suspension may be made with tablets and a 6:1 mixture of simple syrup, NF and methylcellulose 1%. Crush ten 12 mg tablets in a mortar and reduce to a fine powder. Add 17 mL of methylcellulose 1% gel and mix to a uniform paste; mix while adding simple syrup, NF in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a graduated cylinder, rinse mortar with syrup, and add quantity of syrup sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Store in amber plastic prescription bottles; stable for 42 days at room temperature or 91 days refrigerated (preferred).",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adkins JC and Noble S, &ldquo;Tiagabine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Management of Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 55(3):437-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/9530548/pubmed\" id=\"9530548\" target=\"_blank\">",
"        9530548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gustavson LE, Boellner SW, Granneman GR, et al, &ldquo;A Single-Dose Study to Define Tiagabine Pharmacokinetics in Pediatric Patients With Complex Partial Seizures,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(4):1032-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/9109895/pubmed\" id=\"9109895\" target=\"_blank\">",
"        9109895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalviainen R, Brodie MJ, Duncan J, et al, &ldquo;A Double-Blind, Placebo-Controlled Trial of Tiagabine Given Three-Times Daily as Add-On Therapy for Refractory Partial Seizures. Northern European Tiagabine Study Group,&rdquo;",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 1998, 30(1):31-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/9551842 /pubmed\" id=\"9551842 \" target=\"_blank\">",
"        9551842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leach JP and Brodie MJ, &ldquo;Tiagabine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 351(9097):203-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/9449883/pubmed\" id=\"9449883\" target=\"_blank\">",
"        9449883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(5 Pt 1):1106-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/10545555/pubmed\" id=\"10545555\" target=\"_blank\">",
"        10545555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samara EE, Gustavson LE, El-Shourbagy T, et al, &ldquo;Population Analysis of the Pharmacokinetics of Tiagabine in Patients With Epilepsy,&rdquo;",
"      <i>",
"       Epilespy",
"      </i>",
"      , 1998, 39(8):868-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/40/39558/abstract-text/9701378/pubmed\" id=\"9701378\" target=\"_blank\">",
"        9701378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12841 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39558=[""].join("\n");
var outline_f38_40_39558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227535\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055711\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055704\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227513\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227499\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913264\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055716\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055707\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055715\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227567\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055719\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055703\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055702\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227556\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055722\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227509\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7793146\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055710\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055714\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055701\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055718\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055709\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055720\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11459924\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=related_link\">",
"      Tiagabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/29/20949?source=related_link\">",
"      Tiagabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39559="Candida infections of the central nervous system";
var content_f38_40_39559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candida infections of the central nervous system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39559/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/40/39559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida infections of the central nervous system (CNS) most often involve the meninges. However, intracranial abscesses can occur either as an isolated phenomenon or associated with meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/1\">",
"     1",
"    </a>",
"    ]. The abscesses are usually small microabscesses, multiple, and associated with disseminated infection in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candida meningitis can occur as a manifestation of disseminated candidiasis, which most often occurs in premature neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], in the presence of ventricular drainage devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], and as isolated chronic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. In addition to hematogenous spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3,4,11\">",
"     3,4,11",
"    </a>",
"    ], Candida can enter the CNS at the time of craniotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5\">",
"     5",
"    </a>",
"    ] or through a ventricular shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of Candida meningitis will be reviewed here. An overview of Candida infections is presented separately. Candidemia and invasive candidiasis also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=see_link\">",
"     \"Clinical features and diagnosis of candidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with Candida infections at most other sites, patients who develop central nervous system (CNS) infections are usually immunosuppressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to occurring in premature neonates and after neurosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3-8\">",
"     3-8",
"    </a>",
"    ], the risk is also in increased HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/10\">",
"     10",
"    </a>",
"    ] and in those with leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of candidemia in children\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833985779\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida central nervous system (CNS) infections are almost always due to C. albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] but can occur with other species, such as C. parapsilosis and C. tropicalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. C. glabrata is a rare cause of CNS infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833985676\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of Candida meningitis are often the same as in patients with acute bacterial meningitis (eg, fever, stiff neck, altered mental status, headache). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever may be the only manifestation in patients who are neutropenic, whereas signs of sepsis and multiorgan failure often predominate in neonates. Patients with multiple cerebral microabscesses can develop a diffuse encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, among patients with hematogenous seeding, other signs of dissemination may be seen, such as endophthalmitis, endocarditis, skin lesions, and renal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Premature neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features of Candida meningitis in premature neonates were evaluated in a ten-year review of 106 patients with systemic candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis developed in 23 patients (22 percent) and was present in 0.4 percent of admissions to the neonatal intensive care unit.",
"     </li>",
"     <li>",
"      The median gestational age was 26 weeks and the median age at onset of clinical disease was eight days.",
"     </li>",
"     <li>",
"      The children were severely ill with respiratory decompensation, acidosis, and hypotension. A few patients had other signs of disseminated infection such as an intracardiac vegetations, endophthalmitis, and hypoechogenic hepatic lesions on ultrasonography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of Candida meningitis in neonates are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Central nervous system infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CNS shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage device infection usually occurs within several months of the surgical procedure and probably results from implantation during the procedure rather than hematogenous seeding of the device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In a study that included three patients with neurosurgery-related Candida meningitis and reviewed 15 others that were previously reported, most had received antibiotics and nine had a recent history of bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another report evaluated 24 patients with Candida shunt infections, all but one with a ventriculoperitoneal shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/6\">",
"     6",
"    </a>",
"    ]. The major predisposing factors were recent bacterial meningitis, neurosurgery other than shunt placement, and abdominal complications, such as intestinal perforation.",
"   </p>",
"   <p>",
"    The symptoms and signs associated with Candida ventricular drainage device infections are similar to those seen with the more common bacterial infections of these devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In addition to fever, shunt malfunction can result in manifestations of increased intracranial pressure, such as headache, nausea, vomiting, and mental status changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among children, the CNS shunt is typically implanted in premature babies because of hydrocephalus. In a series of 48 CNS shunt infections in children, eight (17 percent) were due to Candida spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/7\">",
"     7",
"    </a>",
"    ]. The onset of infection ranged from one month to one year after shunt insertion. The clinical manifestations were subtle and slowly progressive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic Candida meningitis occurs uncommonly, and clinically resembles meningitis caused by tuberculosis or cryptococcosis. In a review of 18 cases, headache, fever, and nuchal rigidity were the most common findings, but vomiting, confusion, visual disturbances, and cranial nerve palsies also were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9\">",
"     9",
"    </a>",
"    ]. Five of the patients (28 percent) had no underlying illness or risk factor for candidiasis.",
"   </p>",
"   <p>",
"    In a review of 14 HIV-infected patients (median CD4 cell count",
"    <span class=\"nowrap\">",
"     135/microL)",
"    </span>",
"    with Candida meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/10\">",
"     10",
"    </a>",
"    ], the major clinical features were headache and fever in the absence of focal neurologic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible presence of central nervous system (CNS) Candida infection should be suspected in patients with neurologic symptoms who have one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of Candida from the cerebrospinal fluid (CSF).",
"     </li>",
"     <li>",
"      Isolation of Candida from another normally sterile site in patients who have pleocytosis on CSF analysis. Finding Candida species in blood cultures is helpful, but candidemia may not be documented in patients with Candida meningitis.",
"     </li>",
"     <li>",
"      Lack of adequate response of presumed bacterial or mycobacterial meningitis to appropriate therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CSF analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture to obtain CSF for culture and analysis is essential for establishing the diagnosis. The overall rate of culture positivity is approximately 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ]. A positive CSF culture should not be considered a contaminant, particularly in immunocompromised patients; this is true even if other pathogens are identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of neonatal infection, Candida was isolated from the CSF in 17 of 23 patients (74 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3\">",
"     3",
"    </a>",
"    ]. The initial CSF analysis was not always helpful. Twelve patients had a normal CSF white cell count. The mean CSF glucose concentration was 95",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    with only five patients having a glucose concentration below 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the mean CSF protein concentration was 214",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The Gram stain was negative for yeast in all patients, and eight of the neonates had sterile blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CSF findings are also variable in patients with neurosurgery-related Candida meningitis. Some have a neutrophilic pleocytosis similar to that seen in bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5\">",
"     5",
"    </a>",
"    ], whereas others have a lymphocytic predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is more difficult in patients with chronic meningitis because the organism is present in low numbers and the yield of standard cultures of CSF is poor. In the above review of 18 cases, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF analysis showed a mononuclear or neutrophilic pleocytosis, an elevated protein concentration, and reduced glucose concentration.",
"     </li>",
"     <li>",
"      The CSF smear was positive in only three patients.",
"     </li>",
"     <li>",
"      The initial cultures were positive in eight patients. Use of special techniques resulted in the growth of Candida species in four patients, but the cultures remained negative in three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with chronic Candida meningitis, large volume (10 to 20 mL) spinal taps are often required to obtain sufficient CSF for culture. The microbiology laboratory should be asked to culture the entire sample or to filter the sample through a Millipore filter and culture the filter on appropriate media. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4424?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the patient with chronic meningitis\", section on 'CSF examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the utility of neuroimaging in Candida meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"     2",
"    </a>",
"    ]. Computed tomography (CT) can detect hydrocephalus, which is particularly common in patients with infected CNS shunts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the CT scan is often normal and may not detect microabscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2,11,13\">",
"     2,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, magnetic resonance imaging (MRI) can detect microabscesses, which appear as multiple, small enhanced ring lesions, sometimes with a hemorrhagic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/14\">",
"     14",
"    </a>",
"    ]. When such lesions are seen, MRI is also used to monitor the response to antifungal therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard induction therapy for Candida meningitis has been",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15\">",
"     15",
"    </a>",
"    ]. Amphotericin B is used because of its fungicidal activity against almost all Candida species, even though drug levels in the cerebrospinal fluid (CSF) and brain are low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Flucytosine is added because of its anticandidal activity and excellent penetration into CSF and brain tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of Candida CNS infections, we recommend a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef87680 \" href=\"mobipreview.htm?23/47/24315\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    (AmBisome) is preferred because it appears to give higher concentrations in the brain compared with other lipid formulations or amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, in neonates, amphotericin B deoxycholate (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) is the formulation used. Neonates tolerate the deoxycholate formulation better than adults, and there is little experience using the lipid formulations in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Therapy with an amphotericin B formulation with or without flucytosine should continue for at least a few weeks and until the patient has shown clinical improvement as well as improvement in the CSF profile. We suggest repeating the lumbar puncture after one to two weeks of therapy to ascertain that the WBC count is decreasing and that culture no longer yields Candida.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is given at a dose of 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day in four divided doses in patients with normal renal function. Careful attention to serum levels is warranted to avoid bone marrow toxicity, particularly in patients with renal dysfunction. Monitoring of serum 5-FC concentrations is recommended after three to five days of therapy, when available, and should be obtained two hours after a dose has been administered. The target peak concentration is between 30 and 80",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    concentrations &gt;100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    should be avoided. Serum drug concentrations should be repeated if renal function worsens, or if leukopenia or thrombocytopenia occurs. With decreasing renal function (often due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ), toxicity is more common and patients must be monitored particularly carefully. If amphotericin B-induced nephrotoxicity occurs, the dose of flucytosine should be reduced.",
"    <br/>",
"    <br/>",
"    All patients receiving flucytosine should undergo regular monitoring of complete blood counts (CBC). In settings in which serum 5-FC concentrations are not available, CBC monitoring two to three times per week provides an indirect method of screening for excessive dosing. An otherwise unexplained reduction in the neutrophil or platelet count may reflect flucytosine toxicity and either the drug should be stopped or the dose reduced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Serum concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has excellent central nervous system (CNS) penetration and is active against most Candida isolates causing CNS infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/19\">",
"     19",
"    </a>",
"    ]. However, treatment outcomes have varied with the use of fluconazole alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/7-9,20\">",
"     7-9,20",
"    </a>",
"    ]. In patients infected with a fluconazole-susceptible Candida spp, we recommend that oral fluconazole be used as step-down therapy after an initial several week course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    with or without flucytosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. In adult patients with a normal serum creatinine, oral fluconazole should be given at a dose of 400 to 800 mg (6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    daily.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    achieves excellent CSF concentrations and is active against most Candida species causing CNS infection. However, clinical experience with voriconazole for Candida CNS infections is limited. It should be useful as step-down therapy, but not initial therapy, for the rare cases of CNS infections due to C. glabrata or C. krusei.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    does not achieve adequate CSF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15,21\">",
"     15,21",
"    </a>",
"    ], and there is little experience in using this agent for invasive candidiasis. Therefore, posaconazole should",
"    <strong>",
"     not",
"    </strong>",
"    be used for CNS Candida infections.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    and the other echinocandins do not achieve adequate CSF concentrations to treat Candida meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/22\">",
"     22",
"    </a>",
"    ]. In a case report, new cerebral abscesses developed in a patient being treated with caspofungin for Candida endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/23\">",
"     23",
"    </a>",
"    ]. Pending evidence of efficacy, the echinocandins should",
"    <strong>",
"     not",
"    </strong>",
"    be used for CNS candidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal therapy should continue until all abscesses, if seen at presentation, have resolved on magnetic resonance imaging (MRI); the CSF glucose, pleocytosis, protein, and culture have returned to normal; and the patient's symptoms and signs have resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15\">",
"     15",
"    </a>",
"    ]. It may take weeks to months for the above measures to be accomplished.",
"   </p>",
"   <p>",
"    There are no data available concerning the frequency of testing, but the following approach seems reasonable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with cerebral abscesses, MRI should be repeated at two weeks (or earlier if the patient is deteriorating) and then monthly until resolution.",
"     </li>",
"     <li>",
"      For patients with acute meningitis, lumbar puncture should be repeated every one to two weeks for the first few weeks to be sure that the CSF changes are returning toward normal and that cultures are negative.",
"     </li>",
"     <li>",
"      For patients with chronic meningitis, lumbar puncture should be repeated as for acute meningitis. The best parameters to follow are the CSF white cell count and protein and glucose concentrations. The organism is present in low numbers and the yield of standard cultures of CSF is poor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have cerebral abscesses, are markedly immunosuppressed, or have chronic Candida meningitis need longer courses of therapy, and patients with ventricular shunt infections must have the device removed to achieve cure of the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5-7,15\">",
"     5-7,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term suppressive therapy is warranted in AIDS patients who remain immunosuppressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Removal of ventricular devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected ventricular devices should be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15\">",
"     15",
"    </a>",
"    ]. Systemic antifungal therapy should also be administered to patients with infected ventricular devices, as discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Antifungal therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on mortality comes from the relatively small case series described above. The following illustrate the range of findings in the different settings noted above &mdash; neonates, neurosurgery patients, and chronic meningitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the review of 26 neonates, 9 (35 percent) died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3\">",
"       3",
"      </a>",
"      ]. However, only three deaths (12 percent) could be related to the candidal infection. All three died before antifungal therapy was given and had disseminated candidiasis on postmortem examination.",
"     </li>",
"     <li>",
"      Another report compared 25 premature neonates (birth weight below 1250 g [2.75 lb]) with candidemia or Candida meningitis to controls matched for gestational age and birth weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/4\">",
"       4",
"      </a>",
"      ]. The neonates with Candida infection had a higher mortality rate (44 versus 16 percent in controls) and, among survivors, there was a trend toward a greater likelihood of neurodevelopmental disabilities (29 versus 14 percent).",
"     </li>",
"     <li>",
"      In two reviews with a total of 40 patients with Candida meningitis in neurosurgery patients, 4 died (10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. In one series, 1 of the deaths was in the only patient among the 22 total patients in whom the shunt was not removed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the review of 18 patients with chronic Candida meningitis, the overall mortality rate was 53 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9\">",
"       9",
"      </a>",
"      ]. However, among the 12 patients who were appropriately treated and followed, only 4 (33 percent) died. A similar mortality rate (31 percent) has been noted in HIV-infected patients with chronic Candida meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39559/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833985349\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833986194\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida infections of the central nervous system (CNS) most often involve the meninges. However, intracranial abscesses can occur either as an isolated phenomenon or associated with meningitis. The abscesses are usually small microabscesses, multiple, and associated with disseminated infection in immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida meningitis can occur as a manifestation of disseminated candidiasis, which most often occurs in premature neonates, in the presence of ventricular drainage devices, and as isolated chronic meningitis. In addition to hematogenous spread, Candida can enter the CNS at the time of craniotomy or through a ventricular shunt. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with Candida infections at most other sites, patients who develop CNS infections are usually immunosuppressed. In addition to occurring in premature neonates and after neurosurgery, the risk is also in increased HIV-infected patients and in those with leukemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of Candida meningitis can be the same as in patients with acute bacterial meningitis (eg, fever, stiff neck, altered mental status, headache). Fever may be the only manifestation in patients who are neutropenic, whereas signs of sepsis and multiorgan failure often predominate in neonates. Patients with multiple cerebral microabscesses can develop a diffuse encephalopathy. (See",
"      <a class=\"local\" href=\"#H1833985676\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drainage device infection usually occurs within several months of the surgical procedure and probably results from implantation during the procedure rather than hematogenous seeding of the device. The symptoms and signs associated with Candida ventricular drainage device infections are similar to those seen with the more common bacterial infections of these devices. In addition to fever, shunt malfunction can result in manifestations of increased intracranial pressure, such as headache, nausea, vomiting, and mental status changes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CNS shunts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833986186\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possible presence of CNS Candida infection should be suspected in patients with neurologic symptoms who have one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Isolation of Candida from the cerebrospinal fluid (CSF).",
"     </li>",
"     <li>",
"      Isolation of Candida from another normally sterile site in patients who have pleocytosis on CSF analysis. Finding Candida species in blood cultures is helpful, but candidemia may not be documented in patients with Candida meningitis.",
"     </li>",
"     <li>",
"      Lack of adequate response of presumed bacterial or mycobacterial meningitis to appropriate therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbar puncture to obtain CSF for culture and analysis is essential for establishing the diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'CSF analysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1833986178\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the treatment of Candida CNS infections in adults, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef87680 \" href=\"mobipreview.htm?23/47/24315\">",
"       table 1",
"      </a>",
"      ). For neonates,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate, 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily, is recommended. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      should continue for at least a few weeks and until the patient has shown clinical improvement as well as improvement in the CSF profile has been noted. We suggest repeating the lumbar puncture after one to two weeks of therapy to ascertain that the WBC count is decreasing and that culture no longer yields Candida. In patients infected with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -susceptible Candida strain, we recommend that oral fluconazole be used as step-down therapy after the initial course of amphotericin B with or without flucytosine. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifungal therapy should continue until all abscesses, if seen at presentation, have resolved on magnetic resonance imaging; the CSF glucose, pleocytosis, protein, and culture have returned to normal; and the patient's symptoms and signs have resolved. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infected ventricular devices should be removed. Systemic antifungal therapy should also be administered to patients with infected ventricular devices, as discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Removal of ventricular devices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/1\">",
"      Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005; 131:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/2\">",
"      S&aacute;nchez-Portocarrero J, P&eacute;rez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000; 37:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/3\">",
"      Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/4\">",
"      Lee BE, Cheung PY, Robinson JL, et al. Comparative study of mortality and morbidity in premature infants (birth weight, &lt; 1,250 g) with candidemia or candidal meningitis. Clin Infect Dis 1998; 27:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/5\">",
"      Nguyen MH, Yu VL. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 1995; 21:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/6\">",
"      S&aacute;nchez-Portocarrero J, Mart&iacute;n-Rabad&aacute;n P, Salda&ntilde;a CJ, P&eacute;rez-Cecilia E. Candida cerebrospinal fluid shunt infection. Report of two new cases and review of the literature. Diagn Microbiol Infect Dis 1994; 20:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/7\">",
"      Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994; 19:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/8\">",
"      Cruciani M, Di Perri G, Molesini M, et al. Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis 1992; 11:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/9\">",
"      Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994; 19:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/10\">",
"      Casado JL, Quereda C, Oliva J, et al. Candidal meningitis in HIV-infected patients: analysis of 14 cases. Clin Infect Dis 1997; 25:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/11\">",
"      McCullers JA, Vargas SL, Flynn PM, et al. Candidal meningitis in children with cancer. Clin Infect Dis 2000; 31:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/12\">",
"      Lipton SA, Hickey WF, Morris JH, Loscalzo J. Candidal infection in the central nervous system. Am J Med 1984; 76:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/13\">",
"      Pendlebury WW, Perl DP, Munoz DG. Multiple microabscesses in the central nervous system: a clinicopathologic study. J Neuropathol Exp Neurol 1989; 48:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/14\">",
"      Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. AJNR Am J Neuroradiol 1997; 18:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/15\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/16\">",
"      Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/17\">",
"      Slavoski LA, Tunkel AR. Therapy of fungal meningitis. Clin Neuropharmacol 1995; 18:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/18\">",
"      van den Anker JN, van Popele NM, Sauer PJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995; 39:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/19\">",
"      Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/20\">",
"      Epelbaum S, Laurent C, Morin G, et al. Failure of fluconazole treatment in Candida meningitis. J Pediatr 1993; 123:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/21\">",
"      Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/22\">",
"      Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39559/abstract/23\">",
"      Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004; 39:1253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2453 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39559=[""].join("\n");
var outline_f38_40_39559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1833985349\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833985779\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833985676\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Premature neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CNS shunts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CSF analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Removal of ventricular devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833985349\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1833986194\">",
"      Epidemiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1833986186\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1833986178\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2453\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2453|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/47/24315\" title=\"table 1\">",
"      Treatment of Candida CNS infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4424?source=related_link\">",
"      Approach to the patient with chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=related_link\">",
"      Clinical features and diagnosis of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39560="Endovascular devices for thoracic aortic repair";
var content_f38_40_39560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endovascular devices for thoracic aortic repair",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Ronald M Fairman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Rabih A Chaer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39560/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/40/39560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H861295075\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic endovascular aortic repair (TEVAR) is becoming increasingly popular due to reduced perioperative morbidity and mortality compared with open surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/1\">",
"     1",
"    </a>",
"    ]. Although TEVAR was developed for the treatment of degenerative aneurysmal disease, other pathologies can be treated using these devices including aortic dissection, aortic transection, intramural hematoma and penetrating aortic ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Endovascular aortic repair requires that specific anatomic criteria be fulfilled, and, for those with appropriate anatomy, this technique allows the treatment of patients who might not otherwise be candidates for aortic repair. Advanced endovascular aortic devices that allow flow into specific aortic branches depending upon the level of repair (eg, innominate, left subclavian, renal artery, internal iliac artery) are available to treat more complex anatomy.",
"   </p>",
"   <p>",
"    The placement of aortic endografts is associated with device-related complications that can include component disconnection, stent-graft buckling and migration over time often due to disease progression (eg, aortic dissection). In the thoracic aorta, secondary intervention is needed in 10 to 60 percent of patients, more commonly in patients undergoing endovascular repair of thoracic dissection and more complicated hybrid repairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. As such, these devices require lifelong surveillance; the long-term outcomes continue to be studied.",
"   </p>",
"   <p>",
"    The specific devices available for endovascular repair of the thoracic aorta will be reviewed here. The indications for, placement of, and complications of these devices are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295082\">",
"    <span class=\"h1\">",
"     AORTIC ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aorta is the major arterial conduit conveying blood from the heart to the systemic circulation. It originates immediately beyond the aortic valve ascending initially. Then it curves forming the aortic arch, and descends caudally adjacent the spine. The ascending thoracic aorta gives off the coronary arteries. The aortic arch branches are typically the brachiocephalic trunk (branches to the right common carotid and right subclavian arteries), left common carotid and left subclavian arteries; however, aortic arch anatomy is variable (",
"    <a class=\"graphic graphic_figure graphicRef54048 \" href=\"mobipreview.htm?5/47/5878\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The descending thoracic aorta provides paired thoracic arteries (T1-T12) and continues through the hiatus of the diaphragm to become the abdominal aorta which extends retroperitoneally to its bifurcation into the common iliac arteries at the level of the fourth lumbar vertebra (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"mobipreview.htm?42/14/43234\">",
"     figure 2",
"    </a>",
"    ). The abdominal aorta lies slightly left of the midline to accommodate the inferior vena cava which is in close apposition. The branches of the aorta (superior to inferior) include the left and right inferior phrenic arteries, left and right middle suprarenal arteries, the celiac axis, superior mesenteric artery, left and right renal arteries, left and right internal spermatic arteries, inferior mesenteric artery, left and right common iliac artery, middle sacral artery and the paired lumbar arteries (L1-L4).",
"   </p>",
"   <p>",
"    The common iliac artery bifurcates into the external iliac and internal iliac arteries at the pelvic inlet (",
"    <a class=\"graphic graphic_figure graphicRef60420 \" href=\"mobipreview.htm?39/52/40777\">",
"     figure 3",
"    </a>",
"    ). The internal iliac artery gives off branches to the pelvic viscera and also supplies the musculature of the pelvis. The external iliac artery passes beneath the inguinal ligament to become the common femoral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295089\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aneurysm repair refers to the insertion of endovascular graft components, usually via a femoral approach. A thoracic endograft is constructed by the delivery and deployment of these components in an established order in vivo (",
"    <a class=\"graphic graphic_figure graphicRef66551 \" href=\"mobipreview.htm?37/21/38228\">",
"     figure 4",
"    </a>",
"    ). Upon deployment, the thoracic endograft self-expands, contacting the aortic wall proximally and distally excluding the native aortic wall from aortic blood flow and pressure.",
"   </p>",
"   <p>",
"    Although there are significant variations in endovascular graft design, three types of components are common: the delivery system, the main device, and device extensions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295096\">",
"    <span class=\"h2\">",
"     Delivery system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic endografts are typically delivered through the femoral artery, percutaneously or by direct surgical cutdown. The size of the delivery system varies depending upon the diameter of the device that is needed to provide proper endograft fixation.",
"   </p>",
"   <p>",
"    If the femoral or iliac artery is too small to accommodate the delivery system, access can be obtained by direct puncture of the iliac artery or aorta through a retroperitoneal incision or by suturing a synthetic graft to the iliac artery (ie, iliac conduit). An alternative method creates an endovascular conduit by first lining the iliac artery with a covered stent and then allowing a contained rupture of the diseased iliac segment as the endograft is passed through.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295103\">",
"    <span class=\"h2\">",
"     Main device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main thoracic endograft device is straight or tapered, and two distinct device components are often used (eg, straight graft proximally, tapered graft distally). Endovascular grafts rely primarily upon tension in the proximal graft to maintain the positioning of the graft. Fixation systems may include barbs or uncovered proximal stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295110\">",
"    <span class=\"h2\">",
"     Extensions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more extension devices (proximal or distal) may be needed to provide a complete seal. Following the deployment of the main device, an aortogram is performed to assess for endoleak. If additional ballooning of the device does not firmly appose it to the aortic wall and eliminate a type I endoleak (",
"    <a class=\"graphic graphic_figure graphicRef64707 \" href=\"mobipreview.htm?36/13/37074\">",
"     figure 5",
"    </a>",
"    ), placement of additional proximal or distal aortic extensions may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295117\">",
"    <span class=\"h1\">",
"     THORACIC DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for endovascular treatment of thoracic aortic pathologies are broadening. Although thoracic endovascular aortic repair was developed for the treatment of degenerative aneurysmal disease, other pathologies can be treated using these devices including aortic dissection, aortic transection, intramural hematoma and penetrating aortic ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endovascular aortic repair requires that specific anatomic criteria be fulfilled, and, for those with appropriate anatomy, this technique allows the treatment of patients who might not otherwise be candidates for thoracic aortic repair. Advances in endograft design have allowed the treatment of patients with increasingly complex anatomy, but the ideal graft suited to all the possible combinations of pathology and anatomy does not exist. Thus, it is not surprising that a number of thoracic stent-graft devices are commercially available and the design of the available grafts is ever-evolving to address problems that are frequently encountered with the delivery, deployment, and fixation of thoracic endografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled comparisons of the various thoracic endografts have not been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/8\">",
"     8",
"    </a>",
"    ]. Data supporting the use of these devices are primarily from clinical trials performed to seek approval from the United States Food and Drug Administration (FDA) or Conformit&eacute; Europ&eacute;enne (CE) mark. Devices that are currently approved or under investigation for treatment of descending thoracic aneurysms include the Gore TAG&trade;, Cook Zenith&reg; Tx2&reg;, Medtronic Talent Thoracic Stent-Graft System, Medtronic Valiant Thoracic Stent-Graft System, Bolton Relay&trade;, TAArget&trade;, and E-Vita&reg; grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/9\">",
"     9",
"    </a>",
"    ]. The Conformable TAG&reg; graft (CTAG) has also been approved in the United States for the treatment of blunt aortic injury (see",
"    <a class=\"local\" href=\"#H861295124\">",
"     'TAG&trade;'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/1\">",
"     1",
"    </a>",
"    ]. A number of investigational devices are in early phases.",
"   </p>",
"   <p>",
"    The essential features of the various thoracic endografts and clinical data supporting their use are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295124\">",
"    <span class=\"h2\">",
"     TAG&trade;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TAG&trade; device (W.L. Gore &amp; Associates), is a self-expanding tube-shaped stent-graft supported by a nitinol exoskeleton lined with expanded polytetrafluoroethylene (ePTFE) and covered with an additional reinforcing sleeve of ePTFE and fluorinated ethylene propylene (FEP), which reduces the potential for type IV endoleak (",
"    <a class=\"graphic graphic_figure graphicRef64707 \" href=\"mobipreview.htm?36/13/37074\">",
"     figure 5",
"    </a>",
"    ). The proximal and distal ends of the graft have scalloped flares that are also lined with graft material and an ePTFE sealing cuff at the base of each flare. A radiopaque band is located at the base of each flared end to facilitate placement under fluoroscopy. The flared sealing regions are designed to improve conformity and better apposition of the graft to the aortic wall.",
"   </p>",
"   <p>",
"    The TAG&trade; device is available in diameters ranging from 26 to 45 mm in 10, 15, and 20 cm lengths. The delivery sheath ranges from 20 to 24 French (6.67 to 8 mm) in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/10\">",
"     10",
"    </a>",
"    ]. The device is constrained within a deployment line. Once the device is positioned, the deployment line unlaces from the middle of the device toward both ends, thus avoiding a &ldquo;windsock&rdquo; effect. Once deployed, the device is ballooned open with a trilobed balloon that allows aortic flow during inflation.",
"   </p>",
"   <p>",
"    The TAG&trade; pivotal trial compared open surgical repair with endovascular repair in patients with descending thoracic aortic aneurysm, but was interrupted due to device failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/11\">",
"     11",
"    </a>",
"    ]. After modification of the device, a multicenter study compared 51 patients treated with the TAG&trade; device with the surgical group from the pivotal study, and an additional 80 patients were enrolled as part of a confirmatory study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/12\">",
"     12",
"    </a>",
"    ]. Significantly improved aneurysm-related survival (96 versus 88 percent) was found at five years (original pivotal) and three years (confirmatory study) for patients treated with thoracic endovascular repair and a reduced incidence of major adverse events (71 versus 21 percent at 30 days, 37 versus 21 percent long-term) compared with open surgery. No device fractures were reported since the device modification consisting of removal of a longitudinal spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A next generation device, the Conformable TAG&reg; graft (CTAG), has received approval for use and is available in a wider range of diameters (21 to 45 mm) with a sheathless delivery system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/14\">",
"     14",
"    </a>",
"    ]. The design is intended to conform to smaller, more tortuous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tapered thoracic aortic anatomy and to provide treatment of pathologies that can affect nonaneurysmal (normal diameter) aortas such as blunt aortic injury, penetrating aortic ulcer, aortic dissection. A nonrandomized study evaluated the safety and efficacy of the CTAG device for the repair of traumatic aortic transection in 51 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/15\">",
"     15",
"    </a>",
"    ]. Technical success was 100 percent with no operative mortality. No major device events have been reported. Perioperative (30-day) mortality was 8 percent, which was not felt to be device- or procedure-related. No conversions to open repair have been reported to date. Endovascular repair for the treatment of blunt aortic injury is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8921?source=see_link\">",
"     \"Surgical and endovascular repair of blunt thoracic aortic injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295131\">",
"    <span class=\"h2\">",
"     Zenith&reg; TX2&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Zenith&reg; TX2&reg; (Cook Medical) endograft is a two-piece system. Both components are constructed from modified Gianturco Z-stents (stainless steel) sutured to woven polyester graft material (ie, Dacron&reg;). The graft material lines the graft and is also external to the stent structure at the proximal and distal ends of the graft to allow apposition of the graft to the aortic wall. Active fixation with external barbs at the proximal and distal aspects of the device is present for each component. Straight and tapered proximal components are available. A bare metal stent is attached to the distal graft and is similar to the suprarenal stent component of the Zenith&reg; device for endovascular repair of abdominal aortic aneurysm. The extension allows for active fixation of the device over the origins of the visceral vessels. A suture modification of the device (Pro-form) is intended to improve conformability of the graft in the aortic arch during very proximal descending thoracic aortic deployments to minimize the risk of graft infolding and collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proximal and distal Zenith&reg; TX2&reg; device components are available in diameters ranging from 28 to 42 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/17\">",
"     17",
"    </a>",
"    ]. The components range in length from 12 to 21.6 cm. The devices are delivered through a 20 or 22 French (6.67, 7.33 mm) sheath depending upon the diameter of the device. The device is constrained with several trigger wires which are released sequentially once the device is positioned. After deployment, the device is self-expanding; subsequent ballooning is an option.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and effectiveness of the Zenith&reg; TX2&reg; was evaluated in a multicenter study of 230 patients with descending thoracic aortic aneurysms or thoracic aortic ulcers who were treated with endovascular repair using the TX2&reg; (n = 160) or open surgery (n = 70) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/18\">",
"       18",
"      </a>",
"      ]. Perioperative (30-day) mortality was not significantly different between the groups; however, perioperative morbidity was lower for endovascular repair (composite index 1.3 versus 2.9). Although endovascular repair was associated with fewer cardiovascular, pulmonary, and vascular adverse events, the incidence of neurologic events was not significantly different. At 12-months follow-up, aneurysm growth was identified in 7.1 percent of endovascular patients, endoleak in 3.9 percent, and migration &gt;10 mm in 2.8 percent.",
"     </li>",
"     <li>",
"      In another study of patients considered at high risk for open surgery, the TX2&reg; graft was used to treat primarily thoracic aneurysms in 100 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/19\">",
"       19",
"      </a>",
"      ]. The overall mortality was 17 percent and aneurysm-related mortality was 14 percent. Secondary interventions were needed in 15 percent of patients. Stroke and paraplegia rates were 3 and 6 percent, respectively. Stent migration occurred in 6 percent of patients at one-year follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Zenith&reg; TX2&reg; dissection system is designed to treat acute complicated type B aortic dissection. It is a two-component system composed of a proximal TX2 graft combined with a distal bare stainless steel Z-stent. The proximal component covers the entry tear and the bare stents are intended to expand the true lumen while allowing flow to branch vessels. The bare stent can be deployed to the aortic bifurcation, if needed. The distal stent is available in 8.2, 12.3 and 16.4 cm lengths and a single 46 mm diameter that accommodates aortic diameters from 24 to 38 mm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and effectiveness of the Zenith&reg; TX2&reg; dissection system was evaluated in a multicenter study of 40 patients in which the indications for enrollment included branch vessel malperfusion, impending rupture, aortic diameter &ge;40 mm, rapid aortic expansion, and persistent pain or hypertension despite maximum medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/20\">",
"       20",
"      </a>",
"      ]. Most patients",
"      <span class=\"nowrap\">",
"       (31/40)",
"      </span>",
"      were treated for impending aortic rupture or branch vessel malperfusion. The mean time from symptom onset to treatment was 20 days (range, 0 to 78 days). Seven different combinations of stent-grafts and dissection stents were used. The perioperative (30-day) mortality rate was 5 percent and one-year survival rate was 90 percent. Perioperative morbidity included stroke (7.5 percent), transient ischemic attack (2.5 percent), paraplegia (2.5 percent), retrograde progression of dissection (5 percent), and renal failure (12.5 percent). None of the patients with renal failure became dialysis-dependent. Favorable aortic remodeling was observed during the course of follow-up, completely thrombosed thoracic false lumen observed in 31 percent of patients. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295138\">",
"    <span class=\"h2\">",
"     Talent&reg; Thoracic Stent-Graft System",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Talent&reg; Thoracic Stent-Graft System (Medtronic) consists of two components. The stent-graft components are made of a woven polyester graft with an external self-expanding support structure of M-shaped nitinol stents and a longitudinal support bar throughout its length. The proximal component is a straight stent-graft with an uncovered stent proximally that allows placement across the left subclavian or carotid artery. The distal component can be a straight or tapered tubular graft and has a closed web design that is intended to assure fixation of the components in the region of overlap.",
"   </p>",
"   <p>",
"    The proximal component is available in diameters ranging from 22 to 46 mm in lengths from 11.2 to 11.6 cm. The distal component is available in diameters ranging from 26 to 46 mm in lengths from 11.0 to 11.4 cm. The delivery sheath ranges from 22 to 25 French (7.33 to 8.33 mm) in diameter. The device is delivered through the Xcelerant delivery system (same as AneuRx&reg; and Valiant&trade; grafts) which is a ratcheted system for controlled initial deployment to position of the device, and then a more rapid release of the remainder of the device to avoid a &ldquo;windsock&rdquo; effect. Once deployed, the device is self-expanding; subsequent ballooning of the device is an option.",
"   </p>",
"   <p>",
"    The safety and efficacy of the Talent&reg; Thoracic Stent-Graft System was evaluated in the VALOR I study which was a multicenter study that compared endovascular repair (n = 195) with retrospective open surgical data obtained from three centers (n = 189) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/23\">",
"     23",
"    </a>",
"    ]. An average of 2.7 stent-graft components was used per patient. Technical success was 99.5 percent for vessel access and endograft deployment at the intended site. Perioperative (30-day) mortality was 2.1 percent and major adverse events overall occurred in 41 percent of patients, with paraplegia in 1.5 percent; paraparesis in 7.2 percent; and stroke in 3.6 percent. At one-year follow-up, all-cause mortality was 16.1 percent and aneurysm-related mortality was 3.1 percent. Late complications included conversion to open surgery (0.5 percent), target aneurysm rupture (0.5 percent), stent graft migration &gt;10 mm (3.9 percent), and endoleak (12.2 percent). Compared with open surgery, the Talent&reg; Thoracic Stent-Graft was found to have significantly lower perioperative mortality (2 versus 8 percent), fewer perioperative major adverse events (41 versus 84.4 percent) and lower aneurysm-related mortality at one year (3.1 versus 11.6 percent).",
"   </p>",
"   <p>",
"    The INSTEAD trial randomly assigned 597 patients with stable aortic dissection (&gt;2 weeks) to elective aortic stent-grafting plus medical therapy or medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/24\">",
"     24",
"    </a>",
"    ]. The Talent&reg; Thoracic Stent-Graft System was used in all cases. There was no significant difference in overall mortality between the groups at two years, with a cumulative survival rate of 95.6 percent for medical therapy alone compared with 88.9 percent for endovascular repair. No differences were seen in aorta-related death rates or the combined end-point of aorta-related death (rupture) and progression of disease. Three neurological events occurred in the endovascular repair group (one paraplegia, one stroke, and one transient paraparesis), compared with one case of paraparesis in the medical therapy alone group. Aortic remodeling with recovery of the true-lumen and thrombosis of the false-lumen was found in significantly more patients undergoing endovascular repair (91.3 versus 19.3 percent) compared with medical therapy alone. In spite of favorable aortic remodeling, no improvements were seen in two-year survival or adverse event rates, and the impact on long-term aneurysmal degeneration of the dissected aortic segment remains to be studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295145\">",
"    <span class=\"h2\">",
"     Valiant&trade; Thoracic Stent-Graft System",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Valiant&trade; Thoracic Stent-Graft System (Medtronic Vascular) is a third-generation device based upon the Talent&reg; Thoracic Stent-Graft System. The Valiant&trade; graft has a modified proximal bare stent with eight shorter bare stents proximally compared with five longer bare stents found in the Talent&reg; stent-graft. The longitudinal support bar of the Talent&reg; device was removed to provide improved device flexibility for the Valiant&trade; device.",
"   </p>",
"   <p>",
"    The graft is available in straight or tapered configurations with diameters ranging from 24 to 46 mm and lengths up to 22.7 cm. The device is also delivered through the Xcelerant delivery system.",
"   </p>",
"   <p>",
"    The initial experience of the Valiant&trade; endograft was reported in a multicenter retrospective study of 180 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/25\">",
"     25",
"    </a>",
"    ]. A variety of indications were treated including thoracic aneurysms (n = 66), thoracoabdominal aneurysms (n = 22), acute aortic syndrome (n = 19), aneurysm degeneration of chronic aortic dissection (n = 52), and traumatic aortic dissection (n = 21). The perioperative (30-day) mortality for the series was 7.2 percent with perioperative morbidity that included stroke in 3.8 percent and paraplegia in 3.3 percent. Mortality rates differed significantly depending upon indications, with the highest rate for thoracoabdominal aneurysms at 27.3 percent and lowest (none) for acute traumatic rupture.",
"   </p>",
"   <p>",
"    The VALOR II study has been completed using the Valiant stent-graft resulting in approval of the Captivia Delivery System for use in the United States. Commercial release is ongoing and the one-year results demonstrate safety and efficacy comparable with the Talent&reg; stent-graft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295173\">",
"    <span class=\"h2\">",
"     Investigational devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several devices for thoracic endovascular repair are investigational and not commercially available in the United States. These include the Bolton Relay&trade;, the LeMaitre TAArget&trade;, and the JOTEC E-Vita&reg; stent-graft system. These are briefly reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114903255\">",
"    <span class=\"h3\">",
"     Relay&trade;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Relay&trade; (Bolton Medical) device is composed of self-expanding nitinol stents sutured to a polyester fabric graft with a curved longitudinal nitinol wire intended to provide longitudinal strength. It has a proximal bare stent that remains constrained until the endograft is fully deployed. The safety and efficacy of this device has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Relay&trade; device is available in straight and tapered configurations in diameters ranging from 22 to 46 mm and lengths from 10 to 25 cm. The delivery sheath ranges from 20 to 26 French (6.67 to 8.33 mm) in diameter depending upon the diameter of the device.",
"   </p>",
"   <p>",
"    A study from the RESTORE registry, which is a multicenter, European, prospective clinical registry of patients who have undergone endovascular repair with the Relay&trade; device, found a technical success rate of 97.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/27\">",
"     27",
"    </a>",
"    ]. Among 150 patients evaluated, thoracic aortic aneurysm was treated in 64.7 percent of patients and dissections were treated in 19.3 percent. The perioperative (30-day) mortality rate was 10 percent. Perioperative morbidity included paraplegia in 3.3 percent, recovered paraparesis in 3.3 percent and stroke in 0.6 percent. The reintervention rate during two-year follow-up was 8.9 percent due to two stent graft migrations, three proximal type I endoleaks, four type III endoleaks and five distal type I endoleaks. No open conversions were needed during follow-up.",
"   </p>",
"   <p>",
"    Another study of the RESTORE registry evaluated the performance of the Relay&trade; device in 91 patients with acute or chronic aortic dissections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/28\">",
"     28",
"    </a>",
"    ]. Most patients (84 percent) had descending thoracic aortic (type B) dissection, of which 61 were classified as chronic and 30 as acute. The overall technical success rate was 95 percent. Perioperative mortality (30-day) was 8 percent with greater mortality in acute (13 versus 5 percent) compared with chronic aortic dissections. Paraplegia, paraparesis, and stroke occurred in four, one, and two patients, respectively. Type I endoleak rate occurred in 7 percent of patients. The two-year survival rate was 83 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114903262\">",
"    <span class=\"h3\">",
"     TAArget&trade;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TAArget&trade; (formerly called EndoFit, LeMaitre Vascular) thoracic stent graft consists of a nitinol skeleton of Z-shaped stents between two thin sheets of expanded polytetrafluoroethylene (ePTFE). The proximal graft is available with and without a bare stent and the device can be straight or tapered, allowing four different configurations which can be used alone or in combination.",
"   </p>",
"   <p>",
"    The TAArget&trade; graft is available in diameters that range from 34 to 42 mm with lengths up to 20 cm. The device is deployed through a 22 or 24 French (7.33, 8 mm) sheath depending upon the diameter of the device.",
"   </p>",
"   <p>",
"    In a study of 41 patients, indications for treatment were thoracic aneurysm (n = 24), acute contained aortic rupture (n = 5), aortic dissection (n = 6), penetrating atherosclerotic ulcers (n = 4), posttraumatic pseudoaneurysm (n = 1), and postcoarctation repair aneurysm (n = 1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/29\">",
"     29",
"    </a>",
"    ]. The technical success rate was 100 percent. Perioperative mortality was 7.3 percent. One patient suffered from spinal cord ischemia with ongoing symptoms of lower extremity weakness. Three postoperative endoleaks were recorded, two type I endoleaks (one proximal and one distal) resolved spontaneously. A third patient with persistent type Ia endoleak required operative conversion at one year. Overall long-term mortality was 17 percent at two-year follow-up with aneurysm-related mortality of 11 percent.",
"   </p>",
"   <p>",
"    A retrospective review of 46 patients with thoracic aortic aneurysm and 41 with thoracic aortic dissection evaluated the EndoFit graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/30\">",
"     30",
"    </a>",
"    ]. Twenty percent of the cases were performed emergently and technical success was achieved in all the patients. Perioperative mortality (30-day) was 9.2 percent. Perioperative morbidity included neurological complications in 9.3 percent of patients, including five strokes (two fatal) and three cases of paraplegia. Five patients had immediate proximal type I endoleak; three were remedied with a proximal cuff, one was rescued with tri-lobe balloon, and one was left untreated. The mortality rate over an average follow-up of 15.2 months was 11.5 percent but was not felt to be related to the aneurysm or stent-graft. There were no conversions required during the follow-up period.",
"   </p>",
"   <p>",
"    A registry to follow the acute and chronic treatment of type B aortic dissection using the TAArget&trade; graft has been established (DEDICATED registry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114903269\">",
"    <span class=\"h3\">",
"     E-Vita&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The E-Vita&reg; stent-graft system (JOTEC) is composed of a woven polyester graft with a nitinol spring support structure sutured to the interior surface without any form of continuous longitudinal support, making the graft very flexible.",
"   </p>",
"   <p>",
"    The graft is available in 24 to 44 mm diameters in lengths of 13, 15, 17, and 23 cm. Multiple graft configurations are available, and can be used in combination (straight, tapered, open stent).",
"   </p>",
"   <p>",
"    A review of 126 patients (71 percent men; age 64 [19 to 86] years) evaluated the performance of E-Vita&reg; stent-graft in the treatment of type-B dissection (n = 56), thoracic aortic aneurysm (n = 25), penetrating aortic ulcer (n = 17), blunt thoracic injury (n = 10), mobile atheroma (n = 1), suture aneurysms (n = 7) and revision of prior endograft (n = 22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/32\">",
"     32",
"    </a>",
"    ]. The procedure was emergent in 50 percent of the patients and the graft was successfully placed in 77 percent of patients. An average of 1.3 stents was implanted per patient with a mean covered aortic length of 20.4 cm. The overall perioperative mortality (30-day) was 12.3 percent (1.5 for elective and 22 percent for emergency procedures). Transient spinal cord dysfunction was observed in two cases. Stroke occurred in 2.8 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295180\">",
"    <span class=\"h1\">",
"     TEVAR TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials comparing the outcomes of specific endovascular stent-grafts to each other for the management of thoracic aortic pathology. It is unlikely that such studies will ever be performed.",
"   </p>",
"   <p>",
"    Two studies have compared endovascular with open surgical repair of thoracic aortic aneurysm. These studies are discussed above and the implications of these results for the treatment of thoracic aortic aneurysm are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H861295124\">",
"     'TAG&trade;'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies comparing endovascular repair with open repair for the treatment of aortic dissection and traumatic aortic transection are also presented above. (See",
"    <a class=\"local\" href=\"#H861295138\">",
"     'Talent&reg; Thoracic Stent-Graft System'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H861295124\">",
"     'TAG&trade;'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295250\">",
"    <span class=\"h1\">",
"     ADVANCED DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When aortic disease is more extensive and involves branch vessels, the complexity and risks associated with endovascular repair increase. Approaches to address these issues include debranching procedures and the use of fenestrated and branched endografts.",
"   </p>",
"   <p>",
"    Debranching procedures involve the ligation and surgical revascularization (eg, carotid-subclavian bypass) of an aortic branch that will be covered by the endograft. The role of debranching in the treatment of thoracic aneurysm is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295257\">",
"    <span class=\"h2\">",
"     Fenestrated grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fenestrated-endovascular aneurysm repair (FEVAR) to manage more challenging aortic anatomy continues to evolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/33-44\">",
"     33-44",
"    </a>",
"    ]. The Zenith&reg; Fenestrated AAA Endovascular Graft (Cook Medical) is the primarily studied device. The Zenith&reg; Fenestrated graft is still investigational in the United States and its use is limited to sites with an investigation device exemption (IDE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295264\">",
"    <span class=\"h2\">",
"     Branched grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Branched grafts have separate smaller side arm grafts sutured to the basic endovascular graft for deployment into a vessel to preserve flow into it. Another approach places a self-expanding stent-graft through the opening of a fenestrated graft. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link&amp;anchor=H620227574#H620227574\">",
"     \"Endovascular devices for abdominal aortic repair\", section on 'Fenestrated grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Branched grafts have been used in patients with thoracic or thoracoabdominal aneurysms, or thoracic dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/45\">",
"     45",
"    </a>",
"    ]. Initial experience with branched aortic grafts has shown similar perioperative mortality as conventional endovascular repair, but the rate of aneurysm repair-related morbidity may be higher.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic arch branch devices &ndash; Single and double branch thoracic aortic endografts are available primarily for investigational use (Cook Medical, Australia, Yu Heng Jia Scientific Technology Co., Beijing) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/46\">",
"       46",
"      </a>",
"      ]. These grafts are intended to preserve flow into the innominate, carotid or subclavian artery during thoracic endograft placement. A separate access is needed to deploy the branch grafts.",
"     </li>",
"     <li>",
"      Visceral devices &ndash; Branched grafts to the visceral vessels allow endovascular repair of more extensive aortic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39560/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. The use of visceral branch devices is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H444449#H444449\">",
"       \"Endovascular repair of abdominal aortic aneurysm\", section on 'Advanced devices and techniques'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iliac devices &ndash; Iliac branched grafts are intended to preserve flow into the internal iliac artery during abdominal aortic or iliac aneurysm repair that requires extension beyond the internal iliac artery orifice. The PRESERVE-Zenith&reg; Iliac Branch System clinical study (ClinicalTrials.gov identifier: NCT01208415) will evaluate the safety and efficacy of the Zenith&reg; Iliac Branch Device (Cook Medical). The use of iliac branch devices is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=see_link&amp;anchor=H519609340#H519609340\">",
"       \"Surgical and endovascular repair of iliac artery aneurysm\", section on 'Branched grafts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295271\">",
"    <span class=\"h1\">",
"     CHOICE OF DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;No one device is appropriate for all clinical indications or has been shown to be superior to any other device for the endovascular repair of the thoracic aorta. Most devices were originally designed for excluding thoracic aortic aneurysm and the evaluation of specific designs to manage acute aortic syndromes (aortic rupture, aortic dissection) is in early stages. With time, and with the addition of disease-specific endografts, a clear preference for one device over another may emerge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861295278\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endovascular repair of the thoracic aorta is becoming increasingly popular due to reduced perioperative morbidity and mortality compared with open surgical repair. Endovascular repair with stent-graft devices can be used to treat thoracic aortic aneurysm, aortic dissection, aortic rupture including traumatic rupture, penetrating aortic ulcer and nontraumatic aortic intramural hematoma. Endovascular aortic repair requires that specific anatomic criteria be fulfilled, and, for those with appropriate anatomy, this technique allows the treatment of patients who might not otherwise be candidates for aortic repair. (See",
"      <a class=\"local\" href=\"#H861295075\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular aneurysm repair refers to the stepwise insertion of endovascular graft components, usually via a femoral approach. Although there are significant variations in endovascular graft design, three types of components are common to all: a delivery system, main body device, and graft extensions. Upon deployment, the endograft expands, contacting the thoracic aortic wall proximally and distally excluding the degenerated aortic wall from aortic blood pressure and flow. (See",
"      <a class=\"local\" href=\"#H861295089\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When aortic disease is more extensive and involves branch vessels, the complexity and risks associated with endovascular repair increase. Approaches to address these issues include debranching procedures and the use of fenestrated and branched endografts. Advanced endovascular aortic devices are designed to allow perfusion into specific aortic branch arteries depending upon the level of repair (eg, carotid, subclavian, renal). (See",
"      <a class=\"local\" href=\"#H861295250\">",
"       'Advanced devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for endovascular treatment of thoracic aortic pathologies are expanding, and the cases being treated are increasingly complex. Although graft design has evolved, an ideal graft suited to all circumstances is not available. A number of thoracic stent graft devices are available and include the TAG&trade;, Zenith&reg; Tx2&reg;, Talent&reg; Thoracic Stent-Graft System, and Valiant&trade; Thoracic Stent-Graft System. The Relay&trade;, TAArget&trade;, and E-Vita&reg; grafts remain investigational in the United States. (See",
"      <a class=\"local\" href=\"#H861295117\">",
"       'Thoracic devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no trials comparing the outcomes of specific endovascular stent-grafts to each other for the management of thoracic aortic pathology. The placement of aortic endovascular grafts is associated with device-related complications that can include component disconnect, stent-graft buckling and migration over time. In the thoracic aorta, secondary intervention is needed in 10 to 60 percent of patients, more commonly in patients undergoing endovascular repair of thoracic dissection. As such, these devices require lifelong surveillance; long-term outcomes continue to be studied. (See",
"      <a class=\"local\" href=\"#H861295180\">",
"       'TEVAR trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/1\">",
"      Murad MH, Rizvi AZ, Malgor R, et al. Comparative effectiveness of the treatments for thoracic aortic transection [corrected]. J Vasc Surg 2011; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/2\">",
"      Clough RE, Mani K, Lyons OT, et al. Endovascular treatment of acute aortic syndrome. J Vasc Surg 2011; 54:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/3\">",
"      Geisb&uuml;sch P, Hoffmann S, Kotelis D, et al. Reinterventions during midterm follow-up after endovascular treatment of thoracic aortic disease. J Vasc Surg 2011; 53:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/4\">",
"      Manning BJ, Dias N, Ohrlander T, et al. Endovascular treatment for chronic type B dissection: limitations of short stent-grafts revealed at midterm follow-up. J Endovasc Ther 2009; 16:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/5\">",
"      Eggebrecht H, Nienaber CA, Neuh&auml;user M, et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. Eur Heart J 2006; 27:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/6\">",
"      Sandhu RS, Pipinos II. Isolated iliac artery aneurysms. Semin Vasc Surg 2005; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/7\">",
"      Kiguchi M, Chaer RA. Endovascular repair of thoracic aortic pathology. Expert Rev Med Devices 2011; 8:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/8\">",
"      Gawenda M, Brunkwall J. Comparison of CE approved TEVAR devices. J Cardiovasc Surg (Torino) 2010; 51:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/9\">",
"      Lin PH, El Sayed HF, Kougias P, et al. Endovascular repair of thoracic aortic disease: overview of current devices and clinical results. Vascular 2007; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.goremedical.com/contentTypeDetail.jsp?action=contentDetail&amp;N=8083 8239&amp;contenttype=8327&amp;R=1234725569231 (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/11\">",
"      Melissano G, Tshomba Y, Civilini E, Chiesa R. Disappointing results with a new commercially available thoracic endograft. J Vasc Surg 2004; 39:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/12\">",
"      Cho JS, Haider SE, Makaroun MS. Endovascular therapy of thoracic aneurysms: Gore TAG trial results. Semin Vasc Surg 2006; 19:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/13\">",
"      Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. J Vasc Surg 2005; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.goremedical.com/contentTypeDetail.jsp?action=contentDetail&amp;N=8083 8239&amp;contenttype=8327&amp;R=1276629378975 (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     TEVAR using the redesigned TAG device (CTAG) for Traumatic Aortic Transection: A non-randomized multicenter trial. file://scvs.org/symposium/abstracts/2012/12.cgi (Accessed on January 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/16\">",
"      Lee WA, Martin TD, Hess PJ Jr, et al. First United States experience of the TX2 Pro-Form thoracic delivery system. J Vasc Surg 2010; 52:1459.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cookmedical.com/ai/content/mmedia/AI-BM-TX2PFCOI-EN-200909.pdf (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/18\">",
"      Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/19\">",
"      Greenberg RK, O'Neill S, Walker E, et al. Endovascular repair of thoracic aortic lesions with the Zenith TX1 and TX2 thoracic grafts: intermediate-term results. J Vasc Surg 2005; 41:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/20\">",
"      Lombardi JV, Cambria RP, Nienaber CA, et al. Prospective multicenter clinical trial (STABLE) on the endovascular treatment of complicated type B aortic dissection using a composite device design. J Vasc Surg 2012; 55:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/21\">",
"      Melissano G, Bertoglio L, Kahlberg A, et al. Evaluation of a new disease-specific endovascular device for type B aortic dissection. J Thorac Cardiovasc Surg 2008; 136:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/22\">",
"      Mossop P, Nixon I, Oakes J, et al. Immediate \"total\" aortic true lumen expansion in type A and B acute aortic dissection after endovascular aortic endografting and GZSD bare stenting. J Thorac Cardiovasc Surg 2007; 134:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/23\">",
"      Fairman RM, Criado F, Farber M, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR trial. J Vasc Surg 2008; 48:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/24\">",
"      Nienaber CA, Rousseau H, Eggebrecht H, et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation 2009; 120:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/25\">",
"      Thompson M, Ivaz S, Cheshire N, et al. Early results of endovascular treatment of the thoracic aorta using the Valiant endograft. Cardiovasc Intervent Radiol 2007; 30:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/26\">",
"      Funovics M, Blum M, Langenberger H, et al. Endovascular repair of the descending aorta and the aortic arch with the Relay stent graft. Ann Thorac Surg 2009; 88:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/27\">",
"      Riambau V, RESTORE collaborators. European experience with Relay: a new stent graft and delivery system for thoracic and arch lesions. J Cardiovasc Surg (Torino) 2008; 49:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/28\">",
"      Zipfel B, Czerny M, Funovics M, et al. Endovascular treatment of patients with types A and B thoracic aortic dissection using Relay thoracic stent-grafts: results from the RESTORE Patient Registry. J Endovasc Ther 2011; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/29\">",
"      Inglese L, Mollichelli N, Medda M, et al. Endovascular repair of thoracic aortic disease with the EndoFit stent-graft: short and midterm results from a single center. J Endovasc Ther 2008; 15:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/30\">",
"      Qu L, Raithel D. Two-year single-center experience with thoracic endovascular aortic repair using the EndoFit thoracic stent-graft. J Endovasc Ther 2008; 15:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/31\">",
"      Bergeron P, Inglese L, Gay J, Dedicated Registry Collaborators. Setting up of a multicentric European registry dealing with type B dissections in chronic and acute phases with thoracic EndoFit devices. J Cardiovasc Surg (Torino) 2007; 48:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/32\">",
"      Zipfel B, Buz S, Hammerschmidt R, et al. Early clinical experience with the E-vita thoracic stent-graft system: a single center study. J Cardiovasc Surg (Torino) 2008; 49:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/33\">",
"      Tambyraja AL, Fishwick NG, Bown MJ, et al. Fenestrated aortic endografts for juxtarenal aortic aneurysm: medium term outcomes. Eur J Vasc Endovasc Surg 2011; 42:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/34\">",
"      Greenberg RK, Sternbergh WC 3rd, Makaroun M, et al. Intermediate results of a United States multicenter trial of fenestrated endograft repair for juxtarenal abdominal aortic aneurysms. J Vasc Surg 2009; 50:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/35\">",
"      Amiot S, Haulon S, Becquemin JP, et al. Fenestrated endovascular grafting: the French multicentre experience. Eur J Vasc Endovasc Surg 2010; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/36\">",
"      Greenberg RK, Haulon S, O'Neill S, et al. Primary endovascular repair of juxtarenal aneurysms with fenestrated endovascular grafting. Eur J Vasc Endovasc Surg 2004; 27:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/37\">",
"      O'Neill S, Greenberg RK, Haddad F, et al. A prospective analysis of fenestrated endovascular grafting: intermediate-term outcomes. Eur J Vasc Endovasc Surg 2006; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/38\">",
"      Verhoeven EL, Vourliotakis G, Bos WT, et al. Fenestrated stent grafting for short-necked and juxtarenal abdominal aortic aneurysm: an 8-year single-centre experience. Eur J Vasc Endovasc Surg 2010; 39:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/39\">",
"      Semmens JB, Lawrence-Brown MM, Hartley DE, et al. Outcomes of fenestrated endografts in the treatment of abdominal aortic aneurysm in Western Australia (1997-2004). J Endovasc Ther 2006; 13:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/40\">",
"      Anderson JL, Berce M, Hartley DE. Endoluminal aortic grafting with renal and superior mesenteric artery incorporation by graft fenestration. J Endovasc Ther 2001; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/41\">",
"      Kristmundsson T, Sonesson B, Malina M, et al. Fenestrated endovascular repair for juxtarenal aortic pathology. J Vasc Surg 2009; 49:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/42\">",
"      Ziegler P, Avgerinos ED, Umscheid T, et al. Fenestrated endografting for aortic aneurysm repair: a 7-year experience. J Endovasc Ther 2007; 14:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/43\">",
"      Scurr JR, Brennan JA, Gilling-Smith GL, et al. Fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg 2008; 95:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/44\">",
"      Bicknell CD, Cheshire NJ, Riga CV, et al. Treatment of complex aneurysmal disease with fenestrated and branched stent grafts. Eur J Vasc Endovasc Surg 2009; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/45\">",
"      Greenberg RK, Qureshi M. Fenestrated and branched devices in the pipeline. J Vasc Surg 2010; 52:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/46\">",
"      Wang ZG, Li C. Single-branch endograft for treating stanford type B aortic dissections with entry tears in proximity to the left subclavian artery. J Endovasc Ther 2005; 12:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/47\">",
"      Chuter TA, Hiramoto JS, Park KH, Reilly LM. The transition from custom-made to standardized multibranched thoracoabdominal aortic stent grafts. J Vasc Surg 2011; 54:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39560/abstract/48\">",
"      Sweet MP, Hiramoto JS, Park KH, et al. A standardized multi-branched thoracoabdominal stent-graft for endovascular aneurysm repair. J Endovasc Ther 2009; 16:359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16973 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39560=[""].join("\n");
var outline_f38_40_39560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H861295278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295075\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295082\">",
"      AORTIC ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295089\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295096\">",
"      Delivery system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295103\">",
"      Main device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295110\">",
"      Extensions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295117\">",
"      THORACIC DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295124\">",
"      TAG&trade;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295131\">",
"      Zenith&reg; TX2&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295138\">",
"      Talent&reg; Thoracic Stent-Graft System",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295145\">",
"      Valiant&trade; Thoracic Stent-Graft System",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295173\">",
"      Investigational devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114903255\">",
"      - Relay&trade;",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114903262\">",
"      - TAArget&trade;",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114903269\">",
"      - E-Vita&reg;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295180\">",
"      TEVAR TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295250\">",
"      ADVANCED DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295257\">",
"      Fenestrated grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861295264\">",
"      Branched grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295271\">",
"      CHOICE OF DEVICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H861295278\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16973|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/47/5878\" title=\"figure 1\">",
"      Variations of aortic arch branching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/14/43234\" title=\"figure 2\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/52/40777\" title=\"figure 3\">",
"      Pelvic circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/21/38228\" title=\"figure 4\">",
"      Endovascular repair of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/13/37074\" title=\"figure 5\">",
"      Types of endoleak after endovascular repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=related_link\">",
"      Endovascular devices for abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8921?source=related_link\">",
"      Surgical and endovascular repair of blunt thoracic aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8809?source=related_link\">",
"      Surgical and endovascular repair of iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37240?source=related_link\">",
"      Thoracic endovascular aneurysm repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39561="Obstructive sleep apnea in pregnancy";
var content_f38_40_39561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstructive sleep apnea in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Judette Louis, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Grace W Pien, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39561/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/40/39561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13387151\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of obesity in reproductive-aged women has increased in recent years. As a result, the prevalence of obesity-related comorbid conditions complicating pregnancy is also increasing. One of these conditions is obstructive sleep apnea (OSA), which refers to apnea (absent or severely reduced airflow) during sleep despite respiratory effort. OSA is characterized by repetitive partial or complete episodes of upper airway obstruction during sleep. The obstruction results in a reduction of airflow, hypoxemia, sympathetic discharge, and recurrent arousals from sleep. Central sleep apnea, which will not be reviewed here, is a different disorder that is defined by episodes of cessation of airflow due to absent breathing effort. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the diagnosis and management of OSA are similar in pregnant and nonpregnant women, some aspects of the disorder are unique to pregnancy. This topic will discuss OSA in pregnancy. This discussion is limited by the scarcity of studies that address OSA in pregnant women; the only available data come from case studies, case series, small cohort studies, and a few small longitudinal studies. No population based epidemiological studies have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed discussions of sleep related breathing disorders (eg, OSA, central sleep apnea) in nonpregnant individuals are available separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"       \"Sleep related breathing disorders in adults: Definitions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473216504\">",
"    <span class=\"h1\">",
"     PREVALENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of obstructive sleep apnea (OSA) in pregnant women is not known because no large population-based epidemiological studies have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2\">",
"     2",
"    </a>",
"    ]. In the nonpregnant population of reproductive age women, the prevalence of OSA is estimated to be 0.7 to 6.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The prevalence differed, as did the criteria, for the diagnosis of OSA. In the Wisconsin Sleep Cohort Study, a population-based study of American workers, the prevalence of at least mild OSA (defined as an apnea-hypopnea index [AHI] &ge;5",
"    <span class=\"nowrap\">",
"     events/hour",
"    </span>",
"    of sleep) among women 30 to 39 years old was 6.5 percent (95% CI 1.4-11), while moderate to severe OSA (defined as an apnea-hypopnea index [AHI] &gt;15",
"    <span class=\"nowrap\">",
"     events/hour",
"    </span>",
"    of sleep) was 4.4 percent (95% CI 1.1-7.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/6\">",
"     6",
"    </a>",
"    ]. In a separate population based study of sleep disordered breathing, a more stringent definition of OSA was utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/4\">",
"     4",
"    </a>",
"    ]. In that study, OSA (defined as an AHI &gt;10",
"    <span class=\"nowrap\">",
"     events/hour",
"    </span>",
"    of sleep with the presence of clinical symptomatology, eg, daytime sleepiness, hypertension, or other cardiovascular complication) was found to occur in 0.7 percent (95% CI 0.2-2.0) of women 20 to 44 years old. In these studies, increasing age was positively associated with an increasing prevalence of OSA. Among reproductive age women, obesity is the most common risk factor for OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link&amp;anchor=H9969828#H9969828\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473217103\">",
"    <span class=\"h2\">",
"     Physiological changes of pregnancy predisposing to OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The numerous hormonal and physiologic changes occurring in pregnancy may play a role in the prevalence and severity of OSA among pregnant women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oropharyngeal diameter appears to narrow and the Mallampati grade increases as pregnancy progresses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link&amp;anchor=H11#H11\">",
"       \"The difficult airway in adults\", section on 'M: Mallampati score'",
"      </a>",
"      .) Although the role of airway narrowing in OSA has not been studied in pregnancy, there is a significant link between OSA and the internal size of the airway in the general population.",
"     </li>",
"     <li>",
"      Nasal patency is reduced during pregnancy secondary to hyperemia and edema of the nasal mucosa. Changes in the nasal mucosa may be due to increased blood flow and variations in circulating levels of estrogen and progesterone. The increased nasal congestion may lead to increased upper airway resistance and more negative intra-pharyngeal pressure with inspiration, in turn predisposing women in late pregnancy to airway narrowing, and possibly snoring and obstructed breathing in sleep. Pregnant women are more likely to report snoring compared to their nonpregnant counterparts, and the prevalence of frequent snoring (&ge;3",
"      <span class=\"nowrap\">",
"       nights/week)",
"      </span>",
"      increases during pregnancy from the first to the third trimester [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/8,10\">",
"       8,10",
"      </a>",
"      ], as estrogen and progesterone levels increase. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link&amp;anchor=H3#H3\">",
"       \"Respiratory tract changes during pregnancy\", section on 'Upper respiratory system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changes in upper airway patency from other etiologies may also predispose pregnant women to snoring and possibly sleep disordered breathing. In healthy non-pregnant individuals, studies have shown that fluid displacement from the legs into the neck reduces upper airway size and increases upper airway collapsibility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Fluid shifts induced by prolonged sitting and recumbency have been strongly related to the degree of sleep-disordered breathing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/13\">",
"       13",
"      </a>",
"      ], although other data have found that such rostral fluid shifts do not increase the frequency of obstructed breathing events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/14\">",
"       14",
"      </a>",
"      ]. Given that maternal blood volume increases, on average, 40 to 45 percent during pregnancy above nonpregnant levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/15\">",
"       15",
"      </a>",
"      ], recumbency may adversely affect upper airway function and possibly increase the likelihood of sleep-disordered breathing.",
"     </li>",
"     <li>",
"      The increase in progesterone levels during pregnancy leads to increased tidal volume and results in increased minute ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/16\">",
"       16",
"      </a>",
"      ], either due to direct effects on respiratory drive or enhanced sensitivity of the brain&rsquo;s respiratory center to carbon dioxide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/17\">",
"       17",
"      </a>",
"      ]. Increased ventilatory drive during pregnancy may enhance loop-gain and that this may predispose to OSA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473216532\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general clinical manifestations and diagnosis of obstructive sleep apnea (OSA) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The existing literature does not clearly differentiate differences in OSA symptoms and phenotype among reproductive age women and reproductive age men. Among the young and middle aged, men are more likely than women to be referred to a sleep laboratory and diagnosed with OSA; epidemiological studies report a ratio of two to four affected males for each affected female [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2\">",
"     2",
"    </a>",
"    ]. Studies consistently show that women are more likely to be misdiagnosed or diagnosed with OSA at later stages than are men. Although women have the same classic symptoms described in men (witnessed apnea, choking, and restless sleep), women appear to be less likely to self-report these symptoms, leading to misdiagnosis or delayed diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, women have a different spectrum of symptoms than men. In a community-based sample of 551 men and 388 women, women were more likely than men to report daytime fatigue (60.8 versus 49.1 percent), morning headaches (12.5 versus 3.3 percent), and symptoms of depression (6.6 versus 2.7 percent), regardless of the severity of OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difficulty in identifying abnormal sleep symptoms in pregnant women is compounded by the accepted belief that poor sleep and excessive daytime sleepiness are expected during pregnancy. Clinicians and patients fail to identify that abnormal sleep may be a sign of disease and often fail to pursue a diagnosis of OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473216547\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening questionnaires, which are inexpensive and easy to administer, are poorly predictive in women and their weaknesses may be even more prominent in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the largest cohort of pregnant women who completed Berlin questionnaires and underwent overnight polysomnogram, the sensitivity and specificity of the Berlin questionnaire for identifying OSA were only 35 and 63 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our patient population, we do not use the screening questionnaires because of their poor performance. Individuals with obesity related comorbid conditions such as diabetes mellitus and hypertension are considered high risk. If they report snoring, witnessed apneas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    falling asleep while driving, they are referred for evaluation by a sleep medicine specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473216554\">",
"    <span class=\"h2\">",
"     Objective testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that specifically address the best method for objective OSA diagnosis in pregnant women. The gold standard for OSA diagnosis is the full-night, attended, in-laboratory polysomnogram. While unattended, in-home portable monitoring is a reasonable alternative for patients in whom there is a high likelihood of moderate or severe OSA, the American Academy of Sleep Medicine (AASM) guideline for the use of portable monitoring appears to exclude pregnant women from that category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/21\">",
"     21",
"    </a>",
"    ]. This guideline recommended that portable monitoring be used only in populations with substantive data on sensitivity and specificity; such data are not available for pregnancy. The guidelines excluded individuals with comorbid medical or sleep conditions as candidates for portable monitoring; this would exclude a large portion of pregnant women.",
"   </p>",
"   <p>",
"    In our practice, we do not use portable monitoring for diagnosing sleep disorders in pregnant women because of the paucity of data on validity and reliability in this population. All pregnant individuals with suspected sleep abnormalities should be referred to a sleep medicine specialist for evaluation and testing with an in laboratory overnight polysomnogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473216561\">",
"    <span class=\"h2\">",
"     Scoring severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;OSA severity is scored as mild, moderate, or severe, corresponding to an apnea hypopnea index (AHI, average number of apneas plus hypopneas per hour slept) of 5 to 15, 15 to 30, and &gt;30 events per hour, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .) The scoring of individual hypopneic and apneic events is dependent on the scoring criteria used in individual laboratories. The AASM-recommended criteria for identifying a hypopnea event are: &ge;30 percent reduction in nasal pressure signal excursions from baseline and associated &ge;4 percent oxygen desaturation from pre-event baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/22\">",
"     22",
"    </a>",
"    ]. The alternative scoring criteria for a hypopnea event are: &ge;50 percent reduction in nasal pressure signal excursions and associated &ge;3 percent oxygen desaturation or arousal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H7#H7\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Hypopnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies describing normative data in the obstetric population. Some of the physiological changes in pregnancy contribute to the same symptoms as obstructive sleep apnea, such as frequent arousals and daytime sleepiness. Pregnancy related causes of maternal awakening and arousal may be due to fetal movement, urination urge, nocturnal dyspepsia, or leg cramps. All of these symptoms are common in late pregnancy and contribute to sleep fragmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387158\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE OF SNORING AND OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snoring is an acoustic symptom that may be associated with increased upper airway resistance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstructive apneas and hypopneas in some, but not all, patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207469093\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from studies in the general population indicate an increased risk of adverse clinical outcomes associated with untreated OSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic hypertension, mild pulmonary hypertension, coronary artery disease, cerebrovascular disease, cardiac arrhythmias, and ischemic stroke are associated with obstructive sleep apnea (OSA). However, these outcomes may be associated with risk factors common to both OSA and these other conditions. &nbsp;",
"     </li>",
"     <li>",
"      Excessive daytime sleepiness, inattention, and fatigue are also associated with OSA. These outcomes may be caused by OSA; however, sleepiness due to OSA cannot be distinguished behaviorally from sleepiness associated with sleep deprivation.",
"     </li>",
"     <li>",
"      Perioperative complications due to intubation difficulty or impaired arousal from sedatives. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetes or insulin resistance, although this may be due, in part, to risk factors common to both conditions.",
"     </li>",
"     <li>",
"      All-cause mortality, if OSA is moderate or severe. Patients with untreated mild OSA may not be at increased risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions have been mostly described in middle aged men; the significance of OSA in reproductive age women is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, the significance of OSA to maternal and fetal health during the short course of pregnancy remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2379744\">",
"    <span class=\"h2\">",
"     Effect of snoring on pregnancy and infant outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among pregnant women, the prevalence of self-reported snoring has been estimated to be between 14 and 46 percent, with snoring prevalence increasing as gestation advances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Sleep-disordered breathing has been proposed as a risk factor for adverse maternal-fetal outcomes, including preeclampsia and small-for-gestational age births.",
"   </p>",
"   <p>",
"    However, in most individuals, relatively small increases in the number of apneas and hypopneas occur during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This raises the issue of whether other manifestations of sleep-disordered breathing, such as snoring and flow limitation, are important.",
"   </p>",
"   <p>",
"    Several observational studies regarding snoring in pregnant women have reached differing conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/23,24,27-29\">",
"     23,24,27-29",
"    </a>",
"    ]. Two studies recorded higher rates of gestational hypertension, preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/23,28\">",
"     23,28",
"    </a>",
"    ], and delivery of small-for-gestational age infants among habitual snorers compared to non-snorers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/23\">",
"     23",
"    </a>",
"    ]. Another reported new-onset snoring in pregnancy, but not chronic snoring, was a risk factor for preeclampsia and gestational hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, studies focusing primarily on infant outcomes (birth weight, Apgar scores, stillbirth) failed to find significant differences between infants born to snorers and non-snorers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/24,27,30\">",
"     24,27,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473217381\">",
"    <span class=\"h2\">",
"     Effect of OSA on pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207469100\">",
"    <span class=\"h3\">",
"     Maternal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of apnea in pregnancy tend to include women with any one of a number of sleep related breathing disorders (ie, abnormal respiratory pattern or abnormal oxyhemoglobin desaturation), and thus may include a small number of women with central sleep apnea syndrome and hypoventilation syndromes, as well as OSA.",
"   </p>",
"   <p>",
"    The broader classification was used, in part, because most of these studies relied on questionnaires and patient-reported symptoms, without a polysomnogram, so it was not possible to differentiate among the different forms of sleep related breathing disorders. A significant limitation of these studies is that most did not adjust for potential maternal confounders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207468955\">",
"    <span class=\"h4\">",
"     Preeclampsia and gestational hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between OSA and the development of preeclampsia or gestational hypertension has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Retrospective and small cohort studies have reported a two-fold increase in preeclampsia among women with symptoms of sleep disordered breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/31\">",
"     31",
"    </a>",
"    ]. The largest cohort of women with polysomnogram-confirmed OSA (n = 57) found that these women had a significantly higher rate of preeclampsia than normal weight nonpregnant control women (19 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/32\">",
"     32",
"    </a>",
"    ]. This rate was not significantly higher than that associated with obese controls (10 percent), but this may have been due to the relatively small number of cases. Problems in interpretation of these data also include unspecified differences in timing of the polysomnography (some before, and some during the index pregnancy) and unspecified treatment effect (continuous positive airway pressure was titrated in an undisclosed number of the OSA participants; no data regarding the successful use of the positive airway pressure were given). The largest cohort study of women with polysomnogram-confirmed OSA (n = 791) found that, compared to women without the OSA diagnosis, women with OSA had an increased risk of preeclampsia (OR 1.6, 95% CI 2.16&ndash;11.26). The population-based data set lacked body mass index (BMI) data resulting in a reported obesity rate of only 1.6 percent, therefore, the contribution of obesity could not be ascertained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between OSA and hypertension is believed to be a physiological response to intermittent nocturnal hypoxia, which activates the sympathetic nervous system. The recurrent hypoxia and reoxygenation cycles also result in oxidative stress, endothelial dysfunction, and increased oxidative vascular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/35\">",
"     35",
"    </a>",
"    ]. This is believed to be part of the mechanism underlying the development of preeclampsia, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/3\">",
"     3",
"    </a>",
"    ]. This provides a plausible common pathway for the development of early preeclampsia among women with OSA.",
"   </p>",
"   <p>",
"    Data on the clinical course of OSA in the general population also lend support. In two large cohort studies, individuals with untreated OSA were more likely to develop hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/36\">",
"     36",
"    </a>",
"    ]. This association persisted after controlling for confounding variables such as body mass index, ethnicity, and socioeconomic status. However, no studies have associated either presence or severity of nocturnal hypoxemia with any pregnancy outcome.",
"   </p>",
"   <p>",
"    The use of nasal continuous positive airway pressure (CPAP), the first-line therapy for obstructive sleep apnea, for treating the hypertensive conditions of pregnancy was examined in a small, uncontrolled study. When auto-titrating nasal CPAP was administered to 11 women with severe preeclampsia, mean nocturnal blood pressure was modestly reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/37\">",
"     37",
"    </a>",
"    ]. Nevertheless, given the lack of a control group and other study limitations, the results should be interpreted cautiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207468962\">",
"    <span class=\"h4\">",
"     Gestational diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between OSA and insulin resistance in the general population is well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Independent of other risk factors, individuals with OSA have an increased risk of developing type II diabetes, hyperinsulinemia, and metabolic syndrome. While a causal link has not been proven, improved glucose control has been observed after initiating treatment of OSA with continuous positive airway pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies have provided evidence that pregnant women with an increased risk of sleep disordered breathing as assessed by questionnaires, or self-reported snoring or short sleep times, are at increased risk of developing gestational diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Conclusions drawn from such data must take into consideration the limited sensitivity and specificity of standard questionnaires to predict obstructive sleep apnea in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/19\">",
"     19",
"    </a>",
"    ]. Pregnant women with polysomnographic evidence of sleep-disordered breathing have been found to have increased risk of composite adverse pregnancy outcomes including gestational diabetes, pregnancy related hypertension, and preterm birth; these data, however, did not control fully for the effect of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased risk of gestational diabetes in OSA patients is plausible since increasing insulin resistance occurs in pregnancy. Although there is no evidence of the value of early screening in this population, we screen pregnant women with OSA for diabetes early in pregnancy and repeat screening at 24 to 28 weeks in those with an initially negative screen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757881\">",
"    <span class=\"h4\">",
"     Preterm delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study reported an increased risk of preterm birth among pregnant women with OSA compared with normal weight controls (29.8 versus 12.3 percent; OR 2.6; 95% CI 1.02&ndash;6.6 after controlling for comorbid conditions), although preterm birth was mostly associated with preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207470132\">",
"    <span class=\"h3\">",
"     Fetal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small cohort studies have attempted to determine whether maternal OSA affects the fetus. The best data, although sparse and observational, suggest that it does not. Reports of adverse fetal effects are likely related to factors such as lack of adjustment for confounders (eg, preeclampsia), inadequate case ascertainment, and publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/48-52\">",
"     48-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207470139\">",
"    <span class=\"h4\">",
"     Fetal heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although case reports have described an association between OSA and fetal heart decelerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], the best available data come from a cohort study including 100 pregnant women who underwent simultaneous fetal monitoring and in hospital polysomnogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, none of the apnea episodes were associated with any fetal tracing abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207470153\">",
"    <span class=\"h4\">",
"     Birthweight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although case reports have described an association between OSA and impaired fetal growth, confounders such as preeclampsia were generally present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/33,50-52\">",
"     33,50-52",
"    </a>",
"    ]. This association was also observed in a study using a rat model of OSA; however, the pregnant rats were exposed to intermittent hypoxia (10 percent oxygen in air) every 90 seconds until delivery, which does not accurately mimic human OSA pathophysiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/53\">",
"     53",
"    </a>",
"    ]. Better studies in humans are needed, which take into account the multiple factors that affect birth weight negatively (eg, preeclampsia, poor gestational weight gain) and positively (eg, obesity, diabetes, excessive gestational weight gain).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207470484\">",
"    <span class=\"h4\">",
"     Intrauterine fetal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the effect of OSA on risk of intrauterine fetal demise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473217374\">",
"    <span class=\"h2\">",
"     Effect of pregnancy on OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies investigating the difference in clinical outcomes between women with preexisting OSA and those who develop the condition during pregnancy. Evidence from small cohort studies indicates that pregnancy may exacerbate underlying sleep related breathing disorders. In one longitudinal study that included 10 women who presented with a sleep related breathing disorder in the third trimester, apnea severity improved after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/54\">",
"     54",
"    </a>",
"    ]. However, 70 percent of the women still had the disorder up to three months postpartum. This study did not account for possible body position effects on the degree of sleep disordered breathing, the decrease in weight related to delivery, and body fat composition and distribution, all of which possibly contributed to these findings. No large scale longitudinal studies have assessed sleep related breathing disorder in pregnancy using objective measures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387236\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473217578\">",
"    <span class=\"h2\">",
"     Options",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other aspects of obstructive sleep apnea (OSA), the approach to treatment of OSA in pregnancy is based on extrapolation from data in the general population. There are no pregnancy-specific guidelines for OSA treatment, no data on which to base fetal or maternal parameters for treatment, and no evidence that treatment in the short term impacts maternal or neonatal morbidity. In the absence of scientific evidence, clinicians have used their own protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/55\">",
"     55",
"    </a>",
"    ] or followed the published recommendations for treatment in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In our practice, we treat all pregnant women with moderate or severe OSA by apnea hypopnea index (AHI) criteria. In the general population, therapies for OSA include continuous positive airway pressure (CPAP), oral appliances, upper airway surgery, and behavior modification. The indications for treatment and these treatments are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348918127\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No pharmacologic agent prevents or overcomes upper airway obstruction well enough to justify pharmacologic therapy as a primary therapy in the routine management of patients with OSA.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    has been used to treat the sleepiness (not the apnea) associated with OSA. Women with OSA who become pregnant while being treated with modafinil or similar stimulants should be counseled about the paucity of safety data in pregnancy. Listed as an FDA category C, some animal studies have demonstrated embryotoxicity in the absence of maternal toxicity. According to the manufacturer, there were no reported adverse effects in seven human births reported after exposure to modafinil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/58\">",
"     58",
"    </a>",
"    ]. There are no data on excretion of modafinil in human milk. For these reasons, we recommend stopping modafinil during pregnancy and lactation. When discontinued, patients should be warned about increased sleepiness and take appropriate precautions, such as when driving. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3801?source=see_link\">",
"     \"Pharmacologic treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348918134\">",
"    <span class=\"h3\">",
"     CPAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAP is generally regarded as first-line therapy for pregnant women with OSA, similar to the general population. We recommend in-laboratory polysomnography for the initial titration of CPAP, if the study (eg, a single-night split baseline and CPAP titration study, or a titration study performed within a few days of a full-night baseline polysomnography) and subsequent ordering of CPAP therapy can be done expeditiously. In-laboratory CPAP titration allows patients&rsquo; initial experience with CPAP to occur in a monitored setting so that questions and problems (such as CPAP mask leaks) can be addressed in real-time. Following an in-laboratory CPAP titration study, fixed-pressure CPAP therapy is an option; providers should recognize, however, that the therapeutic CPAP pressure may need to be increased over the course of pregnancy according to patient symptoms (eg, snoring while using CPAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/59\">",
"     59",
"    </a>",
"    ]. For this reason, we prefer prescribing auto-titrating CPAP for treatment of OSA during pregnancy, using the results of the CPAP titration study as a guide to the range of pressures to be prescribed. When in-laboratory CPAP titration cannot be obtained quickly, auto-titrating CPAP therapy can be initiated empirically without an additional sleep study. In either case, follow-up should occur within one to two weeks after initiation of CPAP therapy and regularly thereafter (eg, every one to three months during pregnancy) so that adherence to and efficacy of CPAP treatment can be assessed and adjusted as needed.",
"   </p>",
"   <p>",
"    The safety of CPAP therapy in pregnancy has not been systematically studied, but case reports have not described adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2,60\">",
"     2,60",
"    </a>",
"    ]. In the general population, the most common side effects of CPAP use include rhinitis, skin abrasions, mouth dryness and aerophagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/61\">",
"     61",
"    </a>",
"    ]. These complaints are echoed by pregnant patients in our clinics, who often cite nasal congestion and lack of symptomatic improvement as reasons for nonadherence. One theoretical concern of nasal CPAP is the potential for decreased cardiac output due to the applied positive intrathoracic pressure. A study of 24 women with severe preeclampsia observed that their cardiac output decreased during sleep (from 7.7",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    to 5.7",
"    <span class=\"nowrap\">",
"     L/min),",
"    </span>",
"    but remained at baseline when the women were treated with CPAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/62\">",
"     62",
"    </a>",
"    ]. These data may not apply to pregnant persons with OSA who are not preeclamptic.",
"   </p>",
"   <p>",
"    It is estimated that only 50 percent of individuals are adherent to CPAP therapy, but the compliance in pregnancy has not been reported. In our pregnant population, we have found adherence rates that are similar to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/63\">",
"     63",
"    </a>",
"    ]. Pregnant patients in our clinics often cite nasal congestion and lack of symptomatic improvement as reasons for nonadherence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348918141\">",
"    <span class=\"h3\">",
"     Devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Customized oral mandibular repositioning devices, which are noninvasive and keep the airway open by pulling the lower jaw forward, can be an effective treatment for mild to moderate OSA for individuals with good dentition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/64\">",
"     64",
"    </a>",
"    ]. However, only 35 to 40 percent of patients achieve a reduction in the degree of sleep-disordered breathing to normal levels (ie, AHI &lt;5",
"    <span class=\"nowrap\">",
"     events/hour),",
"    </span>",
"    and oxyhemoglobin saturation levels often do not return to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/65\">",
"     65",
"    </a>",
"    ]. This latter point is an important consideration, given the potential for fetal hypoxemia among pregnant women with OSA. Furthermore, the multiple fittings that can be needed to initiate oral appliance use and the potential need for frequent refitting due to the potentially rapid weight gain of pregnancy are likely to make this treatment impractical for pregnant women. No mandibular repositioning device data exist in pregnant women with OSA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1704?source=see_link\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348918148\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the general population, surgical treatments for mild to moderate obstructive sleep apnea, such as uvulopalatopharyngoplasty, generally achieve a reduction in AHI to the normal range in less than half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/66\">",
"     66",
"    </a>",
"    ]. Given the relative lack of efficacy and the potential for adverse consequences associated with surgery and anesthesia (which are likely to be magnified during pregnancy), uvulopalatopharyngoplasty and other surgeries for OSA are generally not suitable approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348918155\">",
"    <span class=\"h3\">",
"     Gestational weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss, which has been demonstrated to improve comorbid conditions and decrease the overall AHI, is not recommended in pregnancy. However, limiting weight gain may benefit an individual&rsquo;s global risk for pregnancy related morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19304?source=see_link&amp;anchor=H4#H4\">",
"     \"Weight gain and loss in pregnancy\", section on 'Recommendations for weight gain during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757923\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;General measures that can be helpful in OSA include position adjustment to favor the lateral recumbent or head elevated position and avoidance of respiratory destabilizing drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380104\">",
"    <span class=\"h2\">",
"     Antepartum management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380111\">",
"    <span class=\"h3\">",
"     Pre-existing OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with known OSA who become pregnant should be evaluated and followed by a sleep medicine provider. This is particularly important if the patient has not been evaluated in the previous six months or is not being treated. Their provider can assess symptoms and evaluate the need for a CPAP titration or, in some cases, repeat polysomnography. These individuals may be at risk for developing pregnancy related hypertensive disease, so blood pressure and urine protein should be monitored closely. Given the high risk of underlying diabetes in individuals with OSA, we suggest early testing for diabetes. In our practice, we perform an early glucose tolerance test. If it is normal, it is repeated at the 24 to 28 weeks gestational age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380126\">",
"    <span class=\"h3\">",
"     Newly diagnosed OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptoms of excessive sleepiness or who are suspected of having OSA should be referred to a sleep medicine specialist for evaluation. This provider can evaluate the patient and participate in her care throughout the pregnancy and after delivery. In the absence of pregnancy specific data to direct treatment, we suggest treatment for all women with moderate or severe OSA. The goal of treatment is to normalize the AHI and to alleviate any nocturnal hypoxemia. Among pregnant women with mild OSA, usual indications for treatment of OSA (such as excessive daytime somnolence) can first be considered when deciding whether to recommend treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Indications for treatment'",
"    </a>",
"    .) In addition, we believe that pregnant women with mild OSA should be treated if they have recurrent oxyhemoglobin desaturations to less than 90 percent, given the potential for adverse effects of hypoxemia on the fetus. Among otherwise asymptomatic pregnant women with mild OSA who develop adverse outcomes that have been associated with OSA (eg, the hypertensive diseases of pregnancy or gestational diabetes), a trial of CPAP therapy may be considered but is not clearly indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387300\">",
"    <span class=\"h2\">",
"     Intrapartum management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancies affected by OSA should be considered &ldquo;high risk&rdquo; pregnancies. Maternal risks include hypoxemia and morbidity from the comorbid conditions that often track with OSA. Many intrapartum issues related to OSA overlap with the risks of obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .) Continuous pulse oximetry during labor and the postpartum period will help identify hypoxemia and help tailor further management.",
"   </p>",
"   <p>",
"    Ideally, the anesthesia service is consulted prenatally, but at least early in the patient&rsquo;s labor. Early placement of regional anesthesia may prevent the need for general anesthesia if emergent cesarean delivery becomes necessary. General anesthesia has been associated with an increase in maternal morbidity and mortality, which is more profound in individuals with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/67\">",
"     67",
"    </a>",
"    ]. Regional anesthesia also avoids the potential need for opioids to manage labor pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who have been using CPAP, another positive pressure modality, or an oral appliance prior to delivery for OSA are instructed to bring their devices when they present for delivery. Patients with OSA should have their oxygenation continuously monitored during labor with a pulse oximeter. If hypoxemia is observed, a comprehensive clinical evaluation should be performed to determine the etiology. The clinical evaluation should focus on respiratory causes of hypoxemia and, in particular, any potentially life-threatening causes such as pulmonary embolus. Pregnant women who are suspected of having OSA, or who are found to have OSA and are not on therapy or adequate therapy, should be referred to a physician with expertise and experience in sleep medicine for possible intrapartum management and postpartum follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387307\">",
"    <span class=\"h2\">",
"     Postpartum management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of opioids in individuals with sleep apnea is an area of significant concern. Opioids can suppress the respiratory drive, blunt the arousal response, and cause nocturnal hypoxemia. There have been reports of sudden death with the use of narcotics in subjects with sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/68\">",
"     68",
"    </a>",
"    ]. The following general guidelines apply to management of postpartum patients with OSA after vaginal delivery and after cesarean delivery: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link\">",
"     \"Postoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with OSA who were receiving therapy (eg, positive airway pressure, oral appliances, etc) prior to delivery should resume the therapy as soon as feasible after delivery. A physician with experience and expertise in sleep medicine should be consulted to participate in management if such a physician has not already been involved in the patient&rsquo;s care. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link&amp;anchor=H2526386#H2526386\">",
"       \"Postoperative management of adults with obstructive sleep apnea\", section on 'OSA-specific therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use an analgesic strategy that minimizes the need for systemic opioids, such as use of nonsteroidal antiinflammatory drugs. Neuraxial analgesia is also acceptable for women who have undergone cesarean delivery, but it must be employed with caution. Use of any drugs that suppresses",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      activity should be minimized. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link&amp;anchor=H2526372#H2526372\">",
"       \"Postoperative management of adults with obstructive sleep apnea\", section on 'Pain control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If hypoxemia is observed, provide supplemental oxygen after delivery to maintain oxygen saturation by pulse oximetry &ge;96 percent while sleeping and undisturbed. This should be continued until the patient is able to maintain her baseline oxyhemoglobin saturation while breathing room air. This management is recommended for all women with diagnosed or suspected OSA. The use of CPAP in women with OSA in the postpartum period may be sufficient to treat the hypoxemia; however, the CPAP settings should be adjusted to assure normoxic values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link&amp;anchor=H2526379#H2526379\">",
"       \"Postoperative management of adults with obstructive sleep apnea\", section on 'Oxygenation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The supine position worsens OSA in some patients. Thus, it seems reasonable to care for patients who have OSA in the lateral or upright position, if possible, especially when they are taking opioids.",
"     </li>",
"     <li>",
"      A scoring system developed by the American Society of Anesthesiologists (ASA) to assess the risk of perioperative complications in patients with OSA may be helpful in identifying patients at increased risk for postdelivery complications (",
"      <a class=\"graphic graphic_table graphicRef70982 \" href=\"mobipreview.htm?21/41/22173\">",
"       table 1",
"      </a>",
"      ); patients with a score of four or more should be monitored with continuous pulse oximetry. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link&amp;anchor=H2526400#H2526400\">",
"       \"Postoperative management of adults with obstructive sleep apnea\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with OSA should be counseled about the risks related to breastfeeding and childcare if they have symptoms of excessive sleepiness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387314\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women diagnosed with, or suspected of having, OSA during pregnancy should be followed postpartum by a physician with specific training and experience in sleep medicine to allow for re-assessment of OSA severity and overall",
"    <span class=\"nowrap\">",
"     management/treatment",
"    </span>",
"    strategy (eg, re-evaluation of CPAP prescription requirements, oral appliance prescription, weight management, etc). Women diagnosed with OSA during pregnancy should have repeat testing, particularly after losing their pregnancy weight. At our institutions, we generally recommend that this evaluation take place 8 to 12 weeks after delivery. However, it is important to keep in mind that although up to 80 percent of gestational weight gain is usually lost within six weeks of delivery, weight loss can continue for several months postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39561/abstract/69\">",
"     69",
"    </a>",
"    ]. Thus, postpartum management of sleep apnea needs to be individualized. In obese women, we recommend weight management strategies which, in addition to providing benefit with regard to OSA, will help in the management of their comorbid conditions and improve overall health before their next pregnancy.",
"   </p>",
"   <p>",
"    There are no data regarding the effect of an interval pregnancy on the natural history of OSA, or regarding whether the development of incident OSA during one pregnancy increases the risk for OSA in subsequent pregnancies. Similarly, whether a prior history of gestational OSA affects risk for adverse maternal-fetal outcomes in subsequent pregnancies (when OSA has not recurred) has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387321\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiological changes related to pregnancy may worsen pre-existing obstructive sleep apnea (OSA) or lead to gestational OSA. (See",
"      <a class=\"local\" href=\"#H473217103\">",
"       'Physiological changes of pregnancy predisposing to OSA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H473217374\">",
"       'Effect of pregnancy on OSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians and patients may think that poor sleep and excessive daytime sleepiness are normal symptoms of pregnancy, and thus fail to evaluate the patient for OSA. (See",
"      <a class=\"local\" href=\"#H473216532\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two potential effects of OSA on pregnancy include increased risks of developing preeclampsia and gestational diabetes. There are no clear adverse fetal effects, apart from sequelae from these pregnancy complications. (See",
"      <a class=\"local\" href=\"#H473217381\">",
"       'Effect of OSA on pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no pregnancy-specific guidelines for OSA treatment, no data on which to base fetal or maternal parameters for treatment, and no evidence that treatment in the short term impacts pregnancy outcome. In the general population, therapies for OSA include continuous positive airway pressure (CPAP), oral appliances, and behavior modification. The indications for treatment and these treatments are reviewed separately. Women with pregestational OSA should have an evaluation by a sleep provider for CPAP management during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H473217578\">",
"       'Options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with OSA should be managed with a sleep medicine specialist. Intrapartum care should include an early consultation with the anesthesia service for placement of regional anesthesia and continuous pulse oximetry. Patients receiving opiates should be observed closely for respiratory suppression. (See",
"      <a class=\"local\" href=\"#H13387300\">",
"       'Intrapartum management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpartum, use an analgesic strategy that minimizes the need for systemic opioids and other drugs that suppress",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      function. (See",
"      <a class=\"local\" href=\"#H13387307\">",
"       'Postpartum management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Edwards N. Sleep-Disordered Breathing in Pregnancy. Sleep Medicine Clin 2008; 3:81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/2\">",
"      Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 1: Clinical features. Sleep 2002; 25:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/3\">",
"      Pien GW, Schwab RJ. Sleep disorders during pregnancy. Sleep 2004; 27:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/4\">",
"      Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/5\">",
"      Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2003; 167:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/6\">",
"      Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/7\">",
"      Edwards N, Middleton PG, Blyton DM, Sullivan CE. Sleep disordered breathing and pregnancy. Thorax 2002; 57:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/8\">",
"      Izci B, Vennelle M, Liston WA, et al. Sleep-disordered breathing and upper airway size in pregnancy and post-partum. Eur Respir J 2006; 27:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/9\">",
"      Pilkington S, Carli F, Dakin MJ, et al. Increase in Mallampati score during pregnancy. Br J Anaesth 1995; 74:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/10\">",
"      Facco FL, Kramer J, Ho KH, et al. Sleep disturbances in pregnancy. Obstet Gynecol 2010; 115:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/11\">",
"      Shiota S, Ryan CM, Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007; 62:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/12\">",
"      Su MC, Chiu KL, Ruttanaumpawan P, et al. Lower body positive pressure increases upper airway collapsibility in healthy subjects. Respir Physiol Neurobiol 2008; 161:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/13\">",
"      Redolfi S, Yumino D, Ruttanaumpawan P, et al. Relationship between overnight rostral fluid shift and Obstructive Sleep Apnea in nonobese men. Am J Respir Crit Care Med 2009; 179:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/14\">",
"      Jafari B, Mohsenin V. Overnight rostral fluid shift in obstructive sleep apnea: does it affect the severity of sleep-disordered breathing? Chest 2011; 140:991.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham, FG, Gant, NF, Leveno, KJ, Gilstrap, LC III. Maternal adaptations to pregnancy. In: Williams Obstetrics, 21st ed, McGraw-Hill, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/16\">",
"      Rees GB, Broughton Pipkin F, Symonds EM, Patrick JM. A longitudinal study of respiratory changes in normal human pregnancy with cross-sectional data on subjects with pregnancy-induced hypertension. Am J Obstet Gynecol 1990; 162:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/17\">",
"      Zwillich CW, Natalino MR, Sutton FD, Weil JV. Effects of progesterone on chemosensitivity in normal men. J Lab Clin Med 1978; 92:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/18\">",
"      Lamberg L. Sleeping poorly while pregnant may not be \"normal\". JAMA 2006; 295:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/19\">",
"      Olivarez SA, Maheshwari B, McCarthy M, et al. Prospective trial on obstructive sleep apnea in pregnancy and fetal heart rate monitoring. Am J Obstet Gynecol 2010; 202:552.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/20\">",
"      Facco FL, Ouyang DW, Zee PC, Grobman WA. Development of a pregnancy-specific screening tool for sleep apnea. J Clin Sleep Med 2012; 8:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/21\">",
"      Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007; 3:737.",
"     </a>",
"    </li>",
"    <li>",
"     Iber, C, Ancoli-Israel, S, Chesson, A, Quan, S. The American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st ed, American Academy of Sleep Medicine, Westchester IL 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/23\">",
"      Franklin KA, Holmgren PA, J&ouml;nsson F, et al. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest 2000; 117:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/24\">",
"      Loube DI, Poceta JS, Morales MC, et al. Self-reported snoring in pregnancy. Association with fetal outcome. Chest 1996; 109:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/25\">",
"      Guilleminault C, Palombini L, Poyares D, et al. Pre-eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk-factors for pre-eclampsia: preliminary findings. Sleep Med 2007; 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/26\">",
"      Maasilta P, Bachour A, Teramo K, et al. Sleep-related disordered breathing during pregnancy in obese women. Chest 2001; 120:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/27\">",
"      Lau SK, Woo PC, Yim TC, et al. Molecular characterization of a strain of group a streptococcus isolated from a patient with a psoas abscess. J Clin Microbiol 2003; 41:4888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/28\">",
"      P&eacute;rez-Chada D, Videla AJ, O'Flaherty ME, et al. Snoring, witnessed sleep apnoeas and pregnancy-induced hypertension. Acta Obstet Gynecol Scand 2007; 86:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/29\">",
"      O'Brien LM, Bullough AS, Owusu JT, et al. Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study. Am J Obstet Gynecol 2012; 207:487.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/30\">",
"      Stacey T, Thompson JM, Mitchell EA, et al. Association between maternal sleep practices and risk of late stillbirth: a case-control study. BMJ 2011; 342:d3403.",
"     </a>",
"    </li>",
"    <li>",
"     Bourjeily, G, Raker, CA, Chalhoub, M, Miller, MA. Sleep disordered breathing symptoms in pregnancy and adverse pregnancy and fetal outcomes. Eur Respir J 2010; :.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/32\">",
"      Louis JM, Auckley D, Sokol RJ, Mercer BM. Maternal and neonatal morbidities associated with obstructive sleep apnea complicating pregnancy. Am J Obstet Gynecol 2010; 202:261.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/33\">",
"      Chen YH, Kang JH, Lin CC, et al. Obstructive sleep apnea and the risk of adverse pregnancy outcomes. Am J Obstet Gynecol 2012; 206:136.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/34\">",
"      Louis J, Auckley D, Miladinovic B, et al. Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women. Obstet Gynecol 2012; 120:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/35\">",
"      Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008; 177:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/36\">",
"      Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/37\">",
"      Edwards N, Blyton DM, Kirjavainen T, et al. Nasal continuous positive airway pressure reduces sleep-induced blood pressure increments in preeclampsia. Am J Respir Crit Care Med 2000; 162:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/38\">",
"      Jean-Louis G, Zizi F, Clark LT, et al. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med 2008; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/39\">",
"      Trakada G, Chrousos G, Pejovic S, Vgontzas A. Sleep Apnea and its association with the Stress System, Inflammation, Insulin Resistance and Visceral Obesity. Sleep Med Clin 2007; 2:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/40\">",
"      Lurie A. Metabolic disorders associated with obstructive sleep apnea in adults. Adv Cardiol 2011; 46:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/41\">",
"      L&eacute;vy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/42\">",
"      Steiropoulos P, Papanas N, Nena E, et al. Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev 2010; 6:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/43\">",
"      Reutrakul S, Zaidi N, Wroblewski K, et al. Sleep disturbances and their relationship to glucose tolerance in pregnancy. Diabetes Care 2011; 34:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/44\">",
"      Qiu C, Enquobahrie D, Frederick IO, et al. Glucose intolerance and gestational diabetes risk in relation to sleep duration and snoring during pregnancy: a pilot study. BMC Womens Health 2010; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/45\">",
"      Bourjeily G, Raker CA, Chalhoub M, Miller MA. Pregnancy and fetal outcomes of symptoms of sleep-disordered breathing. Eur Respir J 2010; 36:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/46\">",
"      Facco FL, Grobman WA, Kramer J, et al. Self-reported short sleep duration and frequent snoring in pregnancy: impact on glucose metabolism. Am J Obstet Gynecol 2010; 203:142.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/47\">",
"      Catalano PM. Management of obesity in pregnancy. Obstet Gynecol 2007; 109:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/48\">",
"      Roush SF, Bell L. Obstructive sleep apnea in pregnancy. J Am Board Fam Pract 2004; 17:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/49\">",
"      Sahin FK, Koken G, Cosar E, et al. Obstructive sleep apnea in pregnancy and fetal outcome. Int J Gynaecol Obstet 2008; 100:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/50\">",
"      Charbonneau M, Falcone T, Cosio MG, Levy RD. Obstructive sleep apnea during pregnancy. Therapy and implications for fetal health. Am Rev Respir Dis 1991; 144:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/51\">",
"      Joel-Cohen SJ, Schoenfeld A. Fetal response to periodic sleep apnea: a new syndrome in obstetrics. Eur J Obstet Gynecol Reprod Biol 1978; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/52\">",
"      Schoenfeld A, Ovadia Y, Neri A, Freedman S. Obstructive sleep apnea (OSA)-implications in maternal-fetal medicine. A hypothesis. Med Hypotheses 1989; 30:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/53\">",
"      Gozal D, Reeves SR, Row BW, et al. Respiratory effects of gestational intermittent hypoxia in the developing rat. Am J Respir Crit Care Med 2003; 167:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/54\">",
"      Edwards N, Blyton DM, Hennessy A, Sullivan CE. Severity of sleep-disordered breathing improves following parturition. Sleep 2005; 28:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/55\">",
"      Louis J, Auckley D, Bolden N. Management of obstructive sleep apnea in pregnant women. Obstet Gynecol 2012; 119:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/56\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/57\">",
"      Holty JE, Guilleminault C. Surgical options for the treatment of obstructive sleep apnea. Med Clin North Am 2010; 94:479.",
"     </a>",
"    </li>",
"    <li>",
"     Reprotox. (Accessed January 7, 2011)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/59\">",
"      Guilleminault C, Kreutzer M, Chang JL. Pregnancy, sleep disordered breathing and treatment with nasal continuous positive airway pressure. Sleep Med 2004; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/60\">",
"      Venkata C, Venkateshiah SB. Sleep-disordered breathing during pregnancy. J Am Board Fam Med 2009; 22:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/61\">",
"      Kakkar RK, Berry RB. Positive airway pressure treatment for obstructive sleep apnea. Chest 2007; 132:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/62\">",
"      Blyton DM, Sullivan CE, Edwards N. Reduced nocturnal cardiac output associated with preeclampsia is minimized with the use of nocturnal nasal CPAP. Sleep 2004; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/63\">",
"      Flemons WW. Clinical practice. Obstructive sleep apnea. N Engl J Med 2002; 347:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/64\">",
"      Wickwire EM, Collop NA. Insomnia and sleep-related breathing disorders. Chest 2010; 137:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/65\">",
"      Chan AS, Lee RW, Cistulli PA. Non-positive airway pressure modalities: mandibular advancement devices/positional therapy. Proc Am Thorac Soc 2008; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/66\">",
"      Won CH, Li KK, Guilleminault C. Surgical treatment of obstructive sleep apnea: upper airway and maxillomandibular surgery. Proc Am Thorac Soc 2008; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/67\">",
"      Passannante AN, Tielborg M. Anesthetic management of patients with obesity with and without sleep apnea. Clin Chest Med 2009; 30:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/68\">",
"      Mickelson SA. Preoperative and postoperative management of obstructive sleep apnea patients. Otolaryngol Clin North Am 2007; 40:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39561/abstract/69\">",
"      Schauberger CW, Rooney BL, Brimer LM. Factors that influence weight loss in the puerperium. Obstet Gynecol 1992; 79:424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14202 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39561=[""].join("\n");
var outline_f38_40_39561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13387321\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13387151\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473216504\">",
"      PREVALENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473217103\">",
"      Physiological changes of pregnancy predisposing to OSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473216532\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473216547\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473216554\">",
"      Objective testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473216561\">",
"      Scoring severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13387158\">",
"      SIGNIFICANCE OF SNORING AND OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H207469093\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2379744\">",
"      Effect of snoring on pregnancy and infant outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473217381\">",
"      Effect of OSA on pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207469100\">",
"      - Maternal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207468955\">",
"      Preeclampsia and gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207468962\">",
"      Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H757881\">",
"      Preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207470132\">",
"      - Fetal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207470139\">",
"      Fetal heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207470153\">",
"      Birthweight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H207470484\">",
"      Intrauterine fetal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473217374\">",
"      Effect of pregnancy on OSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13387236\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473217578\">",
"      Options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348918127\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348918134\">",
"      - CPAP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348918141\">",
"      - Devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348918148\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348918155\">",
"      - Gestational weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H757923\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2380104\">",
"      Antepartum management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2380111\">",
"      - Pre-existing OSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2380126\">",
"      - Newly diagnosed OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13387300\">",
"      Intrapartum management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13387307\">",
"      Postpartum management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13387314\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13387321\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14202\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14202|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/41/22173\" title=\"table 1\">",
"      OSA scoring system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1704?source=related_link\">",
"      Oral appliances in the treatment of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3801?source=related_link\">",
"      Pharmacologic treatment of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=related_link\">",
"      Postoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39562="Adverse effects of neuraxial analgesia and anesthesia for obstetrics";
var content_f38_40_39562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     Gilbert J Grant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/40/39562/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/40/39562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review prevention and treatment of adverse effects of regional anesthetic techniques when used peripartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTEMIC TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic toxicity of local anesthetics is related to high plasma drug concentrations. The most common etiology is accidental injection of local anesthetic into a blood vessel. Systemic toxicity manifests in the central nervous system (CNS) as tinnitus, disorientation, and (ultimately) seizures; in the cardiovascular system toxicity manifests as hypotension, dysrhythmias, and cardiac arrest. CNS toxicity typically precedes cardiovascular toxicity, thus patients may experience cerebral signs without hemodynamic compromise.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    toxicity does not follow this sequence; cardiac toxicity may occur in the absence of CNS toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic toxicity is more common after epidural than after spinal administration because intrathecal drug doses are lower than epidural doses. Nevertheless, the risk of systemic toxicity after epidural labor analgesia is quite low since the drug doses used for analgesia are very low; the risk of systemic toxicity is greater with epidural anesthesia use for cesarean delivery since higher drug doses are used.",
"   </p>",
"   <p>",
"    The likelihood of systemic toxicity can be reduced by aspirating the catheter before injecting to help ascertain that its distal aperture(s) is (are) not located within a blood vessel. Other measures to reduce the risk of toxicity include adding epinephrine to the solution to delay intravascular absorption, using a test dose, injecting a local anesthetic with a lower toxicity profile, reducing the total dose injected, and administering the dose incrementally. Catheter type also affects this risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of flexible epidural catheters has decreased the incidence of inadvertent venous cannulation from 5.7 to 1.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If CNS signs of local anesthetic toxicity develop, the injection should be stopped immediately. Seizures cay be treated with a small dose of benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    2 to 5 mg) or barbiturate (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    50 to 75 mg). Oxygen should be administered, as seizure activity increases maternal oxygen consumption, which will decrease oxygen delivery to the fetus. The patient should be protected from injuring herself during the seizure and her airway should be protected.",
"   </p>",
"   <p>",
"    If cardiovascular toxicity occurs, advanced cardiac life support (ACLS) should be provided with certain considerations specific to local anesthetic toxicity. Airway management is critical, as cardiotoxicity is exacerbated by hypercapnia, hypoxia, and acidosis. Beginning at 20 weeks of gestation, the enlarging uterus may compress the vena cava and aorta, decreasing venous return and cardiac output. Leftward displacement of the uterus to avoid compression of the major vessels is important to maximize the efficacy of cardiopulmonary resuscitation. Another consideration specific to ACLS in pregnant women greater than 20 weeks of gestation is whether to perform an emergency cesarean delivery. This decision is based on both the viability of the fetus and, more importantly, the effect of delivery on the success of maternal resuscitation. By relieving compression of the vena cava and aorta, delivery of the baby has salutary effects on maternal hemodynamics. It also permits access to the baby so that resuscitation efforts may be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20840?source=see_link\">",
"     \"Management of cardiopulmonary arrest in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysrhythmias are difficult to control, especially those resulting from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , a primary drug in the ACLS arrhythmia treatment algorithm, is the favored treatment for severe bupivacaine-induced arrhythmias; administration of the local anesthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to treat local anesthetic toxicity has had equivocal success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/4\">",
"     4",
"    </a>",
"    ], and is best avoided. The dysrhythmias are often recalcitrant to therapy; emergency cardiopulmonary bypass may be lifesaving until the drug dissociates from cardiac tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early administration of lipid emulsion (eg, 20 percent intralipid) is now a major component in resuscitation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    -induced cardiotoxicity. This therapy has rapidly gained acceptance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/6\">",
"     6",
"    </a>",
"    ] since the first case reports documenting its efficacy were published in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Lipid rescue should be initiated at the first signs of severe systemic local anesthetic toxicity, after the airway has been secured. An intravenous bolus of 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    lean body mass of 20 percent lipid emulsion is given over one minute, followed by an infusion of 0.25",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    until at least 10 minutes following successful achievement of circulatory stability. If circulatory stability is not obtained within five minutes, a second 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    bolus may be administered, followed by an infusion of 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/min.",
"    </span>",
"    The maximum total cumulative dose of lipid is 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the anesthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is formulated as a 10 percent lipid emulsion, it should not be used for lipid rescue, since the dose needed to treat local anesthetic toxicity would result in massive hypotension that may counteract any positive effect.",
"   </p>",
"   <p>",
"    While hypotension associated with local anesthetic toxicity should be treated with small doses of epinephrine (eg, 10 to 100 micrograms), vasopressin should be avoided, as it has not been shown to be superior to epinephrine in treating cardiac arrest. Beta blockers and calcium channel blockers should also be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    should also be avoided in the management of local anesthetic induced cardiotoxicity, as it may worsen the toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25977?source=see_link&amp;anchor=H7#H7\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Drugs\", section on 'Bupivacaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Use of test dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;After insertion of an epidural catheter, a small test dose may be injected to exclude intravascular or intrathecal placement. A typical test dose is 3 mL of 1.5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with 1:200,000 epinephrine (ie, 45 mg lidocaine and 15 mcg epinephrine). The patient is monitored for signs and symptoms of intravascular or intrathecal injection. If this test dose is injected intravascularly, the lidocaine produces tinnitus, circumoral numbness, a metallic taste, and dizziness, and the beta-1 adrenergic agonist effect of epinephrine induces tachycardia. However, the wide variations in heart rate that occur with labor pain may mask epinephrine-induced increases in heart rate. Thus, to maximize sensitivity, the test dose should be administered immediately after a uterine contraction. The subjective sensation of palpitations is a reliable symptom of intravascular administration, irrespective of the monitored heart rate. Intrathecal injection of the test dose causes rapid onset of dense lower extremity motor block.",
"   </p>",
"   <p>",
"    The choice of drug and need for a test dose are controversial. For example, epinephrine's alpha adrenergic effects may produce uterine artery constriction and decrease placental blood flow. Therefore, the epinephrine test dose is relatively contraindicated in cases of decreased uteroplacental blood flow, such as diabetes mellitus and preeclampsia. Some have advocated substituting a pure beta adrenergic agonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) to avoid utero-placental vasoconstriction if intravascular injection were to occur. Alternatively, air may be used for the test dose because intravascular injection of 0.5 to 1 mL of air is easily appreciated as a characteristic \"swishing\" sound by Doppler monitoring of the maternal precordium (the fetal Doppler monitor can be temporarily \"borrowed\" from the abdomen for this purpose). If the epinephrine-containing test dose yields equivocal results, an air test dose may be very helpful in determining whether the epidural catheter is indeed located within a blood vessel. The air test dose works best with single port epidural catheters; it may be falsely negative when multi-port epidural catheters are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The low concentration of local anesthetics currently used for epidural analgesia techniques for labor are unlikely to cause untoward effects if they are accidentally injected intravascularly. Under these circumstances, the test dose is more likely to be used to recognize accidental intrathecal injection of local anesthetics. As discussed above, the introduction of softer, more flexible epidural catheters has decreased the incidence of inadvertent venous cannulations from 5.7 to 1.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many anesthesiologists do not use an intravascular test dose with \"walking epidural\" solutions because the low dose of analgesics they contain render them inherently safe, ie, inadvertent intravascular or intrathecal injection of these low dose solutions would not cause catastrophic side effects. Furthermore, if the catheter is properly positioned within the epidural space (the most likely circumstance), a test dose of 3 mL of 1.5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with 1:200,000 epinephrine may produce motor block, an effect that is undesirable during labor. Another undesirable side effect of the 1.5 percent lidocaine with 1:200,000 epinephrine test dose is maternal hypotension due to block of sympathetic nerves. However, the use of a 3 mL test dose is essential when administering more concentrated solutions of local anesthetic, such as 2 percent lidocaine with epinephrine for cesarean delivery. When relatively high concentrations of local anesthetics are administered, for labor analgesia or for cesarean delivery, a test dose should always be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link\">",
"     \"Allergic reactions to local anesthetics\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HIGH SPINAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high spinal refers to more cephalad progression of the level of anesthesia than planned when the neuraxial block was administered. The outcome can be disastrous if the situation is not recognized and corrected immediately. Consequences of high spinal may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Massive sympathectomy that results in hypotension",
"     </li>",
"     <li>",
"      Block of the cardiac accelerator fibers (T1 to T4), which inhibits compensatory tachycardia",
"     </li>",
"     <li>",
"      Hypoperfusion of the brainstem causing respiratory depression and nausea.",
"     </li>",
"     <li>",
"      Dyspnea resulting from anesthesia of the chest",
"     </li>",
"     <li>",
"      Complete diaphragmatic paralysis if the C3 to C5 roots are blocked",
"     </li>",
"     <li>",
"      Aspiration of gastric contents due to loss of consciousness and compromise of airway reflexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One cause of high spinal is accidental intrathecal injection of a local anesthetic dose intended for the epidural space. This is a potential problem when high concentrations of local anesthetics are used, but not as great a risk with ultra-low doses, as the drug mass is insufficient to produce cardiorespiratory compromise. Total spinal may result from a relative drug overdose or from enhanced cephalad spread within the cerebrospinal fluid (CSF) due to issues involving baricity and maternal position. For example, injection of a hyperbaric solution (relative to CSF) and placing the parturient in a steep Trendelenburg position or injection of a hypobaric solution and positioning the parturient in a seated position will result in exaggerated cephalad spread.",
"   </p>",
"   <p>",
"    The clinical presentation of a high spinal may be recognized in a timely fashion if it happens shortly after the injection of high doses of local anesthetics for a neuraxial block. However, it may be difficult to quickly differentiate from other critical events, such as cerebrovascular accident, massive thromboembolism, cardiac arrest, and amniotic fluid embolism if it occurs after the anesthesiologist has left the labor and delivery room following a labor epidural. The unresponsive obstetric patient should be managed with standard resuscitative measures to protect her airway, ensure her ventilation, and support her circulation while the precise diagnosis is ascertained.",
"   </p>",
"   <p>",
"    The cardiovascular system must be supported with vasopressors and inotropes as necessary to maintain blood pressure. Intubation of the trachea may be required to maintain adequate ventilation and protect the lungs from aspiration. The use of supportive care with assisted ventilation and 100 percent oxygen is often sufficient until the local anesthetic that migrated cephalad dissipates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPOTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is a common side effect of local anesthetics administered into the neuraxis (meta-analysis of epidural versus non-epidural or no analgesia in labor: relative risk of hypotension with epidural analgesia 18.23, 95% CI 5.09-65.35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/12\">",
"     12",
"    </a>",
"    ]. It is caused by block of sympathetic nerves, dilation of vascular beds, and decrease of venous return. The precise definition of hypotension in this setting is controversial; criteria include a 20 percent reduction in mean arterial pressure from baseline, or a systolic blood pressure &lt;100 mmHg. These criteria do not account for the pain of labor, which tends to increase baseline blood pressure; specific maternal conditions associated with elevated blood pressure, such as preeclampsia; or a parturient with a low baseline systolic pressure.",
"   </p>",
"   <p>",
"    Hypotension is considered clinically significant if it is associated with maternal symptoms such as lightheadedness and nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deterioration of the fetal heart rate, a sign of compromised utero-placental perfusion. Maintenance of left uterine displacement to avoid aortocaval compression is an important maneuver to decrease the incidence of hypotension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link&amp;anchor=H11#H11\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\", section on 'Supine hypotensive syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic hypotension should be treated with small intravenous doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    (eg, 100 mcg) or ephedrine (eg, 5 mg), and intravenous fluids. Repeated doses of phenylephrine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ephedrine are administered as needed until the hypotension is corrected. Phenylephrine is preferred, but if the maternal heart rate is relatively slow, ephedrine can be a better choice. Prophylactic ephedrine has also been used successfully, mainly prior to spinal anesthesia for cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These drugs have no adverse effects on uterine blood flow, but ephedrine can increase fetal heart rate and variability (including a saltatory pattern); the effect is dose dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hypotension is related to the speed of onset of the neuraxial block and the dose of local anesthetic administered. Although hypotension is more likely to occur after neuraxial blocks are administered for cesarean delivery than for labor analgesia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=see_link&amp;anchor=H10#H10\">",
"     \"Anesthesia for cesarean delivery\", section on 'Prevention and management of hypotension'",
"    </a>",
"    ), it may also occur after a labor analgesia dose is injected, particularly if a relatively high concentration of local anesthetic is used. For example, in one study, administration of 12 mL of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    caused hypotension in 20 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/18\">",
"     18",
"    </a>",
"    ]. The use of ultra-low dose local anesthetic techniques (eg, bupivacaine 0.04 percent) is associated with a lower incidence (9 percent) of hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/19\">",
"     19",
"    </a>",
"    ]. This may be explained by the slow block onset that allows time for compensatory vasoconstriction to occur in unblocked regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hypotension may be decreased by expansion of intravascular volume prior to, or coincident with, the administration of neuraxial anesthesia. This is especially important when relatively high dose spinal or epidural techniques are used for cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=see_link&amp;anchor=H10#H10\">",
"     \"Anesthesia for cesarean delivery\", section on 'Prevention and management of hypotension'",
"    </a>",
"    .) The routine practice of intravenous hydration with crystalloid prior to initiation of epidural analgesia for labor has been questioned, as ultra-low dose \"walking epidural\" techniques are associated with a lower incidence of hypotension. As an example, one study of 95 normotensive women randomized to receive one liter of crystalloid or no preload prior to administration of epidural analgesia for labor found no difference in the frequency of hypotension between the two groups (6 and 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/20\">",
"     20",
"    </a>",
"    ]. The concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    administered was 0.1 or 0.2 percent, considerably higher than the 0.04 percent that we use in our \"walking epidurals.\" In addition, a large intravascular fluid bolus may transiently inhibit uterine contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuraxial opioids (except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , which has local anesthetic effects) usually do not produce hypotension. Reports of hypotension after intrathecal opioid administration during active labor probably represent a relative decrease in blood pressure as a consequence of pain relief, and not a direct effect of the opioid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/22\">",
"     22",
"    </a>",
"    ]. A study in non-laboring parturients showed no decrease in blood pressure after intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    25 mcg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/23\">",
"     23",
"    </a>",
"    ] and another study showed that prehydration in not necessary in parturients receiving intrathecal fentanyl for labor analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INADEQUATE OR FAILED BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A failed neuraxial block may be defined as inadequate",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    following an epidural, spinal, or CSE. The precise incidence of failed block is unknown; it was 12 percent in one retrospective review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failed block may be caused by inadequate drug dosing, technical issues, or patient factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/26\">",
"     26",
"    </a>",
"    ]. If the volume",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concentration of administered",
"    <span class=\"nowrap\">",
"     analgesics/anesthetics",
"    </span>",
"    are insufficient to adequately block the required spinal segments, pain relief will be incomplete. The dose of intrathecal anesthesia needed to obtain a satisfactory block for cesarean is independent of age, weight, height or body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failed block may also be caused by impatience (eg, underestimating the latency of the administered drug and not allowing sufficient time to pass before declaring the block as failed). Operator or equipment related technical issues may also result in a failed block. As an example, if the epidural or spinal needle tip is not properly positioned, the injected drug will not be delivered to the desired location. If the aperture of the epidural or spinal needle is not wholly within the epidural or intrathecal space, respectively, a portion of the injected dose may not reach the intended site. With continuous epidural techniques, despite proper needle placement, the epidural catheter tip may not find its way into the epidural space, or may come to rest too far unilaterally, or protrude through an intervertebral foramen. These situations are more likely to occur if too great a length of catheter is threaded through the needle. More commonly, the catheter is initially inserted correctly within the epidural space, but later moves out of the space, toward the skin. Ideally, the length of epidural catheter inserted is sufficient to prevent inadvertent dislodgement, but not too great so as to minimize the likelihood of unilateral placement. In laboring patients, the optimal catheter length to insert into the epidural space appears to be 5 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other technical causes of failed block relate to patient anatomy (eg, post-surgical scarring that inhibits the spread of medication administered into the epidural space). Some unusual causes of failed spinal anesthesia have been described, and include rare anatomic malformations such as dural ectasia, an abnormal ballooning of the thecal sac, and dural cyst. Injection of local anesthetic into an isolated area of the thecal sac may limit drug exposure to the target neural tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/29\">",
"     29",
"    </a>",
"    ]. Enlarged thecal volumes per se, even in the absence of dural ectasia or cysts, may cause dilution or poor distribution of the hyperbaric local anesthetic dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/30\">",
"     30",
"    </a>",
"    ]. Failure of a block due to an inactive drug is very unlikely, as amide-linked local anesthetics are very stable molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRURITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a common side effect of neuraxial opioid administration. It is more likely to occur after intrathecal rather than epidural techniques. As an example, in one series where",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (25 mcg) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (2 mg) were injected intrathecally, pruritus occurred in 100 percent of parturients and 45 percent required treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/31\">",
"     31",
"    </a>",
"    ]. Pruritus does not occur after the administration of local anesthetics alone. The etiology of neuraxial opioid-induced pruritus is unclear, but is not caused by histamine release. Thus, treatment with an antihistamine such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    is not indicated, but is often used for its soporific effects.",
"   </p>",
"   <p>",
"    The ideal treatment for neuraxial opioid-induced pruritus is a small dose of an opioid antagonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (40 to 160 mcg intravenously),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    (6 mg orally), or the mixed opioid agonist-antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    (2.5 to 5 mg intravenously). Small doses of opioid antagonists are known to selectively reverse opioid side effects without affecting analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/32\">",
"     32",
"    </a>",
"    ]. A common approach is to administer 40 to 80 mcg naloxone intravenously, and titrate additional small doses to effect, although some patients may require larger doses (eg, 400 mcg) to relieve their pruritus. A single dose of naloxone sometimes prevents recurrent itching. Alternatively, the patient may be given intravenous patient-controlled analgesia (PCA) naloxone, to allow her to self-titrate 40 mcg every five minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other strategies for dealing with neuraxial opioid-induced pruritus have been used. A systematic review of placebo-controlled randomized trials of prophylactic serotonin (5-HT3) receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ) found that although the incidence of pruritus in parturients was not reduced, prophylaxis did reduce the incidence of severe pruritus and the need for treatment of the pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NAUSEA AND VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea occurs commonly in laboring patients due to visceral pain, thus neuraxial analgesia would be expected to decrease nausea in parturients. However, while epidural and spinal local anesthetic block effectively diminish or eliminate pain, they may also precipitate nausea and vomiting by decreasing blood pressure and causing hypoperfusion of the area postrema in the medulla. Opioids administered into the neuraxis may also produce nausea and vomiting due to cephalad spread in the CSF to the chemoreceptor trigger zone. The incidence of nausea and vomiting after neuraxial opioid is much greater with the relatively poorly lipid soluble",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    compared to more lipid soluble agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    , because morphine travels more readily within the aqueous CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports of opioid-induced nausea treatment with an opioid antagonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    or the opioid agonist-antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/36\">",
"     36",
"    </a>",
"    ]. Dosing is discussed above&nbsp;(see",
"    <a class=\"local\" href=\"#H10\">",
"     'Pruritus'",
"    </a>",
"    above). However, there are limited data on the use of opioid antagonists. Nausea and vomiting resulting from hypotension are treated by administration of vasopressors.",
"   </p>",
"   <p>",
"    A systematic review of placebo-controlled randomized trials of prophylactic serotonin (5-HT3) receptor antagonists in patients who received intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    for cesarean delivery found that these agents significantly reduced the incidence of postoperative nausea (22 versus 33.6 percent; RR 0.75, 95% CI 0.58-0.96) and vomiting (7.7 versus 16.8 percent; RR 0.49, 95% CI 0.30-0.81) and the use of antiemetic medication (8.8 versus 22.8 percent; RR 0.38, 95% CI 0.21-0.68) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, the prophylactic use of 5-HT3 receptor antagonists is a reasonable option for use in women undergoing cesarean delivery who are to receive intrathecal morphine, which is associated with a much higher incidence of nausea and vomiting than more lipid soluble opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ). 5-HT3 receptor antagonists may also be used as a treatment for nausea and vomiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESPIRATORY DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory depression due to cephalad spread of opioids to brainstem respiratory centers after neuraxial block is a rare complication in laboring patients. Factors that increase the likelihood of respiratory depression include a large opioid dose, poor opioid lipid solubility (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ), concomitant use of additional sedatives and opioids by other routes, and the use of the sitting position soon after injection of opioids (hypobaric relative to cerebrospinal fluid).",
"   </p>",
"   <p>",
"    Treatment is with a specific opioid antagonist, such as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . The dose should be titrated to effect (40 to 80 mcg increments) and then an infusion of a dose sufficient to maintain an adequate respiratory rate should be instituted until the effect of the opioid has dissipated (eg, 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/kg/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559677\">",
"    <span class=\"h1\">",
"     INTRAPARTUM FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and observational studies have consistently observed a frequent and significant association between the use of epidural analgesia and rise in maternal temperature (meta-analysis of randomized trials of epidural versus non-epidural or no analgesia: relative risk of fever with epidural analgesia 3.34, 95% CI 2.63-4.23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/38-46\">",
"     38-46",
"    </a>",
"    ]. Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    does not prevent the maternal temperature elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the temperature increase is incompletely understood, but may be related to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced heat loss in laboring women receiving epidurals since they have less pain-induced hyperventilation and less perspiration because of sympathetic block. A temperature increase has also been reported to occur in non-pregnant patients receiving prolonged postoperative epidural analgesia; thus, it is not necessarily related to pregnancy and labor per se [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infection. Epidurals and increased maternal temperature share risk factors such as nulliparity, induction of labor, internal monitoring, more vaginal examinations, longer labor, and longer duration of rupture of membranes, which are also risk factors for intraamniotic infection.",
"     </li>",
"     <li>",
"      Placental or systemic inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormality in maternal thermoregulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from an historical cohort study of maternal temperature before and after availability of epidural analgesia suggest that the epidural itself is the cause of the increased maternal temperature. When epidural usage increased from 1 to 83 percent, the incidence of maternal temperature greater than 100.4 degrees F also increased from 0.6 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/40\">",
"     40",
"    </a>",
"    ]. The rise in maternal temperature correlates with the duration of epidural analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In one study, there was no discernible effect during the initial four to five hours, but thereafter maternal temperature increased approximately 0.10 degrees C per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/52\">",
"     52",
"    </a>",
"    ]. This may explain why epidural-related fever is more common in nulliparas than multiparas since the latter tend to have shorter labors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of an elevated temperature may be misinterpreted as a sign of infection, since intrapartum fever is the most objective clinical sign of intraamniotic infection. Prompt antibiotic administration and diagnostic work-up may be instituted. The increase in maternal temperature associated with epidural analgesia has been implicated as the cause of an increased rate of neonatal sepsis investigations and morbidity, but is not associated with an increased rate of proven neonatal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/53\">",
"     53",
"    </a>",
"    ]. In a retrospective analysis, only four of 416 neonates evaluated were found to be septic, raising questions regarding the clinical criteria used to trigger such evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform a neonatal septic work-up must be guided by factors in addition to maternal temperature. Triggers for septic work-up in neonates include low birth weight, prematurity, hypothermia at birth, maternal group B beta-hemolytic streptococcal colonization, preeclampsia, and maternal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/54\">",
"     54",
"    </a>",
"    ]. Prior to initiating antibiotic therapy, the clinician should consider whether there was prolonged use of epidural analgesia. Maternal shivering that occurs before the fever developed and a rapid fall in temperature after the epidural is discontinued suggest a noninfectious etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether epidural-related maternal temperature elevation, in the absence of infection, is associated with neonatal brain injury is controversial, in part, because it is difficult to conclusively exclude the presence of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The purported mechanism is induction of fetal inflammatory response syndrome, which has been linked to subsequent neurodevelopmental delay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link&amp;anchor=H19#H19\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Neurodevelopmental outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560887\">",
"    <span class=\"h1\">",
"     PNEUMOCEPHALUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Introduction of air into the CSF during placement of neuraxial block may result in acute onset of severe headache and other neurologic signs and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/58\">",
"     58",
"    </a>",
"    ]. This complication may occur when air, rather than saline, is used to identify the epidural space with the loss-of-resistance technique. If the dura is inadvertently punctured, air may be injected into the CSF. If the parturient is sitting, the onset of headache and other neurologic symptoms may occur within a few seconds, as the air rapidly ascends within the CSF to the cerebral ventricles, where it exerts its irritating effects. Use of saline rather than air for the loss-of-resistance technique can minimize the likelihood of this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561173\">",
"    <span class=\"h1\">",
"     SPINAL EPIDURAL HEMATOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage into the neuraxis, an unusual complication of spinal and epidural techniques, may occur if a vascular structure is punctured by a needle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter. While the precise incidence of spinal hematoma is unknown, a 10-year retrospective survey in Sweden found that it was reported in 1:200,000 obstetric patients receiving epidural block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal hematoma can occur in any patient, but is more likely in patients with disorders of coagulation and in those receiving anticoagulants. It is less likely with a single-shot spinal technique, due to the relatively small size of the spinal needle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/60\">",
"     60",
"    </a>",
"    ] and the lack of an indwelling catheter. Accumulation of even a small quantity of blood may compress neural structures and produce ischemia because the spinal space is nonexpandable.",
"   </p>",
"   <p>",
"    Neural ischemia and cord compression result in radicular pain and loss of sensory, motor, and bladder and bowel function. The appropriate treatment is prompt surgical intervention, usually a laminectomy, and evacuation of the blood. Timely decompression of the hematoma is essential to avoid permanent loss of neurologic function. In one study, for example, good outcomes were obtained in 50 percent of patients when surgery was performed within eight hours of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/60\">",
"     60",
"    </a>",
"    ]. Other studies have also concluded the shorter the time interval between diagnosis and surgical intervention, the more favorable the neurologic outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of spinal epidural hematoma is complicated by the concealed nature of the bleeding, thus a high index of suspicion must be maintained. Since low-dose techniques for labor analgesia produce minimal motor block, their use permits continuous monitoring of lower extremity function in patients at risk for development of neuraxial hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561180\">",
"    <span class=\"h1\">",
"     NEURAXIAL ANALGESIA AND THE ANTICOAGULATED PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women may be treated with anticoagulants for a variety of indications. The most common indications for anticoagulation are the presence of a thrombophilia or prior thromboembolism. The risk of hemorrhage into the neuraxis is increased in anticoagulated patients, thus one must consider the type of anticoagulant used, the dose, and the timing of its administration. For all patients in whom a bleeding tendency is suspected, an evaluation of coagulation status is indicated prior to neuraxial analgesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations below are based on the third edition of the American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines for regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/62\">",
"     62",
"    </a>",
"    ]. European guidelines vary minimally from these recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of nonsteroidal antiinflammatory drugs (NSAIDs), including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , should not influence the decision to place a neuraxial block. However, neuraxial block should be avoided in patients receiving these drugs concurrently with other anticoagulants (eg, unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [UFH], low molecular weight heparin [LMWH], or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The risk of spinal hematoma in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and platelet glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor antagonists is not known. Based on available reports of spinal hematomas, the guidelines currently recommend a waiting period of 14 days between the last dose of ticlopidine and 7 days after the last dose of clopidogrel and the placement of a neuraxial block. For patients receiving glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor antagonists, the guidelines state that neuraxial techniques should be avoided for 24 to 48 hours after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      and for 4 to 8 hours after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Women taking vitamin K antagonists should be transitioned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH or LMWH) no later than 36 weeks of gestation.",
"     </li>",
"     <li>",
"      Women taking LMWH should be transitioned to intravenous or subcutaneous UFH no later than 36 hours before induction of labor or cesarean delivery.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      should be discontinued four to six hours before scheduled delivery.",
"     </li>",
"     <li>",
"      For patients receiving subcutaneous UFH prophylaxis 5000 units two times per day, neuraxial techniques are",
"      <strong>",
"       not",
"      </strong>",
"      contraindicated. However, the safety of neuraxial techniques in patients receiving doses greater than 10,000 units daily, or in patients receiving thrice-daily dosing of UFH, is not known. In these situations, it is advisable to confirm that the partial thromboplastin time has returned to normal prior to performing a neuraxial technique.",
"     </li>",
"     <li>",
"      Postpartum prophylactic anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH or LMWH) should be delayed for 12 hours after vaginal delivery and 24 hours after cesarean delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/64\">",
"       64",
"      </a>",
"      ]. The anesthesiology guidelines addressing the general surgical patient are more permissive, and allow administration of UFH or LMWH after a shorter postoperative interval [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    If anticoagulation with standard intravenous UFH is required in patients who have recently had epidural catheterization, UFH should not be given for at least one hour after the epidural catheter has been inserted or removed.",
"    <br/>",
"    <br/>",
"    In patients receiving intravenous UFH, the epidural catheter may be removed two to four hours after the last",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dose, after the patient's coagulation status has been evaluated.",
"    <br/>",
"    <br/>",
"    Since heparin-induced thrombocytopenia may occur, patients receiving UFH for more than four days should have a platelet count assessed prior to neuraxial block and catheter removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561187\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many disorders are treated with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH). This therapy presents particular challenges because standard laboratory tests cannot be used to assess its activity. Many cases of spinal hematoma have been reported among nonpregnant patients receiving neuraxial analgesia after taking LMWH and other anticoagulant medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/65\">",
"     65",
"    </a>",
"    ]. Concomitant administration of antiplatelet medications or other anticoagulants in patients receiving LMWH may increase the risk of neuraxial hematoma.",
"   </p>",
"   <p>",
"    Neuraxial blocks should not be performed until at least 10 to 12 hours after the last dose of prophylactic LMWH (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg), and not until at least 24 hours after the last dose of therapeutic LMWH (eg, enoxaparin 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, enoxaparin 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    120",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    every 12 hours, dalteparin 200",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    175",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    daily).",
"   </p>",
"   <p>",
"    Given these considerations, induction of labor at term, rather than awaiting spontaneous labor, is reasonable. Many obstetricians switch patients on LMWH to unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    at approximately 36 weeks of gestation, which makes evaluation of anticoagulation status and management easier if the patient goes into labor spontaneously or unexpectedly needs to be delivered before term. While protamine only partially reverses the anticoagulant effect of LMWH, it completely reverses the effects of heparin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561194\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is rarely used in pregnancy because of the concern with fetal warfarin syndrome during the first trimester, and fetal intracranial hemorrhage during the last trimester, it is sometimes used when maternal anticoagulation is needed during the second trimester. Neuraxial blocks should not be performed until laboratory tests of coagulation (prothrombin time, International normalized ratio [INR]) are in the normal range. Patients receiving concurrent therapy with warfarin and another anticoagulant(s) are at particular risk of developing",
"    <span class=\"nowrap\">",
"     spinal/epidural",
"    </span>",
"    hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561201\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    is a synthetic pentasaccharide that inhibits factor Xa and may be used for thromboprophylaxis. The risk of spinal hematoma in patients receiving fondaparinux is unknown. ASRA guidelines discuss administration of fondaparinux postoperatively in patients who have received neuraxial anesthesia: the recommendation is that fondaparinux only be used in patients in whom neuraxial block is achieved with an atraumatic needle placement on the first attempt and in whom indwelling catheters are not used. The ASRA guidelines do not comment on neuraxial anesthesia in patients receiving fondaparinux for thromboprophylaxis.",
"   </p>",
"   <p>",
"    The Department of Anesthesia of the Massachusetts General Hospital institutional guidelines state that for patients with normal renal function receiving once-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    dosing, neuraxial block should not be performed until four days after the last dose in patients receiving 2.5 mg and seven days after the last dose in patients receiving 5 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561208\">",
"    <span class=\"h1\">",
"     NEURAXIAL ANALGESIA AND LOW PLATELETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL)",
"    </span>",
"    occurs in approximately 7 percent of pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/67\">",
"     67",
"    </a>",
"    ]. The most common causes of low platelet counts in the third trimester are gestational thrombocytopenia, immune thrombocytopenic purpura (ITP), or thrombocytopenia related to severe preeclampsia or HELLP syndrome. Gestational thrombocytopenia is the most common etiology, ITP occurs much less frequently. An important difference between ITP and gestational thrombocytopenia is that ITP may be associated with severe neonatal thrombocytopenia. However, with regard to the mother, neither gestational thrombocytopenia nor ITP is associated with a rapid decline in platelet count. This contrasts with hypertensive thrombocytopenia, which may accompany severe preeclampsia or the HELLP syndrome. In hypertensive thrombocytopenia, the platelet count may decline precipitously, and the platelet function may be abnormal as well. With gestational thrombocytopenia and ITP, platelet function is usually normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)An insufficient platelet number or deficient platelet function predispose to an increased risk of",
"    <span class=\"nowrap\">",
"     spinal/epidural",
"    </span>",
"    hematoma upon neuraxial instrumentation.",
"   </p>",
"   <p>",
"    The precise platelet count needed to safely perform neuraxial analgesia is unknown. Currently, practitioners routinely perform neuraxial analgesia with platelet counts below",
"    <span class=\"nowrap\">",
"     100,000/microL,",
"    </span>",
"    although few will instrument the",
"    <span class=\"nowrap\">",
"     spinal/epidural",
"    </span>",
"    space if the platelet count is below",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    It is not necessary to routinely obtain a platelet count before administration of regional anesthesia in uncomplicated parturients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When determining whether it is safe to instrument the epidural or intrathecal space in women with thrombocytopenia, the rate of decline of the platelet count is more important than the absolute platelet number. The platelet count should be assessed prior to performing a neuraxial block, and compared to previous counts. As an example, a relatively low but stable platelet count of",
"    <span class=\"nowrap\">",
"     55,000/microL",
"    </span>",
"    likely presents less of a problem than a platelet count of",
"    <span class=\"nowrap\">",
"     60,000/microL",
"    </span>",
"    that had been",
"    <span class=\"nowrap\">",
"     95,000/microL",
"    </span>",
"    three to four hours previously.",
"   </p>",
"   <p>",
"    Adequacy of platelet function must also be considered, but the laboratory tests needed to assess platelet function are not readily available on short notice. The clinician often must assess the integrity of the coagulation system with a careful history and a physical examination focusing on the presence of petechiae, ecchymoses, or obvious oozing from intravenous catheter sites. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=see_link\">",
"     \"Preoperative assessment of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuraxial anesthesia has been utilized in patients with platelet counts around",
"    <span class=\"nowrap\">",
"     70,000/microL,",
"    </span>",
"    and without evidence of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/67\">",
"     67",
"    </a>",
"    ]. The etiology of the thrombocytopenia, the trend in the platelet number, and the history and physical examination are more important than the absolute platelet count per se. In addition, it may be reasonable to perform a spinal anesthetic with a platelet count under",
"    <span class=\"nowrap\">",
"     70,000/microL",
"    </span>",
"    if there is a compelling indication to do so based on a risk-benefit analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/69\">",
"     69",
"    </a>",
"    ]. A spinal technique is less traumatic than an epidural, and may be preferable if the platelet count is less than",
"    <span class=\"nowrap\">",
"     70,000/microL.",
"    </span>",
"    Soft, flexible catheters are preferred for an epidural technique, as they have a lower incidence of venous cannulation than do stiff catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559684\">",
"    <span class=\"h1\">",
"     FETAL EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928800\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal hypotension resulting from local anesthetic-induced sympathetic block may reduce placental perfusion. The placental bed is not autoregulated and, therefore, its perfusion is entirely dependent upon maternal systolic blood pressure. A decrease in perfusion pressure will result in decreased fetal oxygenation, which is manifested by deterioration in the fetal heart rate pattern (eg, bradycardia, repetitive late decelerations). However, in the absence of hypotension, epidural local anesthetics have been shown to improve intervillous blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/70\">",
"     70",
"    </a>",
"    ], to have minimal effect on uterine or fetal umbilical vasculature as assessed by Doppler velocimetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/71\">",
"     71",
"    </a>",
"    ], and to be associated with improved neonatal acid-base status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11,72\">",
"     11,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relatively large dose of opioid is required when administered as the sole agent for labor analgesia by the epidural route. The opioids may affect the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonate by gaining access to the maternal circulation and undergoing transplacental passage as the plasma kinetics following injection of epidural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    are similar to those seen after an intramuscular injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/73\">",
"     73",
"    </a>",
"    ]. In one study, as an example, a dose of 5 mg epidural morphine produced substantial fetal and maternal plasma levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/74\">",
"     74",
"    </a>",
"    ]. Epidural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    have a faster onset of action, greater systemic absorption and lower concentrations in the fetal circulation than morphine due to their high lipid solubility. Therefore, they have, for the most part, supplanted morphine for epidural labor analgesia.",
"   </p>",
"   <p>",
"    The doses of opioid used for intrathecal administration are considerably lower than epidural doses, and systemic uptake is negligible. Thus, maternal absorption of intrathecally administered opioids does not pose a direct risk for the fetus or neonate. However, fetal bradycardia may be precipitated by the physiologic effects of intrathecal administration of opioid. Although the mechanism is not completely understood, one systematic review found that the incidence of fetal bradycardia is nearly twice as high when opioids are administered by the intrathecal rather than the epidural route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559692\">",
"    <span class=\"h2\">",
"     Fetal bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonreassuring fetal heart rate after induction of neuraxial anesthesia may be due to maternal hypotension, uterine hyperactivity, or increased uterine tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/14,76\">",
"     14,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of opioids intrathecally may induce a tetanic uterine contraction leading to fetal bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/77\">",
"     77",
"    </a>",
"    ]. A meta-analysis of nine trials reported fetal bradycardia within one hour of intrathecal opioid administration occurred in 39 of 535 (7.3 percent) patients versus 19 of 392 (4.8 percent) controls (RR 1.81, 95% CI 1.04-3.14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/75\">",
"     75",
"    </a>",
"    ]. Despite a higher risk of fetal heart rate abnormality, the rate of cesarean delivery was not increased in women receiving intrathecal opioids.",
"   </p>",
"   <p>",
"    One proposed explanation is that the fetal bradycardia is due to intrathecal opioid-induced uterine hypertonus. Combined spinal-epidural analgesia is associated with a significantly greater incidence of FHR abnormalities related to uterine hypertonus compared with epidural analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/76\">",
"     76",
"    </a>",
"    ]. The hypertonus is postulated to be due to rapid onset of analgesia, which causes a sudden decrease in maternal plasma epinephrine and subsequent withdrawal of epinephrine's beta-sympathomimetic relaxant effects on the myometrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/76,78\">",
"     76,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uterine hypertonus may be reversed with one or two doses of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (60 to 90 mcg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/79\">",
"     79",
"    </a>",
"    ]. The hypotension that predictably results is treated with ephedrine (5 to 10 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    (50 to 200 mcg) boluses. Persistent hypertonus can be treated with another dose of nitroglycerin or a beta agonist, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    0.25 mg intravenously; however, terbutaline results in a longer period of uterine relaxation and maternal tachycardia.",
"   </p>",
"   <p>",
"    Prophylactic administration of ephedrine to prevent maternal hypotension and fetal bradycardia has also been studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial showed that prophylactic administration of ephedrine (10 mg injected intravenously followed by a continuous drip of 20 mg over one hour) at the time of epidural initiation reduced the frequency of fetal heart rate changes within 40 minutes of epidural administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/14\">",
"       14",
"      </a>",
"      ]. The labor analgesic dose in this study was relatively high; the blocks were initiated with 3 mL of 2 percent lidocaine followed by 8 mL of 0.25 percent bupivacaine. Fetal heart rate changes occurred in 2 of 72 treated patients versus 11 of 73 controls who did not receive prophylactic ephedrine upon initiation of their epidurals. Seven patients would need to be treated to prevent one case of abnormal fetal heart rate tracing.",
"     </li>",
"     <li>",
"      In another randomized trial, a single intramuscular dose of ephedrine (25 mg) or placebo was administered to 100 parturients immediately prior to receiving combined spinal epidural analgesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/15\">",
"       15",
"      </a>",
"      ]. Significantly fewer women in the ephedrine group developed hypotension",
"      <span class=\"nowrap\">",
"       (10/50",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       34/50",
"      </span>",
"      in controls), but they were more likely to develop fetal tachycardia than controls. There were no significant differences in the prevalence of fetal heart rate decelerations during the hour after the analgesia was administered (variable, late, prolonged) between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic administration of ephedrine prior to labor analgesia does not seem to be indicated, particularly if low-dose \"walking epidural\" techniques are used. Prophylactic administration of vasopressors may be more appropriate in patients who will be receiving relatively high concentrations of local anesthetics (eg, for cesarean), but continuous infusion of ephedrine is not recommended because it has been associated with fetal acidosis in patients undergoing elective cesarean delivery under spinal anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=see_link&amp;anchor=H10#H10\">",
"     \"Anesthesia for cesarean delivery\", section on 'Prevention and management of hypotension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560398\">",
"    <span class=\"h1\">",
"     EFFECT OF NEURAXIAL ANALGESIA ON LABOR AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable controversy concerning the non-analgesic effects of spinal and epidural pain relief on labor and delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560405\">",
"    <span class=\"h2\">",
"     Effect of neuraxial analgesia on the progress and outcome of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longstanding perception among obstetric providers is that neuraxial analgesia tends to slow labor and result in increased rates of instrumental and cesarean delivery. A meta-analysis of randomized trials of epidural versus no epidural or no analgesia in labor found that epidural analgesia was associated with a longer second stage (mean difference 13.66 minutes, 95% CI 6.67-20.66; 13 trials, 4233 women) and no significant effect on the duration of the first stage of labor (mean difference 18.51 minutes, 95% CI -12.91 to 49.92; 11 trials, 2981 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]. Many clinical studies of the non-analgesic effects of neuraxial blocks in parturients have helped to elucidate these issues.",
"   </p>",
"   <p>",
"    With regard to the effect of neuraxial analgesia on the incidence of cesarean delivery, the data show that although there is an association of increased likelihood of cesarean delivery in parturients receiving epidural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal pain relief, there is no causative link. A meta-analysis of 38 randomized trials comparing all modalities of epidural with any form of pain relief not involving regional blockade or no pain relief in labor, concluded epidural analgesia did not significantly increase the risk of cesarean delivery (RR 1.10, 95% CI 0.97-1.25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]. There are many explanations for the observed association of neuraxial analgesia and increased cesarean delivery rate. For example, women who are destined to require cesarean delivery have dysfunctional labor patterns and are more likely to receive neuraxial pain relief during labor (see",
"    <a class=\"local\" href=\"#H12560412\">",
"     'Pain as a marker of dysfunctional labor'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    With regard to instrumental delivery, the same meta-analysis found that neuraxial labor analgesia was associated with an increased risk of instrumental vaginal birth (RR 1.42, 95% CI 1.28-1.57) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]. The reason for the increased frequency of instrumental delivery in patients with neuraxial analgesia is unclear. One possible explanation is that the presence of epidural analgesia prompts a difference in obstetric management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. In one study, for example, there were significantly more instrumental deliveries in patients with epidurals when residents were allowed to use elective outlet forceps or vacuum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/81\">",
"     81",
"    </a>",
"    ]. It may be that the presence of effective pelvic analgesia encourages the use of instrumental delivery.",
"   </p>",
"   <p>",
"    The concentration of local anesthetics used for the epidural may affect the incidence of instrumental delivery. The concentration of local anesthetic used with current epidural techniques is, in some cases,",
"    <span class=\"nowrap\">",
"     1/10th",
"    </span>",
"    of the strength that was used in the past. Newer low-dose techniques, by achieving sensory block while preserving motor strength, have been shown to promote spontaneous vaginal delivery (or decrease the rate of instrumental delivery).",
"   </p>",
"   <p>",
"    For example, a study of low-dose techniques randomly assigned 1054 nulliparous women requesting epidural pain relief to traditional (intermittent 10 mL boluses of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ), low-dose combined spinal epidural (bupivacaine 2.5 mg and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    25 mcg, followed by a 15 mL bolus of 0.1 percent bupivacaine and 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    fentanyl when the spinal component wears off with intermittent 10 ml boluses of this combination of drugs), or low-dose infusion epidural (bolus of 15 mL 0.1 percent bupivacaine and 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    fentanyl followed by an infusion of 10",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    of same) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/83\">",
"     83",
"    </a>",
"    ]. The spontaneous vaginal delivery (SVD) rates in the three groups were 35, 43, and 43 percent, respectively. The higher SVD rate among women receiving low-dose techniques was entirely accounted for by a reduction in the number of instrumental vaginal deliveries; the cesarean delivery rate was 28 to 29 percent in all three groups. Therefore, low-dose techniques should be recommended over traditional epidural administration to reduce the rate of operative vaginal delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560412\">",
"    <span class=\"h2\">",
"     Pain as a marker of dysfunctional labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential confounding variable of all studies examining the effect of regional analgesia on the progress and outcome of labor is that pain itself may be predictive of dysfunctional labor and an increased likelihood of instrumental or operative delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/85\">",
"     85",
"    </a>",
"    ]. This is important because patients with severe pain and protracted, dysfunctional labors are more likely to request or receive epidural or spinal analgesia. Thus, it may be falsely concluded that neuraxial techniques are causally related to poor labor outcomes, whereas the relationship may simply be an associative one. As an example, one study found that patients who experienced pain and distress very early (during the latent phase of labor) had prolonged labor and high rates of instrumental and cesarean delivery compared to patients who experienced mild pain with which they were able to cope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/86\">",
"     86",
"    </a>",
"    ]. Future studies need to account for this potential confounder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560419\">",
"    <span class=\"h2\">",
"     Potential benefits of delayed pushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric practice in the United States often dictates that the parturient begin pushing when the cervix attains full dilation (10 cm). However, randomized prospective studies have questioned this practice and suggested delaying pushing until the presenting fetal part descends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. As an example, a large (n = 1862) randomized multicenter study documented that delayed pushing was an effective means of reducing difficult deliveries in nulliparous women (relative risk 0.79; 95 percent CI 0.66 to 0.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/88\">",
"     88",
"    </a>",
"    ]. The greatest effect was on midpelvic procedures (relative risk 0.72; 95 percent CI 0.55 to 0.93). Delayed pushing predictably increased the duration of the second stage (by 54 minutes), and resulted in lower umbilical cord blood pH, but no difference was detected in overall neonatal morbidity. If delayed pushing is an effective means of reducing instrumental delivery rates, effective epidural analgesia that preserves muscle strength will be of great assistance. Similar findings were reported in a meta-analysis that included this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/90\">",
"     90",
"    </a>",
"    ]. Regardless of the potential benefits of delayed pushing, the practice of discontinuing epidural analgesia in the hope of decreasing the likelihood of instrumental delivery is not supported by the data. In fact, the only predictable effect of decreasing or halting epidural analgesia during the second stage of labor is an increase in pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560426\">",
"    <span class=\"h2\">",
"     Timing of epidural administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;An American College of Obstetricians and Gynecologists Committee Opinion concluded that \"maternal request is sufficient medical indication for pain relief during labor\" and that neuraxial anesthesia does not increase the frequency of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis including five randomized trials and one retrospective cohort study including over 15,000 nulliparous women demonstrated that early administration of neuraxial anesthesia (&le;3 cm, including latent phase administration) did not increase cesarean and instrumental delivery rates compared to later administration (cervical dilation &ge;4 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, some of these trials found that women who have early administration of neuraxial anesthesia have significantly shorter labors than those in whom anesthesia administration was delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/94-97\">",
"     94-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a reasonable approach is to allow the parturient to receive neuraxial analgesia when she desires it, as long as the diagnosis of labor has been established or a commitment to deliver has been made. It is also reasonable to insert an epidural catheter before pain is severe so that analgesics can be injected when the patient begins to experience discomfort. In particular, women should not be required to reach an arbitrary cervical dilation such as 4 to 5 cm before receiving epidural anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560696\">",
"    <span class=\"h1\">",
"     POTENTIAL POSTDELIVERY SEQUELAE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Postdural puncture headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postdural puncture headache (also called post-spinal headache) after neuraxial analgesia is due to leakage of CSF through a dural rent, traction on cranial structures, and cerebral vasodilation. The pathognomonic quality of this headache is its positional nature, worsened by sitting or standing and relieved by lying down. If the headache does not have this quality, other causes of headache should be sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of pencil point spinal needles has diminished the incidence of postdural puncture headache. In a randomized trial of 1000 patients comparing various types of cutting and pencil point needles, the incidence of headache was significantly lower with use of pencil point needles (headache with cutting needles: 5 to 8.7 percent versus headache with pencil point needles 2.8 to 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/98\">",
"     98",
"    </a>",
"    ]. In particular, the incidence of severe headache (as indicated by the need for treatment with epidural blood patch) fell from 55 to 66 percent to 0 to 12.5 percent of headaches.",
"   </p>",
"   <p>",
"    A postdural puncture headache is likely (approximately 80 percent) if the dura is punctured with an epidural needle, due to its large size (17 or 18 gauge). Fortunately, the incidence of accidental dural puncture with an epidural needle is relatively low for an experienced operator (approximately 1 to 2 percent). The high incidence (up to 80 percent) of headache after dural puncture with the epidural needle prompted some practitioners to perform a prophylactic epidural blood patch (see below) at the end of labor, and prior to removal of the epidural catheter. In one trial in which women were randomly assigned to receive or not receive a prophylactic blood patch, there was no difference in the incidence of headache (56 percent in both groups), although women who received prophylactic patches had shorter median duration of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Threading an epidural catheter into the intrathecal space and leaving it in situ for 24 hours has also been reported to reduce the incidence of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/100,101\">",
"     100,101",
"    </a>",
"    ], but the efficacy of this approach has not been established in randomized trials. If this is done and medication is injected into the catheter, it is important to remember that the catheter is now intrathecal, so the dose of medication needs to be adjusted accordingly. Injection of a few milliliters of saline may produce immediate resolution of a headache, but the effects will be temporary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural blood patch is the treatment of choice for severe debilitating postdural puncture headache, and is usually successful. It is performed by injecting 10 to 20 mL of the patient's blood into the epidural space to form a clot over the dural defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. The early, almost immediate, effect is related to volume replacement resulting from dural tamponade, and the latent effect results from sealing of the leak. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20198?source=see_link&amp;anchor=H11#H11\">",
"     \"Post-lumbar puncture headache\", section on 'Epidural blood patch'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conservative management with symptomatic therapy (eg, oral analgesics, caffeine) may be indicated if the patient does not desire epidural blood patch or if the headache is not severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/105\">",
"     105",
"    </a>",
"    ]. A combination pill of an analgesic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), a sedative (butalbital), and caffeine is commonly used for treatment of postdural puncture headaches. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20198?source=see_link&amp;anchor=H10#H10\">",
"     \"Post-lumbar puncture headache\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A new non-invasive approach to treating postdural puncture headache using an old technique, transnasal sphenopalatine ganglion block, has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Although there are no trials comparing this treatment with other treatments of postdural puncture headache, it may be worth considering in the patient with a significant headache who does not desire a blood patch. Most postdural puncture headaches will resolve in 7 to 10 days if untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Backache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of 11,701 women found that long-term backache occurred after delivery more frequently in women who had an epidural during labor than in women who did not (19 versus 11 percent), and concluded there was a causal relationship between epidurals and backache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/108\">",
"     108",
"    </a>",
"    ]. Subsequently, a series of prospective studies by these authors and others found",
"    <strong>",
"     no",
"    </strong>",
"    correlation between epidural labor analgesia and an increased incidence of long-term backache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/109-115\">",
"     109-115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women who have a neuraxial anesthetic may not be able to sense when their bladder is full and may not be able to void spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/116\">",
"     116",
"    </a>",
"    ]. In a meta-analysis of randomized trials of epidural versus no epidural or no analgesia in labor, the relative risk of urinary retention with epidural analgesia was 17.05, 95% CI 4.82-60.39 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"     11",
"    </a>",
"    ]. Catheterization is indicated in affected women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33834?source=see_link&amp;anchor=H154735179#H154735179\">",
"     \"Overview of complications occurring in the post-anesthesia care unit\", section on 'Postoperative urinary retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Shivering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum shivering is a common event, even in the absence of anesthesia for labor and childbirth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link\">",
"     \"Overview of postpartum care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anesthesia-related shivering after neuraxial anesthesia is caused, in part, by sympathetic block induced vasodilation, with redistribution of heat from the core to the periphery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/49\">",
"     49",
"    </a>",
"    ]. The shivering can be bothersome, and can interfere with blood pressure monitoring. Warming the patient with heated blankets or forced-air system is helpful for relieving symptoms. Pharmacologic intervention is an option when symptoms are particularly bothersome and don't respond to conservative measures; the most common treatment is intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    25 mg given slowly (may repeat in five minutes as needed). Other options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    150 micrograms,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and nefopam 10 mg, all of these given intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic technique is important to minimize infection risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/118\">",
"     118",
"    </a>",
"    ]. Epidural abscess or meningitis are uncommon complications of neuraxial block. Epidural abscess is more likely to occur after epidural techniques, whereas meningitis typically occurs after the dura has been punctured, either intentionally as part of a spinal anesthetic, or unintentionally as a complication of an epidural procedure (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Postdural puncture headache'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    A meta-analysis of reports published between 1990 and 2005 identified the incidence of \"deep epidural infection\" in obstetric patients as 1 in 145,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/119\">",
"     119",
"    </a>",
"    ]. A review of postdural puncture bacterial meningitis found 179 reported cases from 1950 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/120\">",
"     120",
"    </a>",
"    ]. In this and other series, the most commonly isolated bacteria were mouth commensals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/121\">",
"     121",
"    </a>",
"    ]. Presumably, droplet contamination from medical personnel was the source of the CSF infection, which argues for a mandatory policy of wearing masks covering the nose and mouth during instrumentation of the neuraxis, and changing the mask between cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/122\">",
"     122",
"    </a>",
"    ]. Postdural puncture meningitis may be more common than appreciated, with an incidence as great as 1:50,000 to 1:10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin bacteria may also be introduced into the neuraxis during instrumentation, emphasizing the importance of meticulous skin cleansing prior to the procedure.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"     Povidone iodine",
"    </a>",
"    is most commonly used for this purpose in the United States. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    is a superior agent for skin decontamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/125,126\">",
"     125,126",
"    </a>",
"    ], it is not currently approved for neuraxial block skin preparation by the US Food and Drug Administration because of controversial data on potential neurotoxicity. However, a practice advisory by the American Society of Anesthesiologists Task Force on infectious complications associated with neuraxial techniques recommends chlorhexidine (preferably with alcohol and allowing for adequate drying time) as the agent of choice for skin decontamination prior to neuraxial techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/127\">",
"     127",
"    </a>",
"    ]. Individual packets of skin preparation are also recommended by this advisory, as microbial contamination may occur when previously opened multiple-use bottles of povidone-iodine are used. This advisory offered additional recommendations for reducing the risk of infection, such as removing all jewelry below the elbow; hand-washing; limiting disconnecting and reconnecting tubing for neuraxial drug delivery; wearing a cap, fresh mask, and sterile gloves; sterile draping of the patient; and placing a sterile occlusive dressing at the catheter insertion site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13183554\">",
"    <span class=\"h2\">",
"     Postpartum neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy after delivery, manifested as sensory change",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weakness, has a reported incidence of 1 to 58 per 10,000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/128\">",
"     128",
"    </a>",
"    ]. Postpartum neuropathy is usually due to compression of nerves of the lumbosacral plexus by the descending fetal head, by extrinsic neural compression (eg, by stirrup supports) or from ischemia due to prolonged stretching of nerves (eg, extreme hip flexion) during the second stage of labor. Rarely, it can result from trauma to the nerve root caused by a spinal or epidural needle or catheter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=see_link&amp;anchor=H8#H8\">",
"     \"Neurologic disorders complicating pregnancy\", section on 'Neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12560963\">",
"    <span class=\"h2\">",
"     Effect on breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential effect of neuraxial analgesia in labor on subsequent breastfeeding success is controversial; studies of the issue to date are inconclusive. There is no definitive evidence that neuraxial analgesia interferes with breastfeeding success. One observational study of 171 postpartum women found that epidural labor analgesia with local anesthetics and opioids did not impede breastfeeding success when assessed at six to eight weeks after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/129\">",
"     129",
"    </a>",
"    ]. A subsequent randomized, prospective trial examined the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    given epidurally during labor on breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/130\">",
"     130",
"    </a>",
"    ]. Women received either 0, &lt;150, or &gt;150 mcg of fentanyl during labor. At 24 hours postpartum, there were no differences between the groups with regard to breastfeeding difficulties. However, at six weeks postpartum, significantly fewer women who received more than 150 mcg fentanyl in the epidural during labor were still breastfeeding. These results should be interpreted with caution due to methodological concerns, and lack of an obvious physiologic or pharmacologic mechanism by which the fentanyl might influence the incidence of breastfeeding six weeks after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists concluded that breastfeeding is not affected by choice of anesthetic; thus anesthetic choice should be based upon other considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559211\">",
"    <span class=\"h1\">",
"     EFFECTS ON THE NEONATE AND CHILD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12559219\">",
"    <span class=\"h2\">",
"     Neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early study found that neonates of mothers who received epidural analgesia with local anesthetics had lower scores as assessed by the Early Neonatal Neurobehavioral Scale (EENS) than neonates of mothers who received no analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/132\">",
"     132",
"    </a>",
"    ]. A subsequent study using the EENS found no difference in scores in neonates of mothers who had received epidural analgesia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , 2-chloroprocaine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or no analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/133\">",
"     133",
"    </a>",
"    ]. Other studies of neurobehavior in neonates of mothers receiving epidural analgesia or systemic opioid analgesia have shown either no difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/134\">",
"     134",
"    </a>",
"    ] or improved scores in neonates of mothers receiving epidurals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/135\">",
"     135",
"    </a>",
"    ]. By comparison, a meta-analysis reported neonates of mothers receiving epidural analgesia were more alert than those of mothers who received systemic opioids or no medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cumulative effect of opioids delivered as part of continuous epidural infusions is another concern. This may result in a potentially significant total opioid dose over time. However, neurobehavioral assessment of neonates using the Neurologic and Adaptive Capacity Score (NACS) has not shown perceptible changes after prolonged epidural infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/137\">",
"     137",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12561018\">",
"    <span class=\"h2\">",
"     Child",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of in utero exposure to anesthetic drugs on long-term brain development is an area of controversy and active investigation. Although in vitro and animal data demonstrate the vulnerability of the developing nervous system to environmental agents, human in vivo data are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/139-141\">",
"     139-141",
"    </a>",
"    ]. As an example, a retrospective cohort study comparing the incidence of learning disabilities between children delivered vaginally with and without neuraxial labor analgesia evaluated the educational and medical records of all children born in one area of Minnesota from 1976-1982 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/139\">",
"     139",
"    </a>",
"    ]. After adjustment of confounders, the use of neuraxial analgesia during labor and vaginal delivery was not independently associated with learning disabilities diagnosed before age 19 years. Given our present state of knowledge, maternal regional anesthesia may be preferable to general anesthesia for the fetus and available data do not definitively confirm or refute a potential effect of anesthetics on cognitive development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/40/39562/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=see_link\">",
"       \"Patient information: Managing pain during labor and delivery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidural and spinal analgesic techniques provide optimal pain relief for parturients. Although generally quite safe, these techniques are also associated with various untoward effects.",
"     </li>",
"     <li>",
"      Side effects such as systemic local anesthetic toxicity or spinal headache are caused by technical factors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dosing, such as inadvertent intravenous injection or unrecognized dural puncture. Spinal hematoma is a rare complication, and is more likely in patients receiving anticoagulants. Epidural abscess",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningitis are uncommon, but serious complications of neuraxial block. Meticulous attention to proper technique reduces the risk of these complications. Should any of these complications occur, prompt treatment is indicated.",
"     </li>",
"     <li>",
"      Other untoward effects are caused by known pharmacological effects of the analgesic medications, such as hypotension, pruritus, nausea and vomiting and respiratory depression. Hypotension may be treated by administering a vasopressor. Opioid-induced side effects are optimally managed by administering appropriate doses of an opioid antagonist.",
"     </li>",
"     <li>",
"      A variety of other side effects have been attributed to regional analgesic techniques, such as long-term backache, effects on the progress and outcome of labor and effects on breastfeeding success. Although an association between regional analgesia and these side effects may exist, a cause-and-effect relationship has not been established. The risk of potential unwanted effects must be weighed against the unparalleled pain relief these techniques provide.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/1\">",
"      Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/2\">",
"      Mhyre JM, Greenfield ML, Tsen LC, Polley LS. A systematic review of randomized controlled trials that evaluate strategies to avoid epidural vein cannulation during obstetric epidural catheter placement. Anesth Analg 2009; 108:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/3\">",
"      Jaime F, Mandell GL, Vallejo MC, Ramanathan S. Uniport soft-tip, open-ended catheters versus multiport firm-tipped close-ended catheters for epidural labor analgesia: a quality assurance study. J Clin Anesth 2000; 12:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/4\">",
"      Weinberg GL. Current concepts in resuscitation of patients with local anesthetic cardiac toxicity. Reg Anesth Pain Med 2002; 27:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/5\">",
"      Soltesz EG, van Pelt F, Byrne JG. Emergent cardiopulmonary bypass for bupivacaine cardiotoxicity. J Cardiothorac Vasc Anesth 2003; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/6\">",
"      Picard J, Ward SC, Zumpe R, et al. Guidelines and the adoption of 'lipid rescue' therapy for local anaesthetic toxicity. Anaesthesia 2009; 64:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/7\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006; 105:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/8\">",
"      Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006; 61:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/9\">",
"      Weinberg GL. Treatment of local anesthetic systemic toxicity (LAST). Reg Anesth Pain Med 2010; 35:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/10\">",
"      Leighton BL, Topkis WG, Gross JB, et al. Multiport epidural catheters: does the air test work? Anesthesiology 2000; 92:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/11\">",
"      Anim-Somuah M, Smyth R, Jones, L. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev 2011; :CD000331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/12\">",
"      Leighton BL, Halpern SH. The effects of epidural analgesia on labor, maternal, and neonatal outcomes: a systematic review. Am J Obstet Gynecol 2002; 186:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/13\">",
"      Ramanathan S, Grant GJ. Vasopressor therapy for hypotension due to epidural anesthesia for cesarean section. Acta Anaesthesiol Scand 1988; 32:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/14\">",
"      Kreiser D, Katorza E, Seidman DS, et al. The effect of ephedrine on intrapartum fetal heart rate after epidural analgesia. Obstet Gynecol 2004; 104:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/15\">",
"      Cleary-Goldman J, Negron M, Scott J, et al. Prophylactic ephedrine and combined spinal epidural: maternal blood pressure and fetal heart rate patterns. Obstet Gynecol 2005; 106:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/16\">",
"      Wright RG, Shnider SM, Levinson G, et al. The effect of maternal administration of ephedrine on fetal heart rate and variability. Obstet Gynecol 1981; 57:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/17\">",
"      Eng M, Berges PU, Ueland K, et al. The effects of methoxamine and ephedrine in normotensive pregnant primates. Anesthesiology 1971; 35:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/18\">",
"      Pham LH, Camann WR, Smith MP, et al. Hemodynamic effects of intrathecal sufentanil compared with epidural bupivacaine in laboring parturients. J Clin Anesth 1996; 8:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/19\">",
"      Breen TW, Shapiro T, Glass B, et al. Epidural anesthesia for labor in an ambulatory patient. Anesth Analg 1993; 77:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/20\">",
"      Kinsella SM, Pirlet M, Mills MS, et al. Randomized study of intravenous fluid preload before epidural analgesia during labour. Br J Anaesth 2000; 85:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/21\">",
"      Zamora JE, Rosaeg OP, Lindsay MP, Crossan ML. Haemodynamic consequences and uterine contractions following 0.5 or 1.0 litre crystalloid infusion before obstetric epidural analgesia. Can J Anaesth 1996; 43:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/22\">",
"      Cohen SE, Cherry CM, Holbrook RH Jr, et al. Intrathecal sufentanil for labor analgesia--sensory changes, side effects, and fetal heart rate changes. Anesth Analg 1993; 77:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/23\">",
"      Grant GJ, Susser L, Cascio M, et al. Hemodynamic effects of intrathecal fentanyl in nonlaboring term parturients. J Clin Anesth 1996; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/24\">",
"      Shannon MT, Ramanathan S. An intravenous fluid bolus is not necessary before administration of intrathecal fentanyl for labor analgesia. J Clin Anesth 1998; 10:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/25\">",
"      Pan PH, Bogard TD, Owen MD. Incidence and characteristics of failures in obstetric neuraxial analgesia and anesthesia: a retrospective analysis of 19,259 deliveries. Int J Obstet Anesth 2004; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/26\">",
"      Birnbach DJ, Ranasinghe JS. Anesthesia complications in the birthplace: is the neuraxial block always to blame? Clin Perinatol 2008; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/27\">",
"      Norris MC. Patient variables and the subarachnoid spread of hyperbaric bupivacaine in the term parturient. Anesthesiology 1990; 72:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/28\">",
"      Beilin Y, Bernstein HH, Zucker-Pinchoff B. The optimal distance that a multiorifice epidural catheter should be threaded into the epidural space. Anesth Analg 1995; 81:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/29\">",
"      Kelly D, Gudin JA, Brull SJ. Subcutaneous cysts: another cause of \"failed\" spinal anesthesia? J Clin Anesth 1996; 8:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/30\">",
"      Spiegel JE, Hess P. Large intrathecal volume: a cause of true failed spinal anesthesia. J Anesth 2007; 21:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/31\">",
"      Wells J, Paech MJ, Evans SF. Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron. Int J Obstet Anesth 2004; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/32\">",
"      Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/33\">",
"      Kendrick WD, Woods AM, Daly MY, et al. Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Anesth Analg 1996; 82:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/34\">",
"      George RB, Allen TK, Habib AS. Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: a systematic review and meta-analysis. Anesth Analg 2009; 109:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/35\">",
"      Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984; 61:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/36\">",
"      Sposito JA, Habib AS. Low-dose naloxone infusion for the treatment of intractable nausea and vomiting after intrathecal morphine in a parturient. Int J Obstet Anesth 2010; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/37\">",
"      Rawal N, Sch&ouml;tt U, Dahlstr&ouml;m B, et al. Influence of naloxone infusion on analgesia and respiratory depression following epidural morphine. Anesthesiology 1986; 64:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/38\">",
"      Fusi L, Steer PJ, Maresh MJ, Beard RW. Maternal pyrexia associated with the use of epidural analgesia in labour. Lancet 1989; 1:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/39\">",
"      Camann WR, Hortvet LA, Hughes N, et al. Maternal temperature regulation during extradural analgesia for labour. Br J Anaesth 1991; 67:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/40\">",
"      Yancey MK, Zhang J, Schwarz J, et al. Labor epidural analgesia and intrapartum maternal hyperthermia. Obstet Gynecol 2001; 98:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/41\">",
"      Lieberman E, Lang JM, Frigoletto F Jr, et al. Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. Pediatrics 1997; 99:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/42\">",
"      Sharma SK, Alexander JM, Messick G, et al. Cesarean delivery: a randomized trial of epidural analgesia versus intravenous meperidine analgesia during labor in nulliparous women. Anesthesiology 2002; 96:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/43\">",
"      Ramin SM, Gambling DR, Lucas MJ, et al. Randomized trial of epidural versus intravenous analgesia during labor. Obstet Gynecol 1995; 86:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/44\">",
"      Philip J, Alexander JM, Sharma SK, et al. Epidural analgesia during labor and maternal fever. Anesthesiology 1999; 90:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/45\">",
"      Mayer DC, Chescheir NC, Spielman FJ. Increased intrapartum antibiotic administration associated with epidural analgesia in labor. Am J Perinatol 1997; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/46\">",
"      Goetzl L, Rivers J, Zighelboim I, et al. Intrapartum epidural analgesia and maternal temperature regulation. Obstet Gynecol 2007; 109:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/47\">",
"      Goetzl L, Rivers J, Evans T, et al. Prophylactic acetaminophen does not prevent epidural fever in nulliparous women: a double-blind placebo-controlled trial. J Perinatol 2004; 24:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/48\">",
"      Segal S. Labor epidural analgesia and maternal fever. Anesth Analg 2010; 111:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/49\">",
"      Sessler DI. Temperature monitoring and perioperative thermoregulation. Anesthesiology 2008; 109:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/50\">",
"      Riley LE, Celi AC, Onderdonk AB, et al. Association of epidural-related fever and noninfectious inflammation in term labor. Obstet Gynecol 2011; 117:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/51\">",
"      Gonen R, Korobochka R, Degani S, Gaitini L. Association between epidural analgesia and intrapartum fever. Am J Perinatol 2000; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/52\">",
"      Kuczkowski KM, Reisner LS. Anesthetic management of the parturient with fever and infection. J Clin Anesth 2003; 15:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/53\">",
"      Palanisamy A, Hepner DL, Segal S. Fever, epidurals, and inflammation: a burning issue. J Clin Anesth 2007; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/54\">",
"      Kaul B, Vallejo M, Ramanathan S, Mandell G. Epidural labor analgesia and neonatal sepsis evaluation rate: a quality improvement study. Anesth Analg 2001; 93:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/55\">",
"      Tarshis J, Camann WR, Datta S. Epidural analgesia and neonatal fever. Pediatrics 1998; 101:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/56\">",
"      Greenwell EA, Wyshak G, Ringer SA, et al. Intrapartum temperature elevation, epidural use, and adverse outcome in term infants. Pediatrics 2012; 129:e447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/57\">",
"      Lieberman E, Lang J, Richardson DK, et al. Intrapartum maternal fever and neonatal outcome. Pediatrics 2000; 105:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/58\">",
"      Smarkusky L, DeCarvalho H, Bermudez A, Gonz&aacute;lez-Quintero VH. Acute onset headache complicating labor epidural caused by intrapartum pneumocephalus. Obstet Gynecol 2006; 108:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/59\">",
"      Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/60\">",
"      Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/61\">",
"      Lawton MT, Porter RW, Heiserman JE, et al. Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/62\">",
"      Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/63\">",
"      Green L, Machin SJ. Managing anticoagulated patients during neuraxial anaesthesia. Br J Haematol 2010; 149:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/64\">",
"      James AH, Abel DE, Brancazio LR. Anticoagulants in pregnancy. Obstet Gynecol Surv 2006; 61:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/65\">",
"      Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/66\">",
"      Fleischmann KH, Kuter DJ, Coley CM, Rathmell JP. Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice patterns. Reg Anesth Pain Med 2010; 35:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/67\">",
"      Beilin Y, Zahn J, Comerford M. Safe epidural analgesia in thirty parturients with platelet counts between 69,000 and 98,000 mm(-3). Anesth Analg 1997; 85:385.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Obstetric analgesia and anesthesia. ACOG practice bulletin #36. Obstet Gynecol 2002; 100;177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/69\">",
"      Douglas MJ. Platelets, the parturient and regional anesthesia. Int J Obstet Anesth 2001; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/70\">",
"      Hollm&eacute;n AI, Jouppila R, Jouppila P, et al. Effect of extradural analgesia using bupivacaine and 2-chloroprocaine on intervillous blood flow during normal labour. Br J Anaesth 1982; 54:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/71\">",
"      Hughes AB, Devoe LD, Wakefield ML, Metheny WP. The effects of epidural anesthesia on the Doppler velocimetry of umbilical and uterine arteries in normal term labor. Obstet Gynecol 1990; 75:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/72\">",
"      Reynolds F, Sharma SK, Seed PT. Analgesia in labour and fetal acid-base balance: a meta-analysis comparing epidural with systemic opioid analgesia. BJOG 2002; 109:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/73\">",
"      Bellanca L, Latteri MT, Latteri S, et al. Plasma and CSF morphine concentrations after i.m. and epidural administration. Pharmacol Res Commun 1985; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/74\">",
"      Nybell-Lindahl G, Carlsson C, Ingemarsson I, et al. Maternal and fetal concentrations of morphine after epidural administration during labor. Am J Obstet Gynecol 1981; 139:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/75\">",
"      Mardirosoff C, Dumont L, Boulvain M, Tram&egrave;r MR. Fetal bradycardia due to intrathecal opioids for labour analgesia: a systematic review. BJOG 2002; 109:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/76\">",
"      Abr&atilde;o KC, Francisco RP, Miyadahira S, et al. Elevation of uterine basal tone and fetal heart rate abnormalities after labor analgesia: a randomized controlled trial. Obstet Gynecol 2009; 113:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/77\">",
"      Clarke VT, Smiley RM, Finster M. Uterine hyperactivity after intrathecal injection of fentanyl for analgesia during labor: a cause of fetal bradycardia? Anesthesiology 1994; 81:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/78\">",
"      Cascio M, Pygon B, Bernett C, Ramanathan S. Labour analgesia with intrathecal fentanyl decreases maternal stress. Can J Anaesth 1997; 44:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/79\">",
"      Mercier FJ, Dounas M, Bouaziz H, et al. Intravenous nitroglycerin to relieve intrapartum fetal distress related to uterine hyperactivity: a prospective observational study. Anesth Analg 1997; 84:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/80\">",
"      Cooper DW, Carpenter M, Mowbray P, et al. Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology 2002; 97:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/81\">",
"      Bofill JA, Vincent RD, Ross EL, et al. Nulliparous active labor, epidural analgesia, and cesarean delivery for dystocia. Am J Obstet Gynecol 1997; 177:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/82\">",
"      Segal S, Blatman R, Doble M, Datta S. The influence of the obstetrician in the relationship between epidural analgesia and cesarean section for dystocia. Anesthesiology 1999; 91:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/83\">",
"      Comparative Obstetric Mobile Epidural Trial (COMET) Study Group UK. Effect of low-dose mobile versus traditional epidural techniques on mode of delivery: a randomised controlled trial. Lancet 2001; 358:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/84\">",
"      Thornton JG, Capogna G. Reducing likelihood of instrumental delivery with epidural anaesthesia. Lancet 2001; 358:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/85\">",
"      Hess PE, Pratt SD, Soni AK, et al. An association between severe labor pain and cesarean delivery. Anesth Analg 2000; 90:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/86\">",
"      Wuitchik M, Bakal D, Lipshitz J. The clinical significance of pain and cognitive activity in latent labor. Obstet Gynecol 1989; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/87\">",
"      Vause S, Congdon HM, Thornton JG. Immediate and delayed pushing in the second stage of labour for nulliparous women with epidural analgesia: a randomised controlled trial. Br J Obstet Gynaecol 1998; 105:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/88\">",
"      Fraser WD, Marcoux S, Krauss I, et al. Multicenter, randomized, controlled trial of delayed pushing for nulliparous women in the second stage of labor with continuous epidural analgesia. The PEOPLE (Pushing Early or Pushing Late with Epidural) Study Group. Am J Obstet Gynecol 2000; 182:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/89\">",
"      Petrou S, Coyle D, Fraser WD. Cost-effectiveness of a delayed pushing policy for patients with epidural anesthesia. The PEOPLE (Pushing Early or Pushing Late with Epidural) Study Group. Am J Obstet Gynecol 2000; 182:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/90\">",
"      Roberts CL, Torvaldsen S, Cameron CA, Olive E. Delayed versus early pushing in women with epidural analgesia: a systematic review and meta-analysis. BJOG 2004; 111:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/91\">",
"      Torvaldsen S, Roberts CL, Bell JC, Raynes-Greenow CH. Discontinuation of epidural analgesia late in labour for reducing the adverse delivery outcomes associated with epidural analgesia. Cochrane Database Syst Rev 2004; :CD004457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/92\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG committee opinion. No. 339: Analgesia and cesarean delivery rates. Obstet Gynecol 2006; 107:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/93\">",
"      Wassen MM, Zuijlen J, Roumen FJ, et al. Early versus late epidural analgesia and risk of instrumental delivery in nulliparous women: a systematic review. BJOG 2011; 118:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/94\">",
"      Wong CA, Scavone BM, Peaceman AM, et al. The risk of cesarean delivery with neuraxial analgesia given early versus late in labor. N Engl J Med 2005; 352:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/95\">",
"      Ohel G, Gonen R, Vaida S, et al. Early versus late initiation of epidural analgesia in labor: does it increase the risk of cesarean section? A randomized trial. Am J Obstet Gynecol 2006; 194:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/96\">",
"      Wong CA, McCarthy RJ, Sullivan JT, et al. Early compared with late neuraxial analgesia in nulliparous labor induction: a randomized controlled trial. Obstet Gynecol 2009; 113:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/97\">",
"      Wang F, Shen X, Guo X, et al. Epidural analgesia in the latent phase of labor and the risk of cesarean delivery: a five-year randomized controlled trial. Anesthesiology 2009; 111:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/98\">",
"      Vallejo MC, Mandell GL, Sabo DP, Ramanathan S. Postdural puncture headache: a randomized comparison of five spinal needles in obstetric patients. Anesth Analg 2000; 91:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/99\">",
"      Scavone BM, Wong CA, Sullivan JT, et al. Efficacy of a prophylactic epidural blood patch in preventing post dural puncture headache in parturients after inadvertent dural puncture. Anesthesiology 2004; 101:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/100\">",
"      Cohen S, Amar D, Pantuck EJ, et al. Decreased incidence of headache after accidental dural puncture in caesarean delivery patients receiving continuous postoperative intrathecal analgesia. Acta Anaesthesiol Scand 1994; 38:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/101\">",
"      Kuczkowski KM, Benumof JL. Decrease in the incidence of post-dural puncture headache: maintaining CSF volume. Acta Anaesthesiol Scand 2003; 47:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/102\">",
"      Charsley MM, Abram SE. The injection of intrathecal normal saline reduces the severity of postdural puncture headache. Reg Anesth Pain Med 2001; 26:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/103\">",
"      Chen LK, Huang CH, Jean WH, et al. Effective epidural blood patch volumes for postdural puncture headache in Taiwanese women. J Formos Med Assoc 2007; 106:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/104\">",
"      Paech MJ, Doherty DA, Christmas T, et al. The volume of blood for epidural blood patch in obstetrics: a randomized, blinded clinical trial. Anesth Analg 2011; 113:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/105\">",
"      Thew M, Paech MJ. Management of postdural puncture headache in the obstetric patient. Curr Opin Anaesthesiol 2008; 21:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/106\">",
"      Cohen S, Sakr A, Katyal S, Chopra D. Sphenopalatine ganglion block for postdural puncture headache. Anaesthesia 2009; 64:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/107\">",
"      Russell, AL. Spenopalatine ganglion block: a simple block in the management of chronic pain. AJPM 1993; 3:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/108\">",
"      MacArthur C, Lewis M, Knox EG, Crawford JS. Epidural anaesthesia and long term backache after childbirth. BMJ 1990; 301:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/109\">",
"      Breen TW, Ransil BJ, Groves PA, Oriol NE. Factors associated with back pain after childbirth. Anesthesiology 1994; 81:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/110\">",
"      Russell R, Dundas R, Reynolds F. Long term backache after childbirth: prospective search for causative factors. BMJ 1996; 312:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/111\">",
"      Macarthur A, Macarthur C, Weeks S. Epidural anaesthesia and low back pain after delivery: a prospective cohort study. BMJ 1995; 311:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/112\">",
"      Macarthur AJ, Macarthur C, Weeks SK. Is epidural anesthesia in labor associated with chronic low back pain? A prospective cohort study. Anesth Analg 1997; 85:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/113\">",
"      Howell CJ, Kidd C, Roberts W, et al. A randomised controlled trial of epidural compared with non-epidural analgesia in labour. BJOG 2001; 108:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/114\">",
"      Howell CJ, Dean T, Lucking L, et al. Randomised study of long term outcome after epidural versus non-epidural analgesia during labour. BMJ 2002; 325:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/115\">",
"      Loughnan BA, Carli F, Romney M, et al. Epidural analgesia and backache: a randomized controlled comparison with intramuscular meperidine for analgesia during labour. Br J Anaesth 2002; 89:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/116\">",
"      Mayberry LJ, Clemmens D, De A. Epidural analgesia side effects, co-interventions, and care of women during childbirth: a systematic review. Am J Obstet Gynecol 2002; 186:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/117\">",
"      Kranke P, Eberhart LH, Roewer N, Tram&egrave;r MR. Single-dose parenteral pharmacological interventions for the prevention of postoperative shivering: a quantitative systematic review of randomized controlled trials. Anesth Analg 2004; 99:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/118\">",
"      Hebl JR. The importance and implications of aseptic techniques during regional anesthesia. Reg Anesth Pain Med 2006; 31:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/119\">",
"      Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology 2006; 105:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/120\">",
"      Baer ET. Post-dural puncture bacterial meningitis. Anesthesiology 2006; 105:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/121\">",
"      Centers for Disease Control and Prevention (CDC). Bacterial meningitis after intrapartum spinal anesthesia - New York and Ohio, 2008-2009. MMWR Morb Mortal Wkly Rep 2010; 59:65.",
"     </a>",
"    </li>",
"    <li>",
"     The Healthcare Infection Control Practices Advisory Committee 2007 guideline for isolation precautions:preventing transmission of infectious agents in healthcare settings file://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/123\">",
"      Lambert DH. Gloved and masked-will gowns be next? Let the data (not logic) decide this issue. Anesthesiology 2007; 106:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/124\">",
"      Hepner DL. Gloved and masked--will gowns be next? The role of asepsis during neuraxial instrumentation. Anesthesiology 2006; 105:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/125\">",
"      Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010; 362:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/126\">",
"      Kinirons B, Mimoz O, Lafendi L, et al. Chlorhexidine versus povidone iodine in preventing colonization of continuous epidural catheters in children: a randomized, controlled trial. Anesthesiology 2001; 94:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/127\">",
"      American Society of Anesthesiologists Task Force on infectious complications associated with neuraxial techniques. Practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: a report by the American Society of Anesthesiologists Task Force on infectious complications associated with neuraxial techniques. Anesthesiology 2010; 112:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/128\">",
"      Wong CA, Scavone BM, Dugan S, et al. Incidence of postpartum lumbosacral spine and lower extremity nerve injuries. Obstet Gynecol 2003; 101:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/129\">",
"      Halpern SH, Levine T, Wilson DB, et al. Effect of labor analgesia on breastfeeding success. Birth 1999; 26:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/130\">",
"      Beilin Y, Bodian CA, Weiser J, et al. Effect of labor epidural analgesia with and without fentanyl on infant breast-feeding: a prospective, randomized, double-blind study. Anesthesiology 2005; 103:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/131\">",
"      Halpern SH, Ioscovich A. Epidural analgesia and breast-feeding. Anesthesiology 2005; 103:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/132\">",
"      Scanlon JW, Brown WU Jr, Weiss JB, Alper MH. Neurobehavioral responses of newborn infants after maternal epidural anesthesia. Anesthesiology 1974; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/133\">",
"      Abboud TK, Khoo SS, Miller F, et al. Maternal, fetal, and neonatal responses after epidural anesthesia with bupivacaine, 2-chloroprocaine, or lidocaine. Anesth Analg 1982; 61:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/134\">",
"      Thorp JA, Hu DH, Albin RM, et al. The effect of intrapartum epidural analgesia on nulliparous labor: a randomized, controlled, prospective trial. Am J Obstet Gynecol 1993; 169:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/135\">",
"      Dailey PA, Baysinger CL, Levinson G, Shnider SM. Neurobehavioral testing of the newborn infant. Effects of obstetric anesthesia. Clin Perinatol 1982; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/136\">",
"      Halpern SH, Leighton BL, Ohlsson A, et al. Effect of epidural vs parenteral opioid analgesia on the progress of labor: a meta-analysis. JAMA 1998; 280:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/137\">",
"      Loftus JR, Hill H, Cohen SE. Placental transfer and neonatal effects of epidural sufentanil and fentanyl administered with bupivacaine during labor. Anesthesiology 1995; 83:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/138\">",
"      Porter J, Bonello E, Reynolds F. Effect of epidural fentanyl on neonatal respiration. Anesthesiology 1998; 89:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/139\">",
"      Flick RP, Lee K, Hofer RE, et al. Neuraxial labor analgesia for vaginal delivery and its effects on childhood learning disabilities. Anesth Analg 2011; 112:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/140\">",
"      Hattori R, Desimaru M, Nagayama I, Inoue K. Autistic and developmental disorders after general anaesthetic delivery. Lancet 1991; 337:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/141\">",
"      Sprung J, Flick RP, Wilder RT, et al. Anesthesia for cesarean delivery and learning disabilities in a population-based birth cohort. Anesthesiology 2009; 111:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/40/39562/abstract/142\">",
"      Flood P. Fetal anesthesia and brain development. Anesthesiology 2011; 114:479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4469 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-562CF1C545-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39562=[""].join("\n");
var outline_f38_40_39562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTEMIC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Use of test dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HIGH SPINAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPOTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prehydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INADEQUATE OR FAILED BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRURITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NAUSEA AND VOMITING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESPIRATORY DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12559677\">",
"      INTRAPARTUM FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12560887\">",
"      PNEUMOCEPHALUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12561173\">",
"      SPINAL EPIDURAL HEMATOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12561180\">",
"      NEURAXIAL ANALGESIA AND THE ANTICOAGULATED PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12561187\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12561194\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12561201\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12561208\">",
"      NEURAXIAL ANALGESIA AND LOW PLATELETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12559684\">",
"      FETAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928800\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12559692\">",
"      Fetal bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12560398\">",
"      EFFECT OF NEURAXIAL ANALGESIA ON LABOR AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12560405\">",
"      Effect of neuraxial analgesia on the progress and outcome of labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12560412\">",
"      Pain as a marker of dysfunctional labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12560419\">",
"      Potential benefits of delayed pushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12560426\">",
"      Timing of epidural administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12560696\">",
"      POTENTIAL POSTDELIVERY SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Postdural puncture headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Backache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Shivering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13183554\">",
"      Postpartum neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12560963\">",
"      Effect on breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12559211\">",
"      EFFECTS ON THE NEONATE AND CHILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12559219\">",
"      Neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12561018\">",
"      Child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20840?source=related_link\">",
"      Management of cardiopulmonary arrest in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25977?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=related_link\">",
"      Neurologic disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_40_39563="Treatment of Candida osteoarticular infections";
var content_f38_40_39563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Candida osteoarticular infections in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Condition or treatment group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alternative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteomyelitis",
"       </td>",
"       <td>",
"        Fluconazole 400 mg (6 mg/kg) orally daily for 6 to 12 months or a lipid formulation of amphotericin B 3 to 5 mg/kg IV daily for several weeks, then fluconazole for 6 to 12 months",
"       </td>",
"       <td>",
"        An echinocandin* or amphotericin B deoxycholate 0.5 to 1 mg/kg IV daily for several weeks then fluconazole for 6 to 12 months",
"       </td>",
"       <td>",
"        Duration of therapy usually is prolonged (6 to 12 months). Surgical debridement is frequently necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic arthritis",
"       </td>",
"       <td>",
"        Fluconazole 400 mg (6 mg/kg) orally daily for at least six weeks or a lipid formulation of amphotericin B 3 to 5 mg/kg IV daily for several weeks, then fluconazole to completion",
"       </td>",
"       <td>",
"        An echinocandin* or amphotericin B deoxycholate 0.5 to 1 mg/kg IV daily for several weeks, then fluconazole to completion",
"       </td>",
"       <td>",
"        Duration of therapy is usually for at least six weeks, but few data are available. Surgical debridement is recommended for all cases. For infected prosthetic joints, removal is recommended for most cases.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Echinocandin dosing in adults is as follows: anidulafungin, 200 mg IV loading dose, then 100 mg IV once daily; caspofungin, 70 mg IV loading dose, then 50 mg IV once daily; and micafungin, 100 mg IV once daily.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39563=[""].join("\n");
var outline_f38_40_39563=null;
var title_f38_40_39564="Polysomnographic values";
var content_f38_40_39564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Polysomnographic values in healthy children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean &plusmn; SD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended normal values",
"       </td>",
"       <td class=\"subtitle1\">",
"        Children classified as abnormal",
"        <br/>",
"        n (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea index (n/h)",
"       </td>",
"       <td>",
"        0.1 &plusmn; 0.5",
"       </td>",
"       <td>",
"        0&nbsp;to 3.1",
"       </td>",
"       <td>",
"        &le; 1&bull;",
"       </td>",
"       <td>",
"        1 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximum PETCO2 (mmHg)",
"       </td>",
"       <td>",
"        46 &plusmn; 4",
"       </td>",
"       <td>",
"        38&nbsp;to 53",
"       </td>",
"       <td>",
"        &le; 53&bull;",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimum PETCO2 (mmHg)",
"       </td>",
"       <td>",
"        38 &plusmn; 3",
"       </td>",
"       <td>",
"        28&nbsp;to 44",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in PETCO2 (mmHg)",
"       </td>",
"       <td>",
"        7 &plusmn; 3",
"       </td>",
"       <td>",
"        2&nbsp;to 11",
"       </td>",
"       <td>",
"        &le; 13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of hypoventilation (percent TST)",
"       </td>",
"       <td>",
"        6.9 &plusmn; 19.1",
"       </td>",
"       <td>",
"        0&nbsp;to 90.5",
"       </td>",
"       <td>",
"        &le; 60&Delta;",
"       </td>",
"       <td>",
"        3 (6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximum SaO2 (percent)",
"       </td>",
"       <td>",
"        100 &plusmn; 1",
"       </td>",
"       <td>",
"        98&nbsp;to 100",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimum SaO2 (percent)",
"       </td>",
"       <td>",
"        96 &plusmn; 2",
"       </td>",
"       <td>",
"        89&nbsp;to 98",
"       </td>",
"       <td>",
"        &ge; 92&Delta;",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desaturation &gt;4 percent/h TST (n)",
"       </td>",
"       <td>",
"        0.3 &plusmn; 0.7",
"       </td>",
"       <td>",
"        0&nbsp;to 4.4",
"       </td>",
"       <td>",
"        &le; 1.4&Delta;",
"       </td>",
"       <td>",
"        1 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in SaO2 (percent)",
"       </td>",
"       <td>",
"        4 &plusmn; 2",
"       </td>",
"       <td>",
"        0&nbsp;to 11",
"       </td>",
"       <td>",
"        &le; 8&bull;",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Apnea index: number of obstructive apneas of any length per hour of sleep; TST: total sleeping time.",
"     <br>",
"      * The number of children classified as abnormal represents the number of children who would be judged to have an abnormality based on the recommended values. Apnea index is defined as the number N of obstructive apneas of any length per hour of sleep.",
"      <br>",
"       &bull; Recommended normal values based on mean &plusmn; 2 SD when parameters follow a normal distribution.",
"       <br>",
"        &Delta; For data that are not normally distributed, the recommended normal values are based on inclusion of 97 percent of subjects tested for one-tailed distribution.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marcus EL, Omlin K, Basinski D, et al. Normal polysomnographic values for children and adolescents. Am Rev Respir Dis 1992; 146:1236.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39564=[""].join("\n");
var outline_f38_40_39564=null;
var title_f38_40_39565="Iron chelating agents";
var content_f38_40_39565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Iron chelating agents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 189px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three general classes of agents capable of chelating iron are shown here. In order to perform  this function, the chelating molecule(s) must complex with all of the iron atom's six available  coordination sites, as shown. Bidentate chelating agents are capable of providing two such links  per molecule; thus three molecules are required to chelate one atom of iron. Similarly, two  tridentate molecules and only one hexadentate molecule are required to accomplish the same  purpose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cohen, A, Porter, J. Transfusion and chelation therapy in thalassemia and sickle cell anemia. In: Disorders of hemoglobin: Genetics, Pathophysiology, and Clinical Managment, Bunn, HF, Steinberg, MH, Forget, BG (Eds), Cambridge University Press, 2001. p. 979. Copyright &copy; 2001 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39565=[""].join("\n");
var outline_f38_40_39565=null;
var title_f38_40_39566="Echo assessment rt ventricle1";
var content_f38_40_39566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Echocardiographic assessment of right ventricle in an infant with congenital diaphragmatic hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 182px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prolonged elevated pulmonary vascular resistance leads to a dilated, non-compliant right ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39566=[""].join("\n");
var outline_f38_40_39566=null;
var title_f38_40_39567="Cell divisions spermatogenesis";
var content_f38_40_39567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Cell divisions during spermatogenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each spermatogonium that undergoes differentiation after puberty gives rise to 16 primary spermatocytes, each of which then enters meiosis and gives rise to&nbsp;four spermatids and finally&nbsp;four spermatozoa. Thus, each of the 3 million spermatogonia that begin the process every day gives rise to 64 spermatozoa. Since about one-half of potential sperm are lost during this process, approximately 100 million sperm are produced each day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Griffin JE, Wilson, JD, Disorders of the testes and male reproductive tract. In: Williams Textbook of Endocrinology, 7th ed, Wilson JD, Foster DW (Eds), Saunders, Philadelphia 1985, p 810.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_40_39567=[""].join("\n");
var outline_f38_40_39567=null;
